var title_f39_46_40672="Avulsion ischial tuberosity";
var content_f39_46_40672=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F62834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F62834&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Apophyseal avulsion injury of the left ischial tuberosity",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 340px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Apophyseal avulsion injury of the left ischial tuberosity at the site of insertion of the hamstring muscles (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Rajvee Shah, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_46_40672=[""].join("\n");
var outline_f39_46_40672=null;
var title_f39_46_40673="Left atrial myxoma five chamber echocardiogram 1";
var content_f39_46_40673=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/58730/5chlamy1_conv.mp4?title=Left+atrial+myxoma+five+chamber+echocardiogram+1\" style=\"width:328px;height:248px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Left atrial myxoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 244px; height: 442px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The five chamber view from a 2-D echocardiogram shows a very large left atrial myxoma which is has a broad stalk and is adherent to the interatrial septum. During diastole the tumor extends into the left ventricle. The presence of left atrial enlargement suggests that there is mitral regurgitation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_46_40673=[""].join("\n");
var outline_f39_46_40673=null;
var title_f39_46_40674="Hepatic candidiasis histology";
var content_f39_46_40674=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F81112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F81112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Histology in hepatosplenic candidiasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 239px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADvAWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDzK6ubmSUSw5TACtgcKB2FK8e+3XymbzM8xgc/UVZkctJ5iNIqOu1iV7+4pLeRnKwDYZIhlXzzgc9fSv3S9lotjw9kSzW7eTEiyp9oUfcPDMPr3NQXCPAoDSBhgFgeCD6fWpXU3CvNbeWXZcsh4ZCO4pUUXdoI9+LgPk7+49vX6VCbW4lprcgeQyMPNJZwOGUdqt2rNJdQJIsZSIFwuAN/+961NJFp9qsghaaWRUwyN8vPqp/pSXtnPbWsFxd2q4uhmFi3JAPUCpc4y02vsPnTRoaPbSapqZ3RCaYP5rQxAAmJCCQg78dhWfd6lc3V7fJIypFcyZzMuSqqeACeRWppds9rpSXmyZJnmKCZW5RSuDyOmM1R1vT5LaVZoJzcW0rnypXH3x3J+tc8JRdRp+i+X9L7jGMk5v8AAiswZiscQaRnwFQDlj7etdakEPh/wjeNqWqyW91cEhdOtJAJJ2HC7yMkDk5HpWbpGnTR2bXl5ZO1pEDIuWVY3x2Y9cZ7Dk1Mlhq954f1XUr2CNY7dUmtm8tRtO4cKey7SeK56841JJcyUU1fbV32/wA9L+ZNWrzpJvRNdtzlb2O3ubi3WOUiCKEKQYyh398DqRnvUCquVBk4HBAX9akYPNKHQbJJD0HOPWpTAuds0bJIBkOXCq3tXpJ8qSudkFyKxFBcyR2rqkhEcrZI243Y9DU7pHPLts5FViAEgXJLHHOT0qss7mGMW6usUJLgZzg8dfepIZJobk3EsCnAPEg7sOuKHHdrcvfVFt2lt5bK42rdExEoxAKg5IIx/s4PFF0Dc29vc3DW8MToQiKuG2j+L8TmqYEqQplXxETsxycNUUUaxJBMyB4mJG0ty34dqlQ69f8AhxqNiWDDKTC0iwqRvCN82D3AprFFKMvlTbME5BBbnnNJMysqsE2vjbuAwR/jxRCC6SuF2gDGSevFX5jv3Nvw7YandaxtsrQzYilC+Xyi5XkZ/wA81lPCrTXC3TNLMFO0knAOegNW7TWPEFrp0Om6NdTR2yOz+XbqA7lupLDniqc0khMiTZ2j92u3sRz/ADrGMZ87btbpbf5/5fiYx5+d81rCQRXCsrgvJM65Vdu9ce/pVqS+vbiA2Ym22Jcv5Q4QeucdcYqK2uVtF3Qqyhowu0ycqTwxH+e9VQY0cBSY0K9xwfXir5eZ3a9DRq/QuWtxCpku1jeEwkLCIjyxPXdnnp6VBLBC11KlnvIVflxyz+tNwDGxeVSYyGKdMD296rspRXMSSZYfdZfuKehBqox1un/X9fmGxegjlhhd1hVWZgmXIJA9h+HNJNDKkkTTSGLcpAkjXIH5c802zMU423JkKjICIMBMD196immDpbSMVeRRh1XKnrwPp70knzEXu7FrTbMRSQXUtxbiNmYEyKTgDg5Uc/jVS78sXE8tuVX5zsjXJXHtmr9hcpaJG63D/a5QyqS2VhOeeO4I6n3qtqUVxbTSWkyxRNE55UBuT6EdQaUW3N3/AK/r+vNR3syOEgttkVQxUfN161OnmzSsIUl2ou5icKgHbjvxmopYkScREhWVQGx2P17mkEy7jG5bBOOF+8O2apq+qBtWJTlwVEsSZ4LfxCnsFleMxyqZgQqtGuAMenofrUMltImSFjG0DgnccdvrVgeWtmcSqjSHBQKPmPXB9ql26E8yI7ox/Zik3mCVGwEUkkjuPY1SR4pi8kiJB/dVcsUH1/xpxkcyHDlUPYjrTVSJXLKwIf5sDjcelaRjZCtrcW4m3JGq4KMct5fJIz1IqrdpLM0MdvM0cQ6SKvzMD61abgOIGBK4AIwOvXOagug7QMLcqLrfkIoJ5H09aqNkTJLckZbgLEl0DKqgKrE8qgOAo/nV7VPP+2JPc30k6ywgqiTZIHZW9MY6VXe3upInknj8i4VhK28/gQB35pLs2806pbW9whcAsJHB59eAOtTu0zNJNqyIVQv88e9I2GQwJKhvQ5psjO1ukTKNvmZwRg59a6O0tmttEtdVFg09sLhlm2zZUFeispHGfXoak1e9s9Su5Gi0+y08FNyREMGBxnk9MkfhWX1i8rKN0r66aWJjW1slf/gHMohAmaEvtIIYevPAFWbeIRXCMwLMuJORwWHYip7ESOZYoUkBERk+TAYqOd/PbFV1XDSZXJxyw9CK1cr3Rve7sT6pIk/kMZczzkySogAWP+6MCqLwh08sSFAfvBev41MY2Cys6YI5Zt3J+lRuV3ZxjkAHIpwXKrIaUbWHqBHb8cMuNu44yD1zRUE584qojZxz8wHWirUV1M2maU88sExkhjULIm10xuVvqD0NVYHWS5iMMDYB+YYBxTi8txPHIAwZAAQg5GO4oknkSdtjEHoCUAJ+o9aySsrdS0nsMniWG6cnC/vP4Tzj0zU9xFEIfluFliBHlnOGUn1qQCE27pNM0tt1Dov7xGPqPSmG5za/KIAVwm1h82BSu3Ya3LnmLcWbpJpzNNBHy0UZDAf3nPp0pLy8ubyw0+0mxi0T90O4U9f/AK1CXN/p73EPnqDNCIpsAN+7YVPo0bxabc3X2Xzbf/j2acnKxFuhI/rWDtFc3np8zJ2Wv3Fyz1aGw8O3+nG2eW6uWVhIj/LEFwcY96y4nSWxbe2G8wfLnG71OO2Kg1qZPNn+w7vLRFVOMFsAAsfqcn8as+F7WHUNT063uxOIppAJBFy59hSVONODq99X9wRjGmnL5iTLLcQR+dcMpVgmWbCKMcAD+tWdQ8QJfaTYaVHFNZRWpcAROds7HHzMPX/Gq+oxC11C6RbcQqgZPJlfeVI4z/vVmhXne3YFXkICBdvXnvVxpxnaT6ary0+41UIytK22w6e3aIbkjkURsBIxPQ/Spbi53NI7SRHLKVGwlsjpx6UjxGMzrLExaNwGZW3BBnkHsaauDC235olbO9VyR9a131ZstSurAynLurM3IQcE1aijMsU2dx8ogjeeMehqOWONP3IRS+fkljJG4epFOCus+y5Kw4O0sy+nrTbvsUmWY5Hku4pLmeb7NyoeLDYAHYHHrRcizEMc1jFIqqSHWYhtg7EH3qIpAbZWLsk+7aCGG3HrSwxeWsicvvPyJkYf3rOy3BLqVShXgZ4AJPY57VOYpEKi6RWGMruyFI/rUzRGVvswfG3Lbc5z7Crd9e3ElqLae2wiJ+7EkrMYuR0Pvihzd0kLm1sZAeRFcQyEb1IJVsYwc4FWIysVnb+UkqlnyH3AKwHWmzTNJudY0jJAUsi7QOMcf1plrmNJIY2Iz1PXJH9Kt6oCS6kee43ui8n5QODSTRNI6vIoBi+d+uGHv/KnW9lCty32qSQK3QRpuAGc4AJ7+tWi0ZadyOG6nHzZ7ADoOf0qHJLSI0n1RRYAXa7bdTFuLhX5G7HQn0psLGG7cCU70IHXIHPX3FTtuZQxGxCNvIODn196RoE80gSKGYndu7f/AK6q6tZhy9gzbR4QSyyRHcQUO0Agf1P8qhuZY2ESQudmBHIc8N6DmlKBgONigFfk5yPakuAxh3SEHBwu44I/xppK5FnfQitXwsu4t5ch2sVxnGamiRRLHuVim0suQMkDoamjhDWvmykFgcELx9M+30pkcuIvMMfzh8iRWztGPu4/KhyvewaohbfNOG3O2eeSc59/YUu6WWQEsDtG3OMZx06VPGZZlLzyDJXJd25b/GmnOw/MAeu5Vxk+hov0DlvqNCs8yRxHJPOMYx7Z9KZNAUcByxUMVbbyRzyBUpjkjaMTKUBAYFxkHI64psiK0sskIeYR8kghPxwf5UJ6kNDJWWWYxwhltwcAueQO2cd/anSTG5tVDxxKkZyoVcMR9e/rVZrhmmECgqmCxx0z2p0b7jIXdk2o2CR7fd/Gr5bWIVnoyUyFxCkjKtvwAABwe546mnT3ETu0cMRiQqQxYYJx05HIpXtWhgs5/NXfKpIhDDegBxk+gPamXBleJpfOAUvtALZ4Hv7VKs3oNxRPbvJLatI32ieNF2M7tkQhugGec55ouXPk2imNN6x+W7r0kwSQTz17fhVSzkczRiCJ5JvMDRheckevvWq7zXSPcSSxI855ZyPMYjJOPQE/yqJLll/X9d/61Mno9CvJHcCyDxtJHbSDDfMVRiv8PvjimTSRZ37UEhPzEkgnjsPTrU1oAFMZw6phirLzkHOAPfvUEstvdz+cmI4m5YbT8p/ur146ULcd7OxPr9kNNMf20qTJGsiqkm8xgjIDH+lUiyliN5ZAgO0c5P8ASrd5aSQ6VHfoI3tZZTEOckPjJUjrkCs8MskirHnZwq4GMmqpax1d7BB2W5OoaYbmCYX5izcDA7D1oIihlinEYMQBO0/MGb3FRTAR3BWc4AwNrNx7ipI5YhA5ZX2Ywuz196q3Yq9yOC7e1+6iKGUgKw6Z60Uiw4E0wizsUfMSAVz0OO9FVypu6Qctya4LbUmXzkOAAx7+9SeTIShWISM+RhzlifpUbhzP5F5JKEjGPlXJUfSrBkNq5mE0cyMhUFW+YDsSPWs23ayL20RVtwFZmEkinH3kHQ+h9atwTQ3E8j3ITzChUvIMKT2bjoelV4YXnjDBGQbstK5wuTRCsg84Qor4wWI5Ufj6USSd+4Oz6k9iESHfKueSC4J4GOK6m50C50bw9Y31zcPGl05ZYhgg8ZTd/UVh6RaG61O1iDLGXmjGX5B+YZNen/GKCA6ZZNlhcIxCqrYyuOePwry8XiXHEU6K+03f7jir13GvTprre55VfmG4uwYcrGpHzHgY/wD15rf8EW+ptJe6jpNkkj2cTYnIBCkDooP8WP0rn7C0Oo3kNtACXlYDaELMg7n6DrXY+LfEcekaW3h3wypitYgEmu06zN/Fgj1PU/hWmJcmlh6au332S63/AMi67k7UYK7e99rHM64mmJpNq9hcTXd3fr512HbLQOCcjp3z+lZlsm8CGGPfMcFWDYwaqQ+a1wvloBO529fXrQkYEvlmXainBcDtnqK7o0+SPLe/X+vyOynDkVrmpaW1pNE0YvJ0leNmkVFJG8H7pHeorWKa6jeH5IokPzFeNxAxzT7wrBJIDbxqkigIztyV7MAKhtVEbeesoBjPQDr7nPFSr2buUr2uAgmQhrhJAqrtQrgEfnTGykZbLBJeXRjnPofrViCWe4k2IJZT5bDaVz8vJP5VFA6mRYmRpYgd7DOCABzz2p3fU0SJbchIgNiBC38fPoM/0p98DBIV2qyKAUHXbnseaRAxLGJcpIONxyefal2p9oRZcBhweegFR1uXZoGVCTNBvWXaAuzjgVnlSkxYTOWYjcrEtWnPKQIwkSQShTzH/Hz1IzgGo0kEmY5WVWPIcDPy/WnCTSuQ0nqQbVkDMUc7eRg4yfeoQVWVBjcqD7pPQ/8A1qveTuWJVA2bgBycnn9artHGZVjlXDBmbKjOP8aqMkDWupZAWLgmTc3yuRycGpBFEomVt/mqF2bRlffPcGmqi+QxjIHlsFCZ5bIzuzSxMpOAxMYTIC9h6VkzWMewxIjLKVjZpAx3ByuBn8KlvbT7HdRrLPA953jjUkqevPapYl8pUuDI0UhJEaBSpYY+8CO1MWSJAwkUNKU+V8n5G7n1Y44zS5nfTYh3vdbFEx4Ziy4YnLYH8vanQRyNHOvloWThnYZMYPfnoferIhcjzNqBAQBnlj3OB3OKa0CSXDKFZQGyHOBxjoc1fOJ2eiKRA3ozKzIBksOmcd6jCFY2jGeTwPX3rSCxTFIgI7aMN88kjEsfqR0HsBVBZNwOCyruKI69OKuMrkKy+Ik3CJSATkgYBHGPSpJdpib5drk5JwMEdhTY23sFjPLcBWGTmmzZeFgikDggE9PfHrmjqDaGlBE3mSyFIWHzZHXHpQVjuntYlQ43Ha5Odw60TI+QjnkANhhwo9hTWtpVjhnaJowMMjLj5wScED8Ka731JtqGy2a3LTSyLOy5WLy+pzxzVSV/KkK/wjuG7+lXISHu8YMjN0ZxjAPVjVZvtEAeGFyyqxDqcfvBjHocVcd7E2s9CfzGllEt1KUDIF3kc4AwPf0qOXFxKu5jIw+XBG1VX1GPzptvM1tJvQglDxnB596e8nlu0kq75CMFm56+wxzRaz0FZETSuHbYxSOL5UAXB4Oc8c1ciBfT5FJZVYFjvUEqSOpPUemKpmIBTmYtKw34z/P/AAqWynS0CecTLGR+8HUlf8c0SV1oZyRNaS7VyTt3KFDk52n2Hf61Xu8pMfmLkj5umB6DiprdiEIlZA5+4SOgzxTJofviNw4U4JBxuNJWUh+ZHFGrG3DSFYgxyCcAeoz2z60jeW1zjau2Rfkz/Bz/AEqONckOAmQM5P3amyqqsKsxPQZ+UDvmre5LV2Ks6iQLLG0m3JyTkE/1FKw82ZQyeREBxz27gUWd0tnc+f5UEw5Uxy5Ktnj9OtXY75rX+0B9kth+5CSQzR7kwSMFf7p75zUSun7qJldO6Rnuomm8+bzJ0KYCjj5ugFFWb+eG6llfS7eS0sVbA3tuI4/z0oqou6108v8Ahildq4sVw8d48qB33IVDuM8EY5xVe3RZR5UaqZASfMycY9KklDQylo42jUcnkNj3qe7Xzo7h5JGa4wDG24fvB3BAqLpbdS9iECSa1jD7hDGreWzH5W9QPfNXre4a2hDWkgiWW2McyE53DPP61Shjt/s5adXcnGxonwIz33KRyKltoZrkysrfu4164HK5A6VM0nvsFu5veC9LivfEmjgOsiiTMqsSowOcZ7njge1eu+LvD+la6LQ6nC0jpJsQo+1uecDnviuV+D9kI7XUr+VmMccgEe7A6Kcn8jXOeLPHFzfaxaahpgmgWxbckEpVlJ6FiB35I6185iIV8ZjbUXbkW/m9f+AeJWp1cTin7N25Vv6/1Y6a01K38PW7aRomitFqnlMXmvWVDznBLdW7cVwvjKwu/DWnWUF3HZfar3LyvFIWk655XoOuMjrVHXdTv/FupGe6ijE+0YhjBG4DnA96XxDqsmtT28N2imW1jFtDIM7yAePMJ6sOlelhsJOjUjKXXWW7d+mt9r+R20MPKnNd3rL16a3MqKF2Rpw2WDHIAwRgU+B0lvkeZUCEbcYIA9zTcPaySJNHtnDhzvzkcdMe9TFp9lxKUVY8gSFByM9Dj0r02z0+moXF200DxyRRmYHaJtvKp/dA7c96ZaSG2XzIW3M6GM7xxg9aCvm48kPKEwQ+PmPHTFNZRvXzBljkYz0+tJJWsVGIRHEG92ZnydgDY256mmptDRsY9ytyN3RhmnMxC7CqxyM2GlPJUegp6qXtip+RUICE8B/Ue1MrUmkmie7lZkKxt8/lKOgxwoPYe9WNu9Y0baLiXBB2jPPbnrWerSp+8JCdVGOfwzV5HmS2ieUARhg/P3gPaspxtaxUXYguI1UzGM70JwCT8ynvnHalKuwAiUKM5BYggY9/Sn3DCa5ZLaFod4LSybs8HnBB/lTfJwUWZ2IlkBVQMYHTkUJ6K4kKFkmyhK+YhJzjH4+wHNLbgsZTkFuRkkAnuD+dXLmBN7RQhmfhSScY4xj3FQxxpGYnl81sHDBMDOOD+IqOdNFW6oAViVfkIkQspBxvB96CGOCYSZJFxkN8oHf6UCSGLzMSTF852qowx/2j2FLKoQq10/7phvXysZ9Onb8aRV7akUUUjgu48wxgr8pwR/hUiAbmjUESZ6n5Sv0OOfrU22S4hh+yrLIAD8oOFQngZz1JqP7PlAmJAWzsjJyxA4J49MY5o5r7mfPG+5HAyxSs1xG0ythA0cmGA6kg9s+pohQyvIVePcuGJJ4HoOageMCRgrGKRu4HBxxT3VwiqqqRyTIBy59c/Sra6oTtF3GTstxJLNJIN7tgk9PwPpUsluWhFwN3ykKFAyF/DvUKqht9gR5A+cBm2lfQ+9TW9wsL+VtZAhy3OQPXg0O6Xuisn0GOkjSloGwHABfsRT5fIhJlg3yxABuVKkeo/Oo/kE7kwqwX7qAHaw75x0p4dIpl8ourkZKb8fLj3oIs73HzXUhnWZo48LjCntjgAj9apyytIXlYO7nIAJxxViZlDrJtDAqVIkHIOOvFRIFDEKJPKU5Ksozu7DNOKSV7E2IoSEkjLvhVDAkndjI/UU1FLq86q6s2Bx0U98dzTmt2SGRmwjnJxuyXGep96eWCfLI/CjChOEJ9SR3rS/YPMq3FuYyyM4ZWALkYH0qWBBEimMDLEI7lQdv0B9uaRChUKwO9SCpI3MDnpg0yJt+1CSQC0jEDJweDmqd2rMTsOvmjlvJpt2I3dmRRjAA6ZHrU+nR2simS9vGjeGBxDEI9xds8JgevqelVvKElsZdpYeYFKKMcYzVySaOa+nezV4YgQsLY3NGo9f15qZbcqJn/ACojgj82KSZ5EjdFLbXH3sdB9T2qsGidnVR8gP8AFgsc+pqdk3QuQn32x19D19s/0qGQkxJGdrDdwwHI9qcRWIXw4eP5k6ANjj6flTkVVAjUnbnIZhjd/hSoxdpH+VYuwbJ57CpbQIJXinl+yqw/u7hj6e9W3ZD5eoxoFWVkunaNxlSsinj344IqWzUC6Ekd2jFOVkuY/wB246Yx6emai3qWjBmLNGMCTaflH93FPtmgBKXnnvDv+fylGT6cnpUu9hSTtcdPEcS+WhguC2JIgdnXkbR3FFMuXSUqUleTcAwEg5jI4xn6elFON0hJOxduxCJrQ26PKJYw8kQXaC3oPUVX2RROztKILpGLeUBlQOwB9afOg+y23lBVuAcoY2JYqexHrUcckTWc4ceUVwAAM7yTznPSs47FR2JN5uJt8tu6yyrk+X8oYD2pgUbo/syOZA+Mk9M9OlWLqSSK2gtbiOMi3/eLID1RucZHap9HlMeqpcnZGkLiZoFIAZRztU+vapcmotoG7RujavdQ1S30K40eGXyraz4uViOTKze/90egrEfSJZ7+yisCpa5A8hM/M+O+3t360kTs8rTTByUBc7iepJK+5r0j4TwXWsXdzr2rTQO8BNtCpiUMrYGWPfpwK4K9X6jSlVSX+bf/AAfwOSvU+qwdRf02Zvwi0i6sfFuoPq1n5d3DD8qyY3qWYfMB6Y7j1rg9XtZbfVb+3nWNZEuXMgZsKDuJ4rsbQnwv8Trq81bVlkhjaV5587i6soITaOhzjjtiqXxE0+WLXvt1sI57LUyLq3fdkEEDj26/rUUKr+t87ek4pp6pXXRX+8jDzf1hyb0kl+Hb8zl/PMhWQh3mZgDI3zKR0Ax7Cl1G2ltNTubRpdwRgGMZ+8OvH+FOut1vciOKQeRbsEcowADHr9eeM1BJ5S7tjNgSE+aOuPpXqR3TW39f1Y9SOuq2JLyUs8bqqRjaAoQ4ZMcDPvUNvJtkVRHubPfqTUhuD5LrsiJOGErLlwR6Gk+5OrkhifnYq3rTWitYpaCENMYimQzfex7Hkipn2jCzKAIAQ4diC2en+NNMiMRCszFG6Erg/Q0RRDznjlJTIyJSM4A6YpPzHe+wxY1CcOHw21Vyc1oG2vX08NEkzQpJ5ZcKSM4+6Ce/tVaKFIimOVZxmXb9ztk+3NbXmK0LJBLcLEg2IJ3+++cF0UdP8KxqzatYb006mO8a/IChmkxgjJyPr/jUtqWileNowru+1S7ZOPrUtvHLLbP5YZGUZZ1GVdepz7e1SWUieQD8u9M+WGXj6k9qUpaNDVrkRmId1eR4we45z7mp7G4SEPiBxNICsbo/T/ZAPTnv1qx4fTS/7eV9UZY7NIzI0ZyPNcAkIMdMnFZ8DEz3E00QBMh+RPmAB/ljiobUm426L+v8wc1JuLRLb26xwFDJtaUk8KSFYnA3N/CPU1RdYo7dJoQjhGZWZgeT06nr68VaiillPkiSKNSOjNxgnPbqfamXwY3ECPG4khbbhgdye5B9KuL97VmU4tS8iCIqkkcItSrBesbFnKnrwTgZ61YaBUTIlgS0Dkb5G+cAHgELnH0qB5PtdxI7RFkLfNJuIDemeM9afbW7SJHHKYwf4osgc9quXdiUlfRiPLHbqHjdJNy5YPkAj0x2/ClSaUxOkcKEOmRwCR+Hbp+VSmOH7OywMsM0bhM5HzjncckUklrAkIeONvLckREYGSDzuPf61N49TOVW7siBbm/MJU7fKHzAGMZHPY4zg+1WZ4gI/MZUUdf3bAgezDqD70wIQmZInkRGwhL8xk/3evvU1xBHO032adZAvI3qRu56D6UNq+mglJ3KttLIYXE+4chwccFT+nbvU0drayJNvMwKMGjdgD/wE+naoIwttdMXZnYjLEDG04747e1S2klvlRIz+cvAcjcGz/nvTl3iac/RiAoxCXau+MlMjaufw6moYi91MSFPHAKHkj3q45jESM74xtWRCPlTBzkEevTFR3VvFHCjRyyIGO5lwFXvgdfX1pKSHdX1I3gRY0AIZlPQ4PBzn6Y4qhAFcEMCCv8AH1GR2xW2Zitp8pjy8ZXDKOPUH6/nVRiHVgjDIIZiq4wT1OOg69vSqhN63FNtlB1kQPK4LSH5QW6qT0pChCMAvljdsYZ68cn9attGRcbs53Eg44yMdie1QtJlpW4EZcMpJJ2/TNaKVyVe6ZPaxwpqaLLPJHCFPyx8HaOdo9Pxqsn7qSVIXYFyCVyfy4/nUxcIhhAkYkEMEbHB7n2xUDOwKt5ZOPkyenTtikk7kqNyOJN1z5bskERYZPIC/hU0bQLeTIokaGNG2/MVyex/rV7S7k6TbyXk0ckodGjR2GQjEYzuIwCM+9Z8sMgtkkORESVDvnc3f8sU+bmbT22Jvd26FJiwUKshIA3Y6CnK5ELKR+7Y5JK8lh71Zgt5pbVZUgKwxth5wNwUnkA+9Mk/e3S7gXUjZGG+X8eK15k9DZMlTMUCiMzCSZflboD2IFRyia0aYoZVUt8zno2PX1pbhkR0SO581Yn3KpBwMdcexp9/O1xJGs6ssQ4CJzgnn8TUq9/JkEETvOUhUYQ/NgjjPrmihk2YOZBKAQV6FaKqzfwuxLT6MsQbQ91C8sW5mwJC3y7h3pYy00zK21VcDH9wkep/rVdY3Sby9g3rhghGSw9KlZlDPujL7+cLwQfSoa7FpE0kMS3WFy1shy7QD5QT6E9qSLHkL+8LKCQQTjp90fjTrlJE063jlXam4mMg/e/+uM0/ymmV5JFO22X51B4CjvUX01Ytlc6J7jTtBvrTy7UX13bslzcStICu/bkRIPRT1J7irvhnxl4huNbitLFLRWvLzz3jEed4YfMCewAGc9eKp+HfB1/rWmfarAbreRTtd8BW3NjA7nGDk/lWv8OvD17beN9l+s9tLYoZMKQA+crnnqpz2ryMRLCqnU52pSiuv+XqefWlh+SXM1KSXX/L1GfGGDS01hoEtZV1CYC4kuS3ysMbQmB9M1xFtqU7rHCbufNqohhySVwOgHoPpXW/Ft2vPGcqvGLcWsKIH/imB5z6Y5wPpXEmNGMlwm3kgAA9D3yK6stgvqlNS10Xn/Wh0YKH7iDfYtiWPyrg+WpupWBQqoKDruJ9+mKQRLPO24iK4EO2IBd3mtnkZ/EnNVbl5LZI42iIiZ9wZ0xnjuKs24w7KLlYwEPlsyYHIP8A+ofWuxqyuju3vYqtGpLMgPKZOeqnociiFWLMgOc/KSe3tUkP7tT8zJIPuDGc/U0pjXa20ENnJIGDV36GnL1GEW+5ow7yKPlUlefwHariRBmihkYIh4yTwce/brUUUaxjzMZUDOR1HrV12IwXDCDAAI5brwTispy6IcYjljhilCsfMhGMbeMAf096haNYpWjlYQyFtqh0I2KeR09akSE7xLjzdoweOacz3EKOkryOjOBh+WB6Dn2rJPXctxtoiKe3RoVk86FSH8t1A4IBypB7+/FPlVZoEmEkcpRtnlrCVG1uc+p9OaUWyTzGFGSKWAb2O4/Mc4Cgf3s+nFPtw9tmSSNljGUJI6c+3ejm89TNbjFiE9mWhjxEh+dlUE46YHpUaQ5ldI5USAEZeL94NpIzz+PXr2qeZIN0CNIZJ5A29EUgR89B/eOOv1p+mTRrer9thV4lQnyEyhbGQAT/AAqOMn24pczSbX9feROS1kVQ/l3oQthQu45XBVR0xj+dSpB++d7qZ3lYsFkBJDdzyf51CitMzLHGgOCXPUH6iiQ4kAjkKRkkbE9B/D9c55qmuiMZybY2O3eadpPJMcgJZRnbtA4Bx1AJqWX5ljk+zqiYEYI5csOM5HU1EIpBLLl1RlKhVfnk84OexHc1r3UbW0FqjpHHtcksoHU8soAz6+lKc7NIz6lJUjDvC0vmbM/Mi5Dg9OSOx7irU8NtFcxxrc/aovK8yYxx4SMk4Cju2OOcYPSkkuIonM1vtLx7STjlTj7p/KtDUrVYj50TqtrcQiVVjfzASOqk9jnPFYSnZq/UVtVdmQBFGzSRz70y26JFI2AdCeO/YDpSQtF9phhiMUGckSMhfaey+5/DvS2zyCMSQK+xlMbSbcMvPTH0qxabLYuk3lp8uxWZGbJwTnHc9K0k7XHJWTZnh4ftc4lMtxL0HAwzY5Pv0qFjBI+Y5/33GV2nZwe3ofrVveqvG0MXkwhw+8AHkdcZ5yOuKu6pEt5+/iBKlQJZCmC0mSSdv4ZFVz8rRHM4synMZd5F2Mj4IDfw+59amvH+2BVkdZIYEGG2hdo7qPWorjzFtI5Y4sGLImAG3OTw23GQDnBB71OyRfYkmjxGsUyhwzhvMUrnOOoAPFU+jNee9myCzt2MFw24btrOAwxu2+/rVdZIzL51vPHIsg3iQHO4EZHA/LmlWXySGjAkCk7+wA9KlkXKsrqFZmDAhPvHrjPXp26cVeqd3sbNpob5oMjgIBMuMcdz1xn8KivG3NHHEql4sEuT82c8/wA6mliklgUpmRCdgYt0br/SoN2d5CqZN33y4Kuf6U423Mr62FvFXzYopGYM+GkyOhPQfrmlUCG4hELvbq6lJV3fKOoJA96WwEKSyveeYwdc5hcY49j1q9ZW6XF3HbLNBD8rSNPMQcEDO1j79APWlKXKrPZClNJamYks8Fiba3kcwuQXUngnPcGia7e6kj+1XLXNz0LSNkgdMD0GMUySZGk3srM2C+x+FJ7jA7VZhWy1O2R7ewTT5ySGQXJZX4/hVuRyO5PtWjtH3mvnp/w/3Gcmou9ip9mZPkZmWJju2HI3EdOB/OoXjZoucfK2WYf09hU7DzJS1urCTgMrHB4649qm8gsJGnUgLwcjGPqBVc1tzTnK115LxW4S3EDoArMWJaQ/3iOgFNEjwhootsbCTcsg7cdc1NPD5YOFyAA/+FMADglI8uODk9fwppq3kF1sNjMDXu64uHMZQlpFUkl8cZzzyaKLbzC7lcxp03soOPeiiS13/r7iJJ30f9fcWJpZgLaYpGrK4KiNPmb606eSRolVYTGEkL5YZJY9qtzxvp0qxXgZDcRhiIW5TjIIXPp9KimtXEUckQZ45DsEZYFgRjJIHIHvWKnF2ZcWnYTzBDiBId05ckhxxgrjOeoxmui+HWjLrXiaOO8iSaCFfNlVhuVwOAD+NYui6Xca5qiWFr8s8zFmAbhFHXJ9BXqln/YPw/XyftTXOryxBHCLknqQSB90Z4615+YYn2cHRpXdSS0t+fkcmLr8sXTp6za0t+Zd8WeMbLwfJDp9npwmfyy/lRERRxjsOnU+npXK/wDC3mae3P8AYqBh/wAfDedkhM/w8fTrXnWr395qV/czzHMsjl3bGE3Hrx6cVXtyuA8sYSeRj86jAA9APSpoZJhoU17WPNLq7vf7zOllVGMUqiu+ruzb8Ta5ceKdWuL2dIYVjHlQKhIJRTwSe5P/ANasuLyEEIuVZbZmyJVUBuOuKZJuZQr4IPzYX681cdoEgubN45GZ0XygHztb2Hoc9OK9KMI0oqnBaI9SnBU4qMFsQvM8qeWJZRay3GWlZQWUDoc+uMU6UMkP2dwXSJmJVmB3HseOSfc1F5rPMhMYl8sBSCMBgPXHpSCI3N1DbxCSWZ+SoGDnrgfhVcqW5pZbsdPcsiqo8oKQOiAYz0BOMk0y3xOHTB2qc7sUpKwbpHjZnRtuxgCM/TtU0BEcZZ8hmGMk5H0xTei0Gk27F1YvLZNxRZCOu05AxkEUqARp8oXepDY7kUlqQsWWBkLKDkDhT0xinKNvmBgSxGcjr7YrmfmdMY6Fi0heeTcGMQGSXyMdM1U+zMFhwjyRyk75HYcsOef8au2riJ28xUQyKQrMM4yO/v8A40g3IS8UcaqY9pZgcKv+NZ8zTE4Nu7IRK8igYIk3580EDI+lPeWM2YVbgK+0hVGCCwIyOcY+vtUacpGygRqHD8rndjGSR39BSXTRSSzNaWxkjDHGA2GwM9ugqrK5jJW2Kt/vBR94Msn+rkT5cjpx6D3qqzsFV2y44ckMWLAHGD/PmpZrlvs5Zdjqny/f3ckZGPpk1a0y3ilE5O5ECKA3YZPJc+vTgVvfkjdnPOS6EqshRVgXYu9eCmN/Q8+v0qS7EbRMrKkDFwVYjkICRtHf/wDVU1oSB5dqwlfnhlPy89B6nHX0okilkZli2vldi8ZbHYAdxnjnmubm1Jtcl0uzUX1k07sbZ8jaFDbVzmnzW7WsxlD73c4IQf6p89/fj9algmlXyoNPjuFePMkyjOwGMbjwOrY3dOlYs95HMVn3Myvncd3zL+eMmoipzlfp/wAP/XmTFXl5F9FuLW0uUZYQs7gBWfa7PkZHHTPvxWnFPbxaFb5Eg3bhJF5uSxU8MOOhzgD2qtLcQzyKrjdGTHtltwMye7NjDYY1r61pVtb3hsrcrLcMWTr81xgE7EA+4SeMe2RWFSabSmtXr9yMpyV1fS+py9talGkDPuaJvMwcsHB7H8KkW7kzLdCOMsJco+Sw6Y2sPTGaFSGIOWmliZWJG1S3UfdI9R0z04qNlXkpGjAkDaPmLEDO4jPP/wBeur4nqa6MsWceI5HkVAkKeYW3Bc5447Y7flQ164m+1Wc+Jo2I+fJZlxnLdjgcU2JUuF8hIo4xtBUsSwZ14Zs9gB7VVaQwh43P78O/UfeUrjkDtUqKk3cxa30LepXIBkZWQPMPMhkX7wXHGffOQR0FZ9hHH/akYkYRefIIGJUYQtgZweo5zS6hePuLkBkeJI8427sAA/yANR2LJa+ZEWjDOu0lgGyvXA9DxgGtYwcaf9f1oEYu1izJZiDUbix8xJBayyRtIgGH29AM9ScUXytgXUNsyxCUIBuyd2M/57VXmtjLJHdxRvBFMxjDK+ApAy2CfTvV+0SS3jwjbYUj8wgPnGeCcdM4x60m7Wd7v+rmid9GzJ8rM4R49isu53Q5VM8hfb/69KYoI0BhzcBk+YIMBCT90nHJqzZlX89JoiIFchSvBJHU88fnRLcLH9niS1kJSTzJVkmB8yPsrYHB9Dz1rXmd7BJ9io7QwJGnG4jOTyG9iO1XILuOeBYvs7YQ/MY8g477ezZ54NQXk8Or6zLJpGnNbpLKiRQKxb079/8A69d54y8N3Oj28ephohJ+7Z54SI2imB6qOmOnTnNYVq8IOEJ6Sl59fl6/5GFSuoOMZbyOPvILQ6v/AKFKJrOWP9y4UQ7n2ghGzwpHesT7TcIqtaQvBdN8y7ByMdMEDn14rc8R3zarfbXlE0Lybiyxhd5wAzMB/F798dKl0VoLa4hupLe9vo7bIWBc4lGcYX+6qjknvWkJuFNOSu7bf1ZfgvuKtKMOaS/r8P0MeaDZPmM5jKAgt1GepOOhzmnCZWxJxuYbd+7pjt79etdhp2nWutC7vPDdrEbJMtNb3s6nk+gB+6McEmuGRil5cxXUqtJ/DIO49u1OjVVa8esd11+YqdZTuuq+8mRkyMxR4X5f3hJx9P54pNhhMpdgQgBwvzZPp9e9QGRXy6t5qo3G9cA/hUbzOsqvBGHRmwwwcDrxntxXQos0k+qEeRFvJWkieTZkYduOnB/Oiu0tfAF5qWi2WoaaDumceZDP8jhc8up9PT2xRXK8xwi0lNXWm/Y5Xj8OtJS1OS815B5bpl5CMytyxx6egpfMKIQkS28gIDFTkkZ96mtYJbmYLArfaE3Ouxc8d847DrmrmrQywxWu/wAtBcwicM+TKVyV+b0GQeB7Vu5pSUTucldI7LSte03wl4OsdSstPin1S5Y21xKAcKRk/MfXGOB61w8eoQXF5Ld6iZ45JSXVbdfmc9ec9AfXtXR+FtA1nWfCt5sRHsY286CKXK+ZMBgsuOoxxzXKajbraXBtpbSe3uISVmWWXczH8Pu/QVxYWnRVSpFO876u+tui+WxyYaMFOaTvJvXXp/wNiHf9plMqqYwTvwfmGKmtV82ZY4/LiL5+aY5ViBnqelRhdwYuSigYBDVJNbE28RZCJX+4Afl2+oP1rvbWx6emwSxxtI0dtMJpiPmf+EsT0X09KZJGY7oxyYjKMMhicg9xmnqYd0fmqFkACOqDGD6g0QQOwWRTIilyoYqWDEnHHr70XtuNWRGzGCfG7cVY4dW456Yp0m8o4lcGSJ1/dbc7j65FP2ETY2/dGCxA+f8ADtRCo2GKR3+cgqo6H0z/APWov1H5jJWluI/3iMkK9QgA2ntViCNZ7cODtkA2qq9cZ6mqqo4UDafKLbec4z6/hT0JSSRIjlU+ZCVwrEd8+lJrSyD4S1BO1w6BAdiuA5A7e/5VMi5cszNuQbdvT2qmsyxphYg+QADnDepNXyrSrnyXRdxV2cZUenvWU1b0NYT7iqcAMYvl+ue/BBqW7u2UxfMzuwJkVxjB5GAPp0qtgG4iZw7QlTkocEdhnPvUjpKEHlBfMZsq24s2O+T07VnZXVzSbTHJBcSWonaOMx7TgM2BycA479DSi4UzRxh2VIV8kwxnaXUZO092z3+tReYWmt4pvNIiQIryElIoyTuVQPUnNVr90h1T9yCIw7GKQAq3oM/hTUeZ2ZyzTe+5BayQuXWRASIzIpHRe2Pqa1LBw8BtkaNIyNxVlzsb3z9OgrJtoxKHWGMbrlo4zGpJwd3UD8q3Lm1a0nt4RtCqgJIQYJ7knrVVmr8phu7FmzjjWeBmMKspZTIW2glhj5j0/wD11FsiilMkTurRSgny2Hz9OV9+e9acNpHdWaqssUcQgJffEWaUAk5HYt/Kk1nSLS4jjvrZ54oEgDIrgAknkjA64FcKqx57SZPtFz2Zm3sMtvcKEklDhfNjwWUgt3x9MZxwcVlhWnnjF0qrGc5dUAZfqB1966Bljka1llnGxo1TfE5LYAxg+nfj361n3U9mXKWdsQjRCMh3yxbpu9O2a3pTe1tTVNNWsJbTPFaPcod8UKfZ87OF3A9PVu/FaXhqfSVSW61J72HU0nDRTpMeIyACfUHk81iQmQBCrxCThge2R3A6A9PyrRaFArmKBhG7kq8gUs7qMFOP4efzpVYJpxbtfsY1afNdN2uVdYWSHU5xH5josjBJJc5aLqDz1GOaz7a5jDFodxVSVRSNme/OOo9a3L9XvYbeHz5t6wkRZGcHJ3b2PJ4HH5dBWUsLyCBJtrKU4J+uM59q0pSThaRcbuKT3Ltr9qluY5do8yGQFWUqBkjoR6f4YqreSE3URAB5yXDZLknnPpmnSxxW8pdZJBOYt6o7hvK5AGT3yM1TaZ7iXepECuQjtg5PYkU4Ru+ZbGO+o27VGkEMqhmbHyK2AVGSqn0+venyFpGed1jUuC0aDkg46Y64AFRmOITYjj2hML5jOcn61cuJ3kkWJXha2iUp5sS4MpHTOefbHtWrdrWC2qY8SS3dgbfIltbcbtjAYjyACVHXt+ZzVKO+M1w9qsrJKykAKpJK+o9BVq3jhZrcw/JOMtKpQ7c5wMgDJp+m2Md0l7bxpb/aYU5u5pPKC88KuOucVneMU7r+u5V1BXK1nbSzIrYQiP5gZJQuQDyMHqx9KnSSW4he5vIf3KuGkEAVFXnAVT+GOKWYf2jPbAWogFupDPbElXI6EjHb9etK0VvdTWUNtqMcBkfYz3jAAEY5+XIUelDlff8A4b7heclY1bS5bRbZNU0mTTLhpEKoWlCSW4zkrtP8fJGec10Gl/ERWtZ4fFcME8Hlh0MK7mk5J5UZAA454rh9Wt4rW/Not+mpQoxVDbjAz1I+g7kGm6ffXGk3bPEls79VMsAOAR6N1HOBXLUwdLEQvJXe6ez8ten3fiYzwdOtG8ld9Hs/6+Rp6p4hg8QW8VtHpum6e6sZFulynB/hPGfqT1xVgX2p6jZjRtPFhp08eLcTkY3q+cjdznI+lQW6wXV9Hq2oXE93YpIJbuKKERKr9ojngjA6CoG1uYa9qFzFZPpySOskOSAI4uwx0BbA+nOKfs425acfh112T+er+7b1IdNfw4x2+5P5np/hfwDpWlaCbW6t1kuZ4gt1IHYb8ZIHXAAzXj2qWO4LLaqxvYS6yInzKgHbI9jn05rT8TeO/Euq6dLbh4rO2PyMYEKmcHtuPTjrjFctb3Ja4jTBWVUEKJ90DHTofmP1p5fhMVTc61ed2+m/9f8AAXoY4PDV6blKrK7ZGRILcK2QF++PRa1dK0lLm2eWS4t7e0VwryuThdwyPl6k/Sq0sAKMHZDcP8wbJOR6YqzeJdLY2T3EMkdqVY2+8BQ5HBKjua9Gc3JJRdr/ANaHZJPZOxteIfGWo6jYQ2Fu8dtYwoIwbZiPOAGBnODjjOBRWFaW8lyJUg8oLGu6RpSFCD0Ge59OtFZ0oUaC5IpIVOnSorkSNPwvLcy6zZWti/2f7a4tpinePIzz24zV34lX1rdeJJooLI25sv3DMWLNOR0+gFdXqMv/AAhVq+p6nfRX/iG4gRLWCSIL5Y7nC/U88ZxivLnllub6W9uiJJp5S7uxwCTya48M1iav1hL3UrJ66vr2ultr8jDD/v6ntktErer69tOmpYW7mlt3H2iZSPlCiRhgfgegqD7KI5GUF3jJJEr5BZiM5qS9+zrEPIUASDLgEjb7Dv8An1pXunurdZLoCN4tsO9E+VQOme54rvV1rHY74u2xBLuWGLziDAMDK8lsdTUjSrLGGVP3MbbVGTuIJ9TxUz3cUljH+7QTWh2QtFwrAnO5s9afbxXl1HJIp2QsN8m0Bs54JC9uwpOVleWhqrpEbJLf3okuIpGlk4yD8wAGOvQ1LHFqSxlbe2vWVNzErGflX1x2+tQi3kidkupZrW3Ubk8+Njv9uKDc3cTfu7iaAuu1mRjh1HIzjmk7vSNrDd2vdEgaNWDo7liu07uM+tOJWRmJKqy42hgRj3Hrmkjhije7czylIlG11Q8Mf5Vax9oVZLZS4JC8uG2+rH3pSaTuPm7lS3d2upBITGAd20jg0O6SXUs8sjcggiEcYPHFFxAFiPmyCVfmAKcbjVllsmt4wkUoQIol28Zbsi/X1ptrcau9tinBEwVym5k2/OFwSB/hVi3uIvtCySNnOT354wKdHbud0MrSrHGSH8p+Bx698VVM0oYMMN8oCkccfgKPjuGzsjUjkMSCMWsbOZfMEm7Lbsfd+nINOBla3inMpWcSF9+CR8vRce9RTENOzxNvWQgMyc4PbJ+lNeZ451R8KYmJ6csCO/bFY2vtubRSaJpmUQNE7iJXUON/8XPQH+vTFUDMBHOrRq6vCVVnz8rk/fX/AGsDFWpyskWD5pgztBxkbj935qv6pp+kW2lWF8t35t68ix3Onbv3iOARuz2GVzQpqFk76v8Ar+tjGrJRtF9TE07Kzx3MwkV3J2SJnOMY6etbF5vdRIFK7UwF3jkZ4OOxPUisK3jKMxneQiM8fOP72Tj655P0rpZd1xF5r5bzoVKSbBlc+p/P5qdfSSZhzcrKdrNKs6eXJuBOchiOnGAPfJ4ro721hk8x7qS3jtopjFGokGHkC4MZI6HPVj06Vjw25sp28qVFnC7kdEzuP97nnn6UzVmjV4oEsfsMoUvPEG3BpDjcV9jxwfeuSa9pNcv9f1/VhSvKSsyjfXM80pW4uS/kDC7CMYzwB7Dpmq0zE24KlNpG0sF7npUpt5ZisZjwJORwPmPJwfTp/WoZZGhx5YAl6jJyUGNvP612wSVkjVyjHRF5owY/MjYGQSBGHlkh8989h7VoWk8KqpijkXyj5hR13efgHLHuCDzt9KzwHgaFJZmWFc7dx/1jY4xjv05pks0s8D7RiOJvmbjnPUVjKPMrdDOS5lozbe8jmtbg+bLPhVQiY4DYHBUDoBzWXD5SRRSrFE1wEdhkFQhJ4DHv2x9ak02UtBHELcpJJ8rynjIJ9PTHX9KtwWC/apllmit0xsmUrjywMZOB2PBrH3ad1/XboZtqG5l3lqu6FInYxz/O3P8AEOqt7jniqcb+YfIEjdSwdhkEjjIHbjtVjX52W+meJS5Yko+3YCcfexnnjpVUypbwjCjzUGHkX5sAgZU+hJJz+VddNNwT7i6ajX2tvjjL+UORlsliTwCe3JNO2qIIwEJdiWby+MEcbvQAfrUCktH5oR5Y1bOegJzjP4VYQygwrG0UuxmbypFO2M9fn9fX8K0asNKxq6LdMdZgBm8mPeGeeJgW+X15AxntTte1OylulTTLia5s5MtIZlCyHk5AOOBWQ6S2ibGiZHmGCcAsUPO4ZHH8+aqMrko8KeTCF+aQsGd/Tauc1kqEZT5/6/rtYbhHmU7mjb3kkV4I1DhX+V0hlKCRfTj9abJFHDE7OsZt9wLIUAYkZyoYdR9PWqSmWN45JH7gCTGWdSPT17VrbUi0uFZ1hRZiA4VgzhF9B/D6Z71U0otW6j1urFXRbCa4tbme4tyYY5FUyBiihcf6sN+Wcc1ZvjC97O8U4CPtYbx91T/AD6Ctzw94ms7DRLXT7/TbeeNWlcPL0YtwvHc8cmqWjfa7S6e6sFaS+UDEax5KMwPAQ53evQ8Vzyq1Oecpq1ttdH+dtvxM1Kd5OStbbXf/ACKhnZLC1gW38myjlaVXkVmadyuCSM9OgHH411tt9nl+Gn2a2xa7JR/aM0sBZ1OSGCBusmNuOwBrm7e4udOeeezlaaa1k3vcIvkSZcYKkN8xGcew9Kh0/Wrm2S5CW0tzFNuRYZ2Zthc5JT1brzjvWVajKqly9Gnv+afrfX7ujwrUJTS5ejT/AKuZbw28yPNZWlzJawybRcTvuxngAgDGT6CuyXV7Ww8NRafBpAs5GkIkM1vvk2EYMioeSSc4Oe1c+zpZvDFp8VxOhlUJDMrY8zH91euPUVBcxXt1qheS4um1eaUxJGQ/zZ6D5uQPQGtqkFWsp7LXd/iFVRqWUtlqRXrraGCIadCJUVl3zyEmXd912X+FgD06ZxxWRcW032kvOwEqAKgbhR9PepLjFsTbXAAnJy54ZtwP8qtQTR296JNQign0xygcFCxwCCSmMYbFdsbwV1r+vp/kVflWmpntEJbqJZSXVVBCoOMfh/OitG8SASG4sCURy2IACGWIHChvQY6DrRT5nJK10WuaauP1zUbnW9Wu7uSaWWOaTKtIgUMoJCgDsAK0vCNnZ/a31LVmt10i0Qu6MwzM46Iqk5JJ7103jDR9G8O6LpKXujtLrM+Y4o7GRlV3GDgk5J6jgD1xXB3U98uoTW02nwWs02N0DW+DED6FuV4GfpXDRqLFUeWiuWO19Nlo7W/PoZUair07U9F8tlpp/mN1DVI7ueRrS38qAys4iYg4zwBnvgVAjhp8SvLEjr1C5we3A68VF9oillnMUgMsL7HwpC5xkD9QadbEl0EatLGPmZAMZI9+td0VFR9074xsrIv6fJ50bRPLF9nYYEco2hvQFh059anWN4re7mKRSJAscbm2cfu1z0Pduep/Wq862AjLW7OkisSYJH28Edd3Q4Paq1pGJWhtWBiM7ruLcYU9yO1Z8t7vZBa+pqG6iuk+U6mNPtlCRs0qsEzkkEHjk54HSohDbiAoWmtLmPLESk4lXH3NoHDHjHaqnkSFi1vbGe2iZoxIsTEPz1OO9NxJGiXUyCVGYqvm5IZh7UlBLSLKUUlZMfcF7d7uGOVo1kOJIm4LY5/KrFtHEDbyPEVkG3GTtD8+nv61HcNE8EUci4YDJXdt3+h55H9afE0soCn98Yow7BnAKrnH4/TrTd+UbdlY9E1Pwhp0uhS2kN/ax62mLpIGYBwGAJjIzz7H6V5krtFcxySIUYOVZgcg+vHart8dPD2LkyC4QMZzjp/dYMTkn/IqokwnHmyOxlXEaFlAVR7r369fzrnwlKdOL55OSfdW/pdf8zGhGVJNSle/4C3M7S+XFbJjJEaRx569snuc1JNIYJIUnkEkMOY5PIH3hnJAPQmrtpFPdrLLBCkUtvbGS3ji6uxIBbnoMZP8qzrOAzJJ9mSWSbGXRQdkajqzVupRenY6Yy3HxqqTOW8wKT+7JAxgnnd7gYomywRDLkFRksS2PQZPekR4fLgtogkMCcm5xmQjOTjsafcyqsvyRHyjgh3AbeuOMU9blxQ3kSeWjSMp2+Zzg8dwKtvbQxzyFkF1KoUpMBsyo+8wB5z/AFHpVBZLddUf7PJEssak7N43qcZwVzx14q1Z3ruZXVtsjA4ZQQyN3GPQjPFQ7tXiDRDOIwxcvCiPuILfMM9enrxUunahNaRFPMaKF2Hy87Wx79sZNSKUjkLlVcvndmLKg/7GPzpIYWuLkIY/MMhJQYyrHr+vpQ2nG0tjCrHqX4fLS4jnSKVUlbDbnwGQ9SrZJB9KtzQRuZVkIRgN7NK+VHB5PGSeOK5+WdredVj86EQ7mMZUYiHcLn+tTi7tIIBBbST3izIC25GRgeflYcg4wDkHnNZSpSdmv6/Qxb1Ev71JLJTDEqhwBh87g3GSMcY49KiskH7x5d42BfmAGWycDHp+tJfk3IguWiJ343SowAPHQ++RzUChEzsaYTjO/PcdQFPqOa3jFclkF+xrJDbm7H2yRVBA3rksqk8gE+uOoAOKdtnubFlCkwRsQrMmNq46k9/x9qwjMCxcqVGTtXfjB9efardvcBUZggJXdtEg5OR19yOtRKk1qJJ7muPJit2kN1O0cTeSGiAA3Fc5HfA49qptM0KTNbyMpIJZ85Lnuv096oR3aROywRzOpJBUOV356gj8qZLd+bdNmCNcbuP7g9OOM040XfX9AWj1HSToQW84eZIMs4GCwPUe2DS26bvlhjcqMFyOdw/vU6xtPOVm8uVm2FjHGpOxfUkDj8auR2U0NjNcADyFCrvT5i7ZwEDdB6mqlOMdB3S3I4lV51EW5AozsyM4P9antle31CVnIikj4M0Y3MpYAcZ4JUd6rpMY5o0SDdJKQsTS4Ozt9APer1o8EWqNKyef5AdZJfK3Absguq/dAzjB9qym2k/QibfQo3CMiO28nYpIk3Elx9fz4rv/AA7Fomj/AAya81NLa4M5JUmMb2bnavrwcnNcZqm6N83t4Li6nUMozhkB+UhlONrE849DUUVuGhRtWu1is7ZiEto3Ds57kLngeufSsK9P29OKcrK6enW3RddzGvD20FrZXW35ENokchxNFIJAA6+mOTjPpiklnAELlVZUhwARnBPAPPfpU0kbSS24hlSWOTDII3z+8PUEjjIHWkgsjrWvW0ERihV1B8yR8A7euPVjjpXRzLWUtjeMkk2zat0t9Ju7P+1IpYka2V0CokrynPUZ4Ga0/EWtw3tnBcaPqD27M5D20YH2pNoIA3DouOvPfvVS+tDJNK0Dm4XToP3stmVDKn8AcngMDklRnpWRDcR2un3EcdgJ72UEl5Ad0CAkkgjue+a4FTjVaqPWS/XyfyZzqCqNVHq1/XX7zLjMBkd2BL/eLO+ST9a3vC2kz6/qUuZM2yfPJtk27VHYZwPwqbwroDXm3UL+WaBSw8jZb+ZvJ9+i/U16TqmoeHfD+hT2M00EUHltG0ERDuxI5yBzk571OOx3I/ZUU5SemnT/ADMMZjeV+ypJuTON8PnQtOvp9TivZbe2MTx2806qSrK3zqiLnovG49c8Vh+MPEiaz4kS6tlmtYEgESSSDa/c7hjOM5wKXRNH3XclgltZ391DCD5F1O0Ekh6jy8ccLjIPvVXw5os/ifW5luGWx060GJ3TChPmPAJ75yKuFOjCpKvUk3Zbu2z2st9fu7dSOSnCpKrN7Lr2/M56CO6uLFZre2aa1icxSTkHAbsC341PJaCGFJbqZX2nEUeT8/PIUdQB6nHtXS+JteWaKHRdEtnttOtj5caKN8ksgPJ461ypKvI0cG5XVTvkLAAL7k/xH0FejSqTqLmkuX87ef8AwPQ6oSlKPNJW/wAiSQtJPItqIcjB2rzsH1z6UUy4Ajkd1cLAWBWLHAHp79KK1SdtC9XsjrvBvjiDTrC4ufEOoXOo3UR8uytWi3MnH3t5Hfp16etcw9/NqN1d39/GDevlmkzhMY5GO56YxVaYLKkIEg8okfKRllH978BUsscEt+LO2CvbJ8qHdjzT3cnsawhhqVOcqkVZy38kui2/4PUqnh6dOTqRWrH30MKxQy2cm+FEBKO+XDdTkD7oyelOSyifSWvE1GJcEmW3YFCG6hVPfimaSqyPI04gaO3TzTE5C7xnp6mq9xKs8kiysIrRcyLD0K5PCj1rW0r8qe39WN7vZdCXTppCC4ZwkR3MTF5g29qvGO0mhubu51G38y5dVCtGxI9WwOw4qoLlLeURW1iYzhdyPKSCOvY96qvNBLPK7xxxLM/3UJPlDPLAd/Shxcndafd/wSrN+X3F8iCPz/sE17M5QgNDGYYwO5I5yMVmztEkKl4t7yAMrB/lA+lXftqWt5IdOheK3wUUyk5KHjJHTJp0F41uHtrVI5Enx5kksQckjsvp+FEeaOtv6+Rok0tBtpBKmTIsZjkUbVJVsn1yemOvrREyrdbTI6k5ErKpyoB7DuP8KqMZBK8jbYpGfARVwR747elOuWGXw7GTd8xzvHvyepquVt6g43ZrXAtUhlfcJ4tw2yyLjOehx61StJrZ4ZXs45CVXcQ6EAjuSDyBRDIsdy8WDuXAGFwQOvT3rVhubS50WYXF3cC7im2W9vnKShl+YEY+XnnPPoKwleC6shvla6mXOxkkjuJBK8zKEJjPXjAx6ADrTE8uRIQyzrIHAWNAMMM9femysYnRWiQqgZdiSeo6nHepbiaFbqIRySrAQpDquXUDggfjmtbbJG0bNWK5YMJRGRHvOPNYZwP7tRzAbC6ncgALHGMk+1W5mWKwt9twiRu75RxhiM4Vj7+lVUaSRWeOQbQ4HLYyW6n9KuL6lJks8SW1xgyQ3Mz4YMqAbhjI5IyQMkY9aS3dvMieV3ibd8oUYyaVt0cfPlSMgACEAhl6dR3B/nRexKkjKqONyiSPe4+X1z61KtsHSzNj+0mOnQWUdtATCxlW7QZl65IJ6FeTx1qvEuyVN75CESHHXPXO3071VKB0TzTbKgXMYjzubnB47VOswMbi4V2ePBjMhz8o6Lnrg1jyKPwmbXLotixdxvqlwxuru1i1EEqtvcDyUaJuQwfpx6H8M1EyTnTTaxbpIw2S29cK3qD1/WjTr6xfVYLjVbD+0ojhDG0nCEfdC8jIHAwewqzJeQsHgl0aO1LEOrwsVA9SOcMP8Kh80Wo229Pw1vp/VznS97ltp8ihkSsqRhMgbnwMNwev69BTJEJJfAcFSvKksR7U+QKGHEn90ggHHoQc9aafI3xbbZ1VSQ5MuCX7MDjitV5FyulZESxoYiSrRsEyqKmDj1z271TkjA258x+oUhiOPbPbPWtZ7pxdSO/Ep6SMqnf+f3ual/tWcw+QspWLbsZTEij1AwBx9RVKc1svx/4BPK2ZaWzJISZAy7cElsBT6mtCOwNmq+bG7Qyj90YwpDe+7pUJuis+3yUY43K+RlfUAHg1DNNdm4kEHzbh98v82fcDpQ+eWgPR7GpHe3v9ntZRFLWI43xwjmTHTeerH8ce1QtJDMztdXM1xecRxJt+UcY59OOmPxqCzS7fiSP7hzjeOT/QU+7Z2u2aSOGB/MCmNOFX6Y6D3rJQSk0vwFyp7Iri3mnvZWuRIgiAGBzgAYAJ6dK7HSPD+ot4Zu7+S6EOkzqVeKIZZ4lP3hgE4znj2rknZ0vGguNzdREU5XPfPt71c0y+vIL+0a0vmtUjU5EkxCNz90p0wc9KnERqTguRpbdO3b/PWxhWhJxtB/f/AF+Ikl9erp8UcX2OWK4MhxtDTcDG4k8jPXFURDDukWSVp0bDqqJsJHcdj69aln2i6ka6jaCYkrtVcNnsMdFFRi7hRPJ+eXZjyXPykZ+8uPX3rSMbL3UaRhZaE/nrJYsySwxy26hIo1TYxXPOT3NXdPtpILA6qyeVBHyhlYfvJM4yo64B9O4p2j6Tc6/cwR2MMQ8ttryMCypn1b1wOBU3iqBrHVJbGdw88LqIpt4bKHjJUcKc/wAIrCVSLn7FPXdryJU1zKmnr28iK11cyaHdWUklqtrG4lSNkbfcSknOcD5jk9W6VoeHLDUJp/7KZLmOO5dVvGSMMYlxwrdx2yM1U0C2UXTW9xFIl0rrBbsrYEMpb5mJPHAr0a6uNL0j7O2haXJq1/DuRp7cg7OMs0snTJ6964sXXVJunTjdy16Wv3vt9/X015cVXVJuFON3L037/wBdTN8cXl9oUMcbrbfZZV8u1CELGm1RwynrnnnPoK4PQLKKW8g1nWYHXTmufLUxsV3OBneM5JXPH1re8W68vjCytPsenXX2izRpJXAyqAgAkYPTIHOK5uxuJri7WF5FFmqrCyhPux5yxHvknmrwdKdPD8slyy+13/DqycNSnGhaStLr3C5fVv7ebVtLk+0aiJprnOzO2MD757AYJqrAJbXQo4lZxPeAecWYBQpPQL6fXnNbHiJ9EDtLot3di22LHKmCwY7icM34dKy5gZUvDdoizzSK4dicgHk4A4yOOvTNdtOXNFNxtt0s9Nl6K5qrNJ27brX+kU2uJGvo2SeOK5kXYHiQrswMZB7cDr35qcQ2q27+WFdk58xuAoJ4Y++T0qlLbGGSY78yLt2EkYyT3qIvKFklCxqyZRlxknPU4NdXLe3KzdQvsLOykLG5kEcfylQM/iaKhZ2t4UNtvj3qdzo/3vbHaitoxb2NFDsaNxePG0cS2yAR/vYVUfcVuob1yKTVmje+ee1hhhtlZUAhYjovOM8+vNFxqElzYWtu8cW1FMam2AEhGOj+vSqd9DJEh2ndEpCMwGcH0PvWMI6q+j1KprvoPzGyzy5Cx7xiM/fI9j6VBGsaQkSqJJnG5st6/wCFNa6m8h4kcmPABQnAK55zx+lOhXzZE8sFmA53gBR+Fa2te5oiUNslVZIsxyruRd/TtuzT/LeGFS7bYZsr8vzbyp6CkmmmjaXehkk+VRIv3cAdMDtipr+8nuY7fdcFnG0rFEAEjxxgAd6jW67D1vYSO6lQMj7m3psIcBjjsD6c1Yhaa5hYRwNI3CqsCldh9MjqaiVjLDI80kYCFQIV+/LjqT647moopB5alBIFyXPzGMA55x/SpavstR7kt3D9kla2lVJnVsSyAFtjf3c9yKHWOKOPc28bs+U67W4/kDUawSvGxCzLArbzu7e59TVhIkkilllaRYpn8uMhN0kmME4pN23ZSdlqQReZLqCTzAs0vK55GMYyfYCpYAiwWx2bi7ckH5SR3qSaO3jlcQwbIsbQ80mWViOAccA+1QR7keRh5Ugjh+bqFiYnA+povzLQlxW5YuD8oUxpkfNnooJ7dPaq7S3EMOIt8UYOGkEY4HoT36VFHKjxNzvbgnJwMA9hUhljlefzMEYChpGO1RjqAKFG2jQ0uU05Ykef7ORDNK1uHnlkOSSRwB6HkcCs6CaV3tjbAYK5Xz0Uhie2P8aNP8wymGyREM8Yjw7BfMPqCe/tSWnlWxKvEJMERSW4chiQeecHAz+NSo8t1uND44S2n7/3ec7lzHgYz0B9c8YNCfZ55bhpLeaMtgoVYER59VPUfTFWbm0jaB54V8p4/wB3cwRvuyCeGHp7+nFVNsaiWNWhkdRkMoJB4/Qj1oUuZNopSuQu7pmLMbgNtG5OVP49KsW0xjmWFmVhv5QNhc+x6c+tVIwxnWOeOInacs7bVOehJqRHitkSNxgpIMyopKuPbPetJJNWCW+pP50q30bW0boQ3yAdUb2/WpoZ9sexWddpwxDD5lPJB/pVTzIlykrSKzkv5j8nb9feq8VyUkRkcqp4UhfpycUvZ8y2MZRuXnuD5DGAIqqQV+XBH4dKdHPHbusse1d6gFckA5/vdqpTyJskYSuLljuJUfd5z09Knkkjd0DMxRx8yIo5A6Z9KXJoF9CwLiY2pidsxK2UjYevXGegPapLxobWJFma0ka4UOAZNzxrn7pxwD/SqHm+dEzOXYkA5DcnB6Z9KJdjAxMjspJw33VAx3HU0vZ6i5n0LIvfOcsyQuqfKpC8D29xRPOktwMIELALuj42/wD16peSomUS7lj4Ulex744qW2jEUrMki4YkJ8p6/wC0abhFaoE0LBcsjukALy78+YcYOOmKZJNJK5acmT5t8h6D6e5q7NE8kK+ZLuEf7oED5UXOce3P86itHRILjzndpFPy4j3D67v4frihNbpCckkMZYljdkLDeCUUtyo7Z96rFDdNI5WJpNu5kJ2jI9cVdmhF84e2DMsKb2lVSd3uxbjrx2rVlh0u80mJo7MxXMcOxjDPvRmzzlcZUjr6YNS6vJbR6/gZzqKNr6/oXHtdO07VrP7Xp9zHpsyGOZppVZ3fA+5nGByvPGAaqwyi6vvJ0qwWGKcmFyy+asKE/e3AZU4AGfes9reRywmkRzFGG2k7srjHGe2K6yPxTd6B4WtYPDWmGNHLI93MpZGk77eeT9a4qinFLk96T01dl3vrf9TmqKUEuTVvTfTvcwLq/v7YTafBdXFnBAWLxJIVHvnGCT71nWyRSSKz+btY5JZst19TRqVzdXcxu9QYNcznMjeXt3HODwOPyrc8PaTe+InfTrG5hgtoCJZGZMgDOAAOpraTjRp80rLu/wCt9Td1I0abnKy7mfIl3cWbNC223STywEfgbvUdSeOTirj3plh/s+XUpIXMbKv2ljHBnqW2D+HbkfWqNncSafBq9te3zWd9FLsaKKLBnO7GQ/oOpFdT4W1weGrmPTPEujR2huD+7vmQZIbqWJzke4P4VjXcoxbjHma2S0b0vdX3+Vzmq1m4Nxje2y6/jv8AI5K1VNOuv+QjMYDEwSWBeSDwRtJ6HniriFPKmWS4WC0SMMJ0jy7nHypj1JOTXVeJ/D+k2On29xpMEctjJuglmEu7ax+6R2PPFcpfxIug2UkkUAnvZzIhXPmeUo2gnsFJyPXiiliI4hKUb66dL/1v/kKniI10mr6u3S5n29wIrFWaAyBtyLERhC56Of1pgsiYmdGMo2jLk4wep7888Zpbp2e3l8qNrZ4cBo24Zge+D0HemPJ5NuGdl2og2jaNwPvXYr7rqbN32K7t507RTywwxk/MX5OQOoIFNDxK0iywtJPGCFkjORjHUiqju07sA2ZC/QnOB9afG7zOm91IzguMLj8e9dPJZG3LZCzyMtokMpWOOWTeyhRwPX1z7UUze0jSRgxMuQfMfg4z1zRVrTyCxaGnyRRLcFkliK7j5L5Kn+6fSmrfMqwxtDDIiv5jLz859DVYmeSOPC4s/mKu5IB+gHXNXB5M0ccUMUUTuv7yVjnH0HbNZPX4tS+mpVYu4WIhdu4uGHVs9vpVl7e50qQNcWqhnXA8whhgjpx3qtINuGLOJIQQ47Yz2/OtGSWG90vMcih4l+aGZsMccZU9/p1pybVu3UUpNWtsU7SFpFKI6xW6fOy7ySoHX8aUNuRUjREDHOVGWx7/AM6qwPJudo+GKEHHXHvVyyEca+a7uy8r5a9ckdT7U5KxopaXHRvlFWK3j2OdoJPzE+5p0UCw3MagRTSrkyo4+T1AJBqBWFvaowiV5nGRID9wZwc+9LKyQoIgd5bLFlH3m7DPeps9kUnc0gzLPuVVkmkXLgjEMY/wFUpbmVUiRnJiVyyuqgNg8ED2pZYZP3scU6TQxsMeU+9c98ken+NKsjNDdvtJkJBklYDsei+lZxS33CK2IZNvkMvlsgbJHHX0/wDrmkR2SICGUhWYKQ/GTjPPtSMzSM8cbSlX5VOpPvSSqioQvJUASNjdz2ArVdmaE8UDPauzERvuCI4jLM7HqB6D3qCdPLmlRhhEJiCr1JHcipVlTyF8y4njmLBSuzK/n2+lQtKrSmRxL5wOS5wBRG92S1qPicS2xDP+9HIU4CAAdcjvU1hOkcbRT+aI503bk5ZSDwR+I61XW3U+XI78N3xwT6VPczr9nl2SCaWQqAyrjy1H8PtSkk9EF+g/zPKinQZiDYz/AHznoG9ajsZUimcmUxOBjG3dvPpUVpMtndJcmBZmhbhH9fXFSw3DSXQnETXSoN0gdQO2CM+lJx0fYryEnaIW/wBnQStGjZMhj+7n2zTBAiIqiVXc52qqMSx7Bgen61OClhNIWt5JYpQY9sjEeXkeo4JHWq4YRjyfMLGM/KWVlPPXNNX6CTuKwhtLmJRGk0ij50dgUJPbIpWji3RPG6QKz4KqcyLzwCDxj0qKcyzAqHRmz8sMK55/ma0ojJZX8d3bR/MiD55GVwpxySMfzok2l5iexVm320zhJIeDglfmY+x96IIZbyJvLENu8bAMzEh3PYLgUGWMxyyvDH5rHl9vljB9B61DB5bNKBNNGjAFQjZw3vRrbzIe3mOkl8m68qSQPtzvUDlj6A461HGwjO7yh5BJk2tkhsHkA9eKdIUCAyrIrowdUIC7h3weuaWRnnjDyNGqqThCeVQdAPx/WqWwSQNO6bGZ9sY6BR29Knhmit5JZJEZ58ARxycqn+1j/H1qCJlRoiELSAc4bcq+5HY+1MkeWKOVN+0OTuB4J75/+tScU9CGrl66nkNsokkQpIfuDAck9WplqYIoH8lsQF9pL9TjpkelNtlAxclZPsGG5DbcyEHpnJ5PYfpUKmVbm3SOSIz5yigfIjN1B7ce9Qo6WRHL2NHSWjgbyryWVbPpMsOSJMcgds9qfp06QT3Vj5Bg82TJeOU7ymQdrZOCv/1qhtLjzfMvJo1KJIFmVB8vsQO3SpFEV5qEd7cJJbWknELwkDaQcYP4c1lJavm/pmE+tywfOllKxuudyqrqcqVz0PvjtWxouh6nr0UUcT3CafGXKMDiIN2wp9+TgZ5rHDqtuZYZlCLnhmAJIyCfx7V6L4X1Cz0GyNtq00VrJcYuI3djskVlzgMe4x0rgxladKnekry6afeYYuvKnT/dq79DgtN8MapqWpyWPmRx3FsxWbzJPmUZ5IH+HrXp1rZDwT4YmOn28upXAfcwC4LsepIA4UD61vwSRTxi4gKMkih/MUDDKehzVbVdY0/SIjNqV5BbxgdGbLEH0HU14eIzCri5Km46fyrq/wAzw6+Oq4mSg46dl1/U8RmWLUNUgRV+zi4nDNG5O2JWbcTk/jXf3LSePtQgiW1MXh+zm3/aJF+afHG1fQVyniu3OqeL4ra1Vo4JWiSN2GMBwG6dcYJ616rf3MOhaJNcRW7Spbx7Y4Il5b0AA7dzXo46vyqlKC99rTyv+vrsd+NxFlTcF7zWnlf9Tz74hP8A2deHSdO8qCyVVumt0HHmt8o47f3vwrib+ZReLHZ3El5Fbr+8kVdgIHZQewJP5Uarq91q0l1eXhDXVwQrnbgADAAX6DiqTGGMbriGU7hwwbYAfX3FezhMM6NOMZavr5vuelhqLp00pb9fNj/MeYxTyyOY93LHn8PWq0jbJydu7DEDPIp8eEdQqrJgnILcOP6UyTyzKrQSOsch+4fvL7Gu2KszqStsPDrOyLGhWWRtojUdG9c+/pSb0ikVGAZcFJCvUUzBNyAishQHnox/CoUJQhSNjBumKaiNIlnCRybB8qYxuXkv7+1FMaOUznK4Zuc+goqrpdRExMSWrFw+/aBEo5yPpT0BaXy5JhkhXlI6r6U2ZygcsrOzIuG/u0wHKSuxYEkbs9XPQCs7MtFid9yMUDktICZpe4HSkZY5Z7qW4Lb84Dxr8mfU+gpJVZolYys+0ZbB4T0H1qWR3kSNxIYmkjPmE/dYDt9TS22AruphXyyV81huB7bfap7eMSMkckvkRlTIrsuAwxz+PaoYGYCScEKRgFQvY+lPmlG8yR7gCCIgRkKfoeood3oPyLDxmCAXEIYI4wodeVA7/jUNqd9x5LIxXY0nmBCQDwOffnj8ala6a5sWjMiEkjEIz8p9R606SSWznWLc8u2MB4zwPpnvWfvWt1BGZoV5YTacw0xGigCmAKFxjByd2fr+tXXlaaIIVBROAEOB/wDXpzMyuZDsEgwWhQfLgd80tzukctPCFnlAbYoCgJ64HGTU0o8kVF207afcu3zNL6jYEm3w+VnKHAPXH/1qa0bby+C8ZJ+aNeOPbsKGV5ER4shSucA/dx1zTnfZKX2shwBEiHbu+voK01uO/YZIeOEfb0UScHPriluZSgjgMnmhTkndnj+7TJpH8zcJQ0icb2PJp8OfKMajMs6nIePn6qadrWbBvuNctPdbo1ZtwKqq/wB0Dp+HrUoZY0Z1mCFH+UDkt9PXHrUESyQFSs6R5QgNkNkN/CfSo2aJE2SowZRtO08e3P15p2voifMtzSwR+akYNzLIgUTnIVW6nA9e1RyXUM9slu8YiaNAq7GO1mzyW/wqExvEqNuRzgsV647Zqy5hmjURsxiiTDAR9SOgB7nuaVkrBfqPEMTrh5/3Y+YxwAjHvz3+lVVuQyhIQUJb53GS5GO5oDiSNo2jeS5BPLZ+RR39M1LCWlAYW3n7xtHlnYffIFO1txshgnmjZXjZGduGYDJU+uexpNisiRhQmxiN7Hbn2NOkMMEoEbI0MnLxmTOzB6E98frS3XmtH5xYeU+fLfbycfyquor9R0skgQQPNu83LuoG47hwASfb0pbuSV7FYd8jLCoXYSCAc5xkdP1qYTXEl5Alqyy3saYQAFznHJ3fTJ9BUuo2d1LbWkws3topPldwu2Jjn7y+v4ZrPmSavZGcpJWTImvYrmCQuTISAioewHUf7Iqvdt5qRpNKhbAKpHyqj0PpUUmxXRYFfyycZzyfxpoUtEQBuWNS20HGB6mrjBLVFWsTxywxIYmJaIuHEcJ+Xj1P6VJLIrzGWUCOZiSMDKjPTj26VXWDIDyAeWoJIVgO386SNlFvtkG6M8CTBxn0ocU9UJrW5a8pcyJBN5yIu5Tg8E4yQP7x/SmWwl3bnDpHFgYCAn8B0/GoZjGCTEQHTGMcYPp9femrMsm+OSR4lzkAHPze9HK7C6F3R1+03fkDaJZCQN2doABPJH0qxJKqWLTKGKhskAfL/nnpWXZzy2N7DPCwE0ZByP4TU0Vwkrybzh925Vxke59vrUTptyv0MakZc1+ht2s6rGpMalh0GwbQT6knjrXUaHr+sXuki1ltNENjbZjf+05SjzgDP7sdOOBk/hXFWdy1pK6K+BMNrowDqw78EHH1qWe2huYdqQ3k90sIxHHDlRJnGDz92uGvh4VNJL0f9WOSrRjUVpf1+Rr6R4kn0280uL7c9xZW87SS28YICA5+XP8AEBnI6Vla/d/2h4rvbyENc+bP+5JHLL/CAO2PT2qefw1qWmrHLc2lisskZUQSTAkgDLOTnAx798VD4Mltx4hkn1N2hitIysJjQswZjtAwBzwTVRjSjzV6WrtbTrr5eYL2SvVp6u3Trr5eZf8AAs9xcePYW1GZ5pyzkmTklwhA/IV23xJ13UtJt7F9Kmij813D/KCzEDpg9utc1FqelxeOnv5B5drbjCyxoQ7fLjDL1JHPNYGv6jdeJdXu72W4CafZI01urLjao/hwepJwK5JYf6xiYVZxtFRV01p10/E5p0fbV4VZRtFLW+3XQw3kLOu9ysh+Z9oyRmomL5IlJCOcbmzzgdD29KYPNCJJM0jebln6AYPQCpXYiSRXYRZ+UgDJr3bWPXEYrJnEmCGHBHLVE+xEyqqjAlQBx+NO2Hyy22NowcZPBP0qNmO0bgflBx7/AFqkhk25SXcbzlcdfm3dvwpsLlmcOoQjg+mexNQlWGGxgjA5Pr3pG4kKq/DAZxz0p8qBssjbujaJTyMncenriimors0gTDKuG3MMCipauS7CySk8HcAQMj2HSpmJKJtQHbguBxk0j5RZVZtzEDJxzSxyJHKGjGIQOd3JapfkWmLKCkaLgFm/eOpPGKWRvMMQEWYyMLEpPI9c/WkRGaJisf7hm37uM4Halk/dxeY+N0wOOPurSGNl1FbaCIT3CovmrGrHlWJ6A+3vTTGFVJFkUMwYsMfd9j9akgSN/M8xQ67M42jg9R19KjhMvlgyIis8W4r1+UnK598YzUJtTa6f1cpJDoJpEdTGgDY2qAMn3NSXEkiqdyOCq7ck889aSCQkqqDarOo46g+xoeTzZELPyMkOec+nFU1rsNbjlDPCgRVw5xsHAYjrzUyRq06pJIZY87WZOx7Ak1TV1ZVDH9yoPQdzznFCrH5q7mG0fPkAjcPShxHqSljE+EKI6sSwPT0xjvxQY2WJSn+sA3bY+cDpuJoZS5gjRUMkmGIGQW9ifoKY8padlRAof5BGOABngE96F5AJB5cuyGQOFJyQiZc+2aljR1vrdHmJA987AfWq86liCZW3K5jGR2A65p6xymNJIY0RRkg5zn2NNrzGEyqWURxHzhkvj5VcA9R+FOwslvuyF+0ORHzxHj7wPv0qW7UiYRBFRVjV2Ve3GcA/jTI5JYoRDGgby5POR+Mo3+cUr3SsTfsWUSGW0URyGN8YlR+HnJPQH0qo80yna7YaEhUCONifQdzUly4KjzohNKcrvlOdxPcDtUYWS2lj8tkSdQFVVHqOpNKK7ghxu1cnz4hmUEkIxyDnv9aQ3MaYa3t1gR+OpZqdYltskTuoDEl2AO5j9ahw0qSSW5MCBSgDNuJwMnnHFOyvYL62Y+AvFcrJGwjdhhBGgy3HXBply96kUkUkxIJHyBgyk/Qd6QsQieaCXMYUIhA2r16+ppqrbxoUDHfIMk4+Vfb3+tVbW7Q/MkjY6dMWdSWeIrkp93PUj19M1LeSbhCs8kxcgGMuxKxrjgKPX6VTlfaEELPsCBMsATk9cU8xHbPahVcrIMMeCDjHFHLrzPcm32gBPlh1CncxVgByn4U3zi8bKzFozlmC8BsdyanYiKzVNxWQEEsvGW9DVa4jjW5/cyMW4JOMDd3wPSnHVjtcdEqgLhFL5xtLdc9MeuKnZizStKD5QbAX+59B0BqFwUtpSejMDHnqGB5OfTrU9yjTt580gaSUBy23Cj6juaT3F1GTxOVaRYyUY5Uk7sZ7Z7mjcWghLoowdhZhhT9R3NI0qm3CLFiRXDhwcZ/CllkzEzkEvNxlufl9vSjXqFmyOQu6kSIrI3CsOMe//wCupDeLGjLAihJIfKIJ5JH8Wf6VEYmKL5YOCM4Y5zU7j9xJJCsXkB1DKy5wx6AfrTdiZRVtSzp8M1r5V0V3plQY2OMA8df1rq72S80kiSa4IvL6AMZYSE8rB4JA7ED681yaXA2jbI0fk4cNjIBPHA+nSrEl+8UE8MbSAPGEKKcBwv3XJ7EHt0rjrUpVJJv+v638+pxTpuci/q/iW81/TBBdmCC1ifLzqPnkB6Lj8KS1vIdDe0vtLScA/LKLhhvkPJDbe6g8Zz1FSfD+xTWvEcElwq7bP9+VCjDHoM+2ea3Pi1JIj2Fqgj8iRHncBcElT6+nPSuaUqcK8cHCOju2un/BObnhGssNGOj37HIzwXMss1zqDE3U/wDpWTGfunkHI4Gaz5dlxIsW1kjGcbBn3yfatiPUZbS6N7dKt1vjXERdkU4AIGB2HpWC7TKiMTGZpH5655Ofpiu6lzPf+v8AhjthzbP+v+GCWZYUaKMiR2O52x8ox0ApZ5DPI7sCZcjDKAM8dxTZZ2ihlhBjdZByFTBBB6ZpsMcTF/tP7shMoVG7n0roSS1NkrajkZpXVQSSchsgAAio1/eYZCoYcBhwD7Ed+tRghpGjwzN/FuP3qbsIjEmCYycYz0NUkiiVlMZdWD7MjqMZ/wAKZCArKzthWyCen4e9OUK1tJIoPmjGFLZBHfPv6dqYNptTIxwVb5WxnPtj0o5ughWOBn5ifUn5dvuaKhiLtOEkCqrNlEboBj2+mfxoqVMmSP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Liver biopsy of chronic disseminated candidiasis showing granulomas on hematoxylin and eosin staining.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Carol A Kauffman, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_46_40674=[""].join("\n");
var outline_f39_46_40674=null;
var title_f39_46_40675="Tinea pedis dorsal foot";
var content_f39_46_40675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F67076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F67076&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Tinea pedis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 291px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A well-demarcated area of scale and erythema is present in this patient with spread of interdigital tinea pedis to the dorsal foot.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Denise W. Metry, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_46_40675=[""].join("\n");
var outline_f39_46_40675=null;
var title_f39_46_40676="Tetanus immune globulin (human): Pediatric drug information";
var content_f39_46_40676=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Tetanus immune globulin (human): Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/293?source=see_link\">",
"    see \"Tetanus immune globulin (human): Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/18/11555?source=see_link\">",
"    see \"Tetanus immune globulin (human): Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F226065\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      HyperTET&trade; S/D",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F226066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      HyperTET&trade; S/D",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F2528420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Immune Globulin",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11445145\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Prophylaxis of tetanus:",
"     </b>",
"     I.M.: 4 units/kg as a single dose; some experts recommend administering 250 units regardless of weight or age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Treatment of tetanus",
"     </b>",
"     : I.M.: 500 units",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F2528430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/293?source=see_link\">",
"      see \"Tetanus immune globulin (human): Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis of tetanus:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants and Children &lt;7 years: I.M.: 4 units/kg as a single dose; some experts recommend administering 250 units regardless of weight or age",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &ge;7 years and Adults: I.M.: 250 units as a single dose; may be increased to 500 units if there has been a delay in initiating prophylaxis or when the wound is considered very tetanus prone",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Additional doses of TIG can be given at 4-week intervals in situations where the risk of tetanus infection persists.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Treatment of tetanus:",
"     </b>",
"     Children and Adults: I.M.: 500-6000 units. Infiltration of part of the dose around the wound is recommended. Tetanus prophylaxis in patients with wounds should consider if the wound is clean or contaminated, the immunization status of the patient, proper use of tetanus toxoid and/or tetanus immune globulin (TIG), wound cleaning, and (if required) surgical debridement and the proper use of antibiotics. Patients with an uncertain or incomplete tetanus immunization status should have additional follow-up to ensure a series is completed. Patients with a history of Arthus reaction following a previous dose of a tetanus toxoid-containing vaccine should not receive a tetanus toxoid-containing vaccine until &gt;10 years after the most recent dose even if they have a wound that is neither clean nor minor. See table.",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <caption>",
"      Tetanus Prophylaxis Wound Management",
"     </caption>",
"     <col align=\"center\" width=\"250\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <col align=\"center\" width=\"50\">",
"     </col>",
"     <thead>",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         History of Tetanus Immunization (Doses)",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         Clean, Minor Wounds",
"        </p>",
"       </th>",
"       <th align=\"center\" colspan=\"2\">",
"        <p style=\"text-indent:0em;\">",
"         All Other Wounds",
"         <sup>",
"          1",
"         </sup>",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          1",
"         </sup>",
"         Such as, but not limited to, wounds contaminated with dirt, feces, soil, and saliva; puncture wounds; wounds from crushing, tears, burns, and frostbite.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          2",
"         </sup>",
"         Tetanus toxoid in this chart refers to a tetanus toxoid containing vaccine. For children &lt;7 years old DTaP (DT, if pertussis vaccine contraindicated) is preferred to tetanus toxoid alone. For children &ge;7 years of age and Adults, Td preferred to tetanus toxoid alone; Tdap may be preferred if the patient has not previously been vaccinated with Tdap.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          3",
"         </sup>",
"         Yes, if &ge;10 years since last dose.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         <sup>",
"          4",
"         </sup>",
"         Yes, if &ge; 5 years since last dose.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         Abbreviations:",
"         <b>",
"          DT",
"         </b>",
"         = Diphtheria and Tetanus Toxoids (formulation for age &le;6 years);",
"         <b>",
"          DTaP",
"         </b>",
"         = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (formulation for age &le;6 years; Daptacel&reg;, Infanrix&reg;);",
"         <b>",
"          Td",
"         </b>",
"         = Diphtheria and Tetanus Toxoids (formulation for age &ge;7 years; Decavac&reg;, Tenivac&trade;);",
"         <b>",
"          TT",
"         </b>",
"         = Tetanus toxoid (adsorbed [formulation for age &ge;7 years]);",
"         <b>",
"          Tdap",
"         </b>",
"         = Diphtheria and Tetanus Toxoids, and Acellular Pertussis (Adacel&reg; or Boostrix&reg; [formulations for age &ge;7 years]);",
"         <b>",
"          TIG",
"         </b>",
"         = Tetanus Immune Globulin",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\" colspan=\"5\">",
"        <p style=\"text-indent:0em;\">",
"         Adapted from the Yellow Book 2010, Chapter 2,",
"         <i>",
"          Routine Vaccine-Preventable Diseases, Tetanus",
"         </i>",
"         ; Available at www.cdc.gov/yellowbook;  and",
"         <i>",
"          MMWR",
"         </i>",
"         , 2006, 55:RR-17.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody>",
"      <tr>",
"       <td align=\"center\">",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Tetanus toxoid",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         TIG",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Tetanus toxoid",
"         <sup>",
"          2",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         TIG",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         Uncertain or &lt;3 doses",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Yes",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Yes",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Yes",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"left\">",
"        <p style=\"text-indent:0em;\">",
"         3 or more doses",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"         <sup>",
"          3",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"         <sup>",
"          4",
"         </sup>",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         No",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F226053\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HyperTET&trade; S/D: 250 units/mL (~1 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F226040\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F2528431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     I.M.: Administer into lateral aspect of midthigh or deltoid muscle of upper arm;",
"     <b>",
"      not for I.V. administration",
"     </b>",
"     .  Avoid gluteal region due to risk of injury to sciatic nerve; if gluteal region is used, administer only in the upper outer quadrant. When administered for treatment of tetanus, may be infiltrated locally around the wound site. Do not administer tetanus toxoid and TIG in same syringe (toxoid will be neutralized); tetanus toxoid may be administered at the same time at a separate site.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F2528427\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Store at 2&deg;C to 8&deg;C (26&deg;F to 46&deg;F). Do not use if frozen. The following stability information has also been reported for HyperTET&trade; S/D: May be exposed to room temperature for a cumulative 7 days (Cohen, 2007).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F2528421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis for tetanus following injury in patients whose immunization for tetanus is incomplete or uncertain [FDA approved in pediatric patients (age not specified) and adults]",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends passive immunization with tetanus immune globulin (TIG) for the following:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Persons with a wound that is not clean or minor and in whom contraindications to a tetanus toxoid-containing vaccine exist and they have not completed a primary series of tetanus toxoid immunization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Persons who are wounded in bombings or similar mass casualty events who have penetrating injuries or nonintact skin exposure and who cannot confirm receipt of a tetanus booster within the previous 5 years. In case of shortage, use should be reserved for persons &ge;60 years of age.",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F226080\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Temperature increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioneurotic edema (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Injection site: Pain, soreness, tenderness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Nephritic syndrome (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic shock (rare)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F2528423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to tetanus immune globulin, thimerosal, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F2528630\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with caution to patients with thrombocytopenia or any coagulation disorder that would be compromised by I.M. injection; administer with caution in patients with IgA deficiency or a prior history of systemic allergic reactions following the administration of human immunoglobulin preparations. Skin testing should not be performed as local irritation can occur and be misinterpreted as a positive reaction.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F2528424\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     As a product of human plasma, this product may potentially transmit infectious agents such as viruses; screening of donors, as well as testing and/or inactivation of certain viruses has reduced this risk. Infections thought to be transmitted by this product should be reported to the manufacturer. Although extremely rare, severe hypersensitivity reactions including anaphylaxis may occur; epinephrine and other anaphylactic treatment agents should be readily available. Not for I.V. administration; serious systemic reactions including hypotension have occurred with inadvertent I.V. administration.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300119\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F226048\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vaccines (Live): Immune Globulins may diminish the therapeutic effect of Vaccines (Live).  Management: Live organism vaccination should be withheld for up to 6 months following immune globulin administration.  Live vaccine given immediately prior to immune globulin may require repeat vaccination.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Yellow Fever Vaccine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F226050\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6742397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. Tetanus immune globulin and a tetanus toxoid containing vaccine are recommended by the ACIP as part of the standard wound management to prevent tetanus in pregnant women.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F2528428\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Passive immunity toward tetanus",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F2528631\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     Duration: A single dose may provide protection for up to 14 weeks",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F2528429\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Absorption: Well absorbed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Time to peak serum concentration: 2 days",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control, &ldquo;Diphtheria, Tetanus, and Pertussis: Recommendations for Vaccine Use and Other Preventive Measures,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 1991, 40(RR-10):1-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/46/40676/abstract-text/1865873/pubmed\" id=\"1865873\" target=\"_blank\">",
"        1865873",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control, &ldquo;Prevention of Pertussis, Tetanus, and Diphtheria Among Pregnant and Postpartum Women and Their Infants,  Recommendations of the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2008, 57(early release):1-47. Available at",
"      <a href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/rr57e0514a1.htm?s_cid=rr57e0514a1_e%20\" target=\"_blank\">",
"       file://www.cdc.gov/mmwr/preview/mmwrhtml/rr57e0514a1.htm?s_cid=rr57e0514a1_e",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control, &ldquo;Recommendations for Postexposure Interventions to Prevent Infection With Hepatitis B Virus, Hepatitis C Virus, or Human  Immunodeficiency Virus, and Tetanus in Persons Wounded During Bombings and Other Mass-Casualty Events-United States, 2008: Recommendations of the Centers for Disease Control and Prevention (CDC),&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2008, 57(RR-6):1-21.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/46/40676/abstract-text/18668022/pubmed\" id=\"18668022\" target=\"_blank\">",
"        18668022",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cohen V, Jellinek SP, Teperikidis L, et al, &ldquo;Room-Temperature Storage of Medications Labeled for Refrigeration,&rdquo;",
"      <i>",
"       Am J Health-Syst Pharm",
"      </i>",
"      , 2007, 64(16):1711-15.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/46/40676/abstract-text/17687059/pubmed\" id=\"17687059\" target=\"_blank\">",
"        17687059",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Center for Immunization and Respiratory Diseases, \"General Recommendations on Immunization - Recommendations of the Advisory Committee on Immunization Practices (ACIP),\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/46/40676/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      <i>",
"       Red Book: 2009 Report of the Committee on Infectious Diseases",
"      </i>",
"      , 28th ed, Pickering LK, ed, Elk Grove Village, IL: American Academy of Pediatrics, 2009.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12834 Version 30.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.244-76F9A528C7-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_46_40676=[""].join("\n");
var outline_f39_46_40676=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226065\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226066\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528420\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11445145\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528430\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226053\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226040\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528431\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528427\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528421\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226080\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528423\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528630\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528424\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300119\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226048\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F226050\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6742397\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528428\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528631\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F2528429\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12834\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12834|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?0/18/293?source=related_link\">",
"      Tetanus immune globulin (human): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/18/11555?source=related_link\">",
"      Tetanus immune globulin (human): Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_46_40677="Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Drug information";
var content_f39_46_40677=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/9/4242?source=see_link\">",
"    see \"Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/1/29717?source=see_link\">",
"    see \"Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F9514407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cervarix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F10135562\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Cervarix&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F9518292\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Vaccine, Inactivated (Viral)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F9559868\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Immunization:",
"     </b>",
"     I.M.: Females &le;25 years: 0.5 mL followed by 0.5 mL at 1 and 6 months after initial dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     CDC recommended immunization schedule: Administer first dose to females at age 11-12 years; begin series in females aged 13-25 years if not previously vaccinated. Minimum interval between first and second doses is 4 weeks; the minimum interval between first and third doses is 24 weeks. Inadequate doses or doses received following a shorter than recommended dosing interval should be repeated. The HPV vaccine series should be completed with the same product whenever possible.",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F9559867\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/1/29717?source=see_link\">",
"      see \"Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Immunization:",
"     </b>",
"     I.M.: Females &ge;9 years: 0.5 mL followed by 0.5 mL at 1 and 6 months after initial dose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     CDC recommended immunization schedule: Administer first dose to females at age 11-12 years; begin series in females aged 13-25 years if not previously vaccinated. Minimum interval between first and second doses is 4 weeks; the minimum interval between first and third doses is 24 weeks. Inadequate doses or doses received following a shorter than recommended dosing interval should be repeated. The HPV vaccine series should be completed with the same product whenever possible.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F9518301\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, suspension [preservative free]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cervarix&reg;: HPV 16 L1 protein 20 mcg and HPV 18 L1 protein 20 mcg per 0.5 mL (0.5 mL [DSC]) [contains aluminum; manufactured using",
"     <i>",
"      Trichoplusia ni",
"     </i>",
"     (insect cells)]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cervarix&reg;: HPV 16 L1 protein 20 mcg and HPV 18 L1 protein 20 mcg per 0.5 mL (0.5 mL) [contains aluminum, natural rubber/natural latex in prefilled syringe; manufactured using",
"     <i>",
"      Trichoplusia ni",
"     </i>",
"     (insect cells)]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F9559847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F9559875\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Shake well prior to use. Do not use if discolored or if containing particulate matter, or if vial or syringe is cracked. Inject I.M. into the deltoid region of the upper arm. Do not administer I.V., SubQ, or intradermally.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     For patients at risk of hemorrhage following intramuscular injection, the ACIP recommends &ldquo;it should be administered intramuscularly if, in the opinion of the physician familiar with the patient's bleeding risk, the vaccine can be administered by this route with reasonable safety. If the patient receives antihemophilia or other similar therapy, intramuscular vaccination can be scheduled shortly after such therapy is administered. A fine needle (23 gauge or smaller) can be used for the vaccination and firm pressure applied to the site (without rubbing) for at least 2 minutes. The patient should be instructed concerning the risk of hematoma from the injection.&rdquo; Patients on anticoagulant therapy should be considered to have the same bleeding risks and treated as those with clotting factor disorders (CDC,  2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Simultaneous administration of vaccines helps ensure the patients will be fully vaccinated by the appropriate age. Simultaneous administration of vaccines is defined as administering &gt;1 vaccine on the same day at different anatomic sites. Separate vaccines should not be combined in the same syringe unless indicated by product specific labeling. Separate needles and syringes should be used for each injection. The ACIP prefers each dose of a specific vaccine in a series come from the same manufacturer when possible. Adolescents and adults should be vaccinated while seated or lying down. In general, preterm infants should be vaccinated at the same chronological age as full-term infants (CDC,  2011).",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     Antipyretics have not been shown to prevent febrile seizures. Antipyretics may be used to treat fever or discomfort following vaccination (CDC, 2011). One study reported that routine prophylactic administration of acetaminophen to prevent fever prior to vaccination decreased the immune response of some vaccines; the clinical significance of this reduction in immune response has not been established (Prymula, 2009).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F9518293\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females 9 through 25 years of age: Prevention of cervical cancer, cervical adenocarcinoma",
"     <i>",
"      in situ",
"     </i>",
"     , and cervical intraepithelial neoplasia caused by human papillomavirus (HPV) types 16, 18",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     The Advisory Committee on Immunization Practices (ACIP) recommends routine vaccination for females 11-12 years of age; catch-up vaccination is recommended for females 13-25 years of age (CDC, 59[20], 2010). Vaccination is also recommended for immunocompromised females through 26 years of age who were not previously vaccinated when they were younger. Although not specifically recommended for their profession, female health care providers within the recommended age groups should also receive the HPV vaccine (CDC, 2013).",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F9518289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Papillomavirus vaccine types 16, 18 (Cervarix&reg;) may be confused with Papillomavirus vaccine types 6, 11, 16, 18 (Gardasil&reg;)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Cervarix&reg; may be confused with Cerebyx&reg;, CeleBREX&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F9559857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      All serious adverse reactions must be reported to the U.S. Department of Health and Human Services (DHHS) Vaccine Adverse Event Reporting System (VAERS) 1-800-822-7967 or online at",
"      <a href=\"https://vaers.hhs.gov/esub/index\" target=\"_blank\">",
"       https://vaers.hhs.gov/esub/index",
"      </a>",
"      .",
"     </b>",
"     In Canada, adverse reactions may be reported to local provincial/territorial health agencies or to the Vaccine Safety Section at Public Health Agency of Canada (1-866-844-0018).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (55%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site reactions: Pain (92%), redness (48%), swelling (44%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myalgia (49%), arthralgia (21%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Urticaria (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site: Pruritus (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Nasopharyngitis (4%), pharyngolaryngeal pain (3%), upper respiratory tract infection (2%), pharyngitis (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Influenza (3%), chlamydia infection (2%), vaginal infection (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1%, postmarketing, and/or case reports: Allergic reactions, anaphylactic/anaphylactoid reactions, angioedema, erythema multiforme, lymphadenopathy, syncope (may be associated with tonic-clonic movements), vasovagal response",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F9559852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to papillomavirus recombinant vaccine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F9559853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anaphylactoid/hypersensitivity reactions: Immediate treatment (including epinephrine 1:1000) for anaphylactoid and/or hypersensitivity reactions should be available during vaccine use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Syncope: Syncope has been reported with use of injectable vaccines and may be accompanied by transient visual disturbances, weakness, or tonic-clonic movements. Procedures should be in place to avoid injuries from falling and to restore cerebral perfusion if syncope occurs.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Acute illness: May consider deferring administration in patients with moderate or severe acute illness (with or without fever); may administer to patients with mild acute illness (with or without fever).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Bleeding disorders: Use with caution in patients with a history of bleeding disorders (including thrombocytopenia) and/or patients on anticoagulant therapy; bleeding/hematoma may occur from I.M. administration.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Human papillomavirus (HPV) infection: There is no evidence that individuals already exposed to or infected with HPV will be protected; those already infected with 1 or more HPV types were protected from disease in the remaining HPV types. Not for the treatment of active disease; will not protect against diseases not caused by HPV vaccine types 16 and 18.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Vaccines: In order to maximize vaccination rates, the ACIP recommends simultaneous administration of all age-appropriate vaccines (live or inactivated) for which a person is eligible at a single clinic visit, unless contraindications exist.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Altered immunocompetence: Use with caution in severely immunocompromised patients (eg, patients receiving chemo/radiation therapy or other immunosuppressive therapy [including high-dose corticosteroids]); may have a reduced response to vaccination. In general, household and close contacts of persons with altered immunocompetence may receive all age appropriate vaccines.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Males: Safety and efficacy have not been established in males.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in females &lt;9 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pregnancy: Not recommended for use during pregnancy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Latex: Packaging may contain natural rubber/natural latex.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Effective immunity: Vaccination may not result in effective immunity in all patients. Response depends upon multiple factors (eg, type of vaccine, age of patient) and may be improved by administering the vaccine at the recommended dose, route, and interval. Vaccines may not be effective if administered during periods of altered immune competence (CDC, 2011).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Maximum efficacy: The entire 3-dose regimen should be completed for maximum efficacy.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299821\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F9613147\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Belimumab: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fingolimod: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Immunosuppressants: May diminish the therapeutic effect of Vaccines (Inactivated).",
"     <b>",
"      Exceptions:",
"     </b>",
"     Cytarabine (Liposomal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F9559848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F9559849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed in animal reproduction studies. Vaccination with papilloma virus vaccine is not recommended in pregnant women. In clinical trials, pregnancy testing was conducted prior to each vaccine administration and vaccination was discontinued if the woman was found to be pregnant; women were also instructed to avoid pregnancy for 2 months after receiving the vaccine. Pregnancies detected within 30 days prior or 45 days after vaccination had a higher rate of spontaneous abortions. A registry has been established for women exposed to Cervarix&reg; during pregnancy (888-452-9622).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;display:inline\">",
"     Administration of the vaccine in pregnancy is not recommended; until additional information is available, the vaccine series (or completion of the series) should be delayed until pregnancy is completed. Pregnancy testing is not required prior to administration of the vaccine (CDC, 2013).",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F9559851\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F16149382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known if this vaccine is excreted into breast milk. The manufacturer recommends that caution be exercised when administering papilloma virus vaccine to nursing women. Lactating women may receive vaccine (CDC, 2010).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F9559877\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Gynecologic screening exam, papillomavirus test as per current guidelines; screening for HPV is not required prior to vaccination and screening for cervical cancer should continue as recommended following vaccination. Monitor for syncope for 15 minutes following administration. If seizure-like activity associated with syncope occurs, maintain patient in supine or Trendelenburg position to reestablish adequate cerebral perfusion.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F9559872\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contains inactive human papillomavirus (HPV) proteins HPV 16 L1, and HPV 18 L1 which produce neutralizing antibodies to prevent cervical cancer, cervical adenocarcinoma, and cervical neoplasia cause by HPV.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F9559863\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Onset: Peak seroconversion was observed 1 month following the last dose of vaccine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Duration: Not well defined; &gt;5 years",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, &ldquo;ACOG Committee Opinion No. 463: Cervical Cancer in Adolescents: Screening, Evaluation, and Management,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2010, 116(2 Pt 1):469-72.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/46/40677/abstract-text/20664421/pubmed\" id=\"20664421\" target=\"_blank\">",
"        20664421",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Advisory Committee on Immunization Practices (ACIP) Recommended Immunization Schedule for Adults Aged 19 Years and Older - United States, 2013,\"",
"      <i>",
"       MMWR Surveill Summ",
"      </i>",
"      , 2013, 62(1):9-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/46/40677/abstract-text/23364303/pubmed\" id=\"23364303\" target=\"_blank\">",
"        23364303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP),&rdquo;",
"      <i>",
"       MMWR Morb Mortal Wkly Rep",
"      </i>",
"      , 2010, 59(20):626-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), &ldquo;Recommendations of the Advisory Committee on Immunization Practices (ACIP): General Recommendations on Immunization,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2011, 60(2):1-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/46/40677/abstract-text/21293327/pubmed\" id=\"21293327\" target=\"_blank\">",
"        21293327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Einstein MH, Baron M, Levin MJ, et al, &ldquo;Comparison of the Immunogenicity and Safety of Cervarix&reg; and Gardasil&reg; Human Papillomavirus (HPV) Cervical Cancer Vaccines in Healthy Women Aged 18-45 Years,&rdquo;",
"      <i>",
"       Hum Vaccin",
"      </i>",
"      , 2009, 5(10):507-19.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/46/40677/abstract-text/19684472/pubmed\" id=\"19684472\" target=\"_blank\">",
"        19684472",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Prymula R, Siegrist CA, Chlibek R, et al, &ldquo;Effect of Prophylactic Paracetamol Administration at Time of Vaccination on Febrile Reactions and Antibody Responses in Children: Two Open-Label, Randomised Controlled Trials,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2009, 374(9698):1339-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/46/40677/abstract-text/19837254/pubmed\" id=\"19837254\" target=\"_blank\">",
"        19837254",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Saslow D, Castle PE, Cox JT, et al,  &ldquo;American Cancer Society Guideline for Human Papillomavirus (HPV) Vaccine Use to Prevent Cervical Cancer and Its Precursors,&rdquo;",
"      <i>",
"       CA Cancer J Clin",
"      </i>",
"      , 2007, 57(1):7-28.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/46/40677/abstract-text/17237032 /pubmed\" id=\"17237032 \" target=\"_blank\">",
"        17237032",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Steering Committee on Quality Improvement and Management, Subcommittee on Febrile Seizures American Academy of Pediatrics, &ldquo;Febrile seizures: Clinical Practice Guideline for the Long-Term Management of the Child With Simple Febrile Seizures,&rdquo;",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2008,  121(6):1281-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?39/46/40677/abstract-text/18519501/pubmed\" id=\"18519501\" target=\"_blank\">",
"        18519501",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8779 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-8641F3AC89-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_46_40677=[""].join("\n");
var outline_f39_46_40677=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9514407\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10135562\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9518292\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559868\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559867\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9518301\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559847\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559875\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9518293\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9518289\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559857\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559852\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559853\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299821\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9613147\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559848\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559849\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559851\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16149382\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559877\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559872\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F9559863\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8779\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8779|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?4/9/4242?source=related_link\">",
"      Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?29/1/29717?source=related_link\">",
"      Human papillomavirus bivalent (types 16, 18) recombinant vaccine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_46_40678="Etiology and clinical manifestations of transient ischemic attack";
var content_f39_46_40678=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Etiology and clinical manifestations of transient ischemic attack",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/46/40678/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/46/40678/contributors\">",
"     Karen L Furie, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/46/40678/contributors\">",
"     Hakan Ay, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/46/40678/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/46/40678/contributors\">",
"     Scott E Kasner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/46/40678/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/46/40678/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/46/40678/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cerebrovascular disease is the third leading cause of death in developed countries after heart disease and cancer; the overall prevalence is 794 per 100,000. It is estimated that more than 700,000 patients have a stroke each year in the United States. The loss of these patients from the work force and the extended hospitalization they require during recovery make the economic impact of the disease one of the most devastating in medicine.",
"   </p>",
"   <p>",
"    Cerebrovascular disease is caused by one of several pathophysiologic processes involving the blood vessels of the brain:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The process may be intrinsic to the vessel, as in atherosclerosis, lipohyalinosis, inflammation, amyloid deposition, arterial dissection, developmental malformation, aneurysmal dilation, or venous thrombosis.",
"     </li>",
"     <li>",
"      The process may originate remotely, as occurs when an embolus from the heart or extracranial circulation lodges in an intracranial vessel.",
"     </li>",
"     <li>",
"      The process may result from inadequate cerebral blood flow due to decreased perfusion pressure or increased blood viscosity.",
"     </li>",
"     <li>",
"      The process may result from rupture of a vessel in the subarachnoid space or intracerebral tissue.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first three processes can lead to transient cerebral ischemia (transient cerebral ischemic attack or TIA) or permanent cerebral infarction (ischemic stroke), while the fourth results in either subarachnoid hemorrhage or an intracerebral hemorrhage (primary hemorrhagic stroke).",
"   </p>",
"   <p>",
"    This topic will discuss the etiology and clinical manifestations of TIA. The definition, clinical diagnosis, and treatment of TIA are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18773?source=see_link\">",
"     \"Definition of transient ischemic attack\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10426?source=see_link\">",
"     \"Initial evaluation and management of transient ischemic attack and minor stroke\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/33/32281?source=see_link\">",
"     \"Secondary prevention for specific causes of ischemic stroke and transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transient ischemic attack (TIA) is a common neurologic problem. In a mainly white population from Rochester Minnesota, a population-based study reported that the incidence rate of TIA was 68 per 100,000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40678/abstract/1\">",
"     1",
"    </a>",
"    ]. In the Cincinnati and Northern Kentucky region of the United States, where the ethnic and socioeconomic demographics are similar to that of the United States as a whole, another population-based study found that the adjusted incidence rate for TIA was 83 per 100,000 people, and that blacks and men had significantly higher rates of TIA than whites and women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40678/abstract/2\">",
"     2",
"    </a>",
"    ]. From these data, it was estimated that 240,000 TIAs occur each year in the United States.",
"   </p>",
"   <p>",
"    The incidence of TIA in other populations has generally been lower than that reported in the United States, ranging from about 10 to 56 per 100,000 in various studies worldwide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40678/abstract/3-6\">",
"     3-6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGIC MECHANISMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A transient ischemic attack (TIA) should be considered a syndrome. These syndromes are conveniently divided into three pathophysiologic mechanisms:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Large artery low-flow TIA (true TIA)",
"     </li>",
"     <li>",
"      Embolic TIA, which may be artery-to-artery, or due to a cardioaortic or unknown source",
"     </li>",
"     <li>",
"      Lacunar or small penetrating vessel TIA",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Large artery low flow TIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Large artery low-flow TIAs are brief (usually minutes to a few hours), recurrent, and stereotyped. They are often associated with a tightly stenotic atherosclerotic lesion at the internal carotid artery origin or in the intracranial portion of the internal carotid artery (siphon) when collateral flow from the circle of Willis to the ipsilateral middle or anterior cerebral artery is impaired (",
"    <a class=\"graphic graphic_figure graphicRef51410 \" href=\"mobipreview.htm?2/4/2122\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef65199 \" href=\"mobipreview.htm?41/34/42531\">",
"     figure 2",
"    </a>",
"    ). Other important causes include atherosclerotic stenotic lesions in the middle cerebral artery stem (",
"    <a class=\"graphic graphic_figure graphicRef81813 \" href=\"mobipreview.htm?9/51/10042\">",
"     figure 3",
"    </a>",
"    ) or at the junction of the vertebral and basilar artery. Any obstructive vascular process in the extracranial or intracranial arteries can cause a low-flow TIA syndrome if collateral flow to the potentially ischemic brain also is impaired.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Embolic TIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embolic TIAs are characterized by discrete, usually single, more prolonged (hours) episodes of focal neurologic symptoms. As an example, in one study that divided patients with TIAs into those with symptoms of short duration (less than 60 minutes) or long duration (60 minutes or greater), the latter group was more likely to have an embolic source (86 versus 46 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40678/abstract/7\">",
"     7",
"    </a>",
"    ]. The embolus may arise from a pathologic process in an artery, usually extracranial, or from the heart (eg, atrial fibrillation or left ventricular thrombus). An ischemic stroke with infarction has occurred if symptoms or signs persist beyond 24 hours. However, as previously mentioned, symptoms that last less than 24 hours (often only as long as one hour) also may be associated with some infarction. If the primary pathologic process is thought to be embolic, a diligent search for its source is necessary before therapy to prevent future stroke can be initiated. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/33/32281?source=see_link\">",
"     \"Secondary prevention for specific causes of ischemic stroke and transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lacunar TIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lacunar or penetrating or small vessel TIAs are due to transient cerebral ischemia induced by stenosis of one of the intracerebral penetrating vessels arising from the middle cerebral artery stem, the basilar or vertebral artery (",
"    <a class=\"graphic graphic_figure graphicRef53412 \" href=\"mobipreview.htm?42/41/43673\">",
"     figure 4",
"    </a>",
"    ), or the circle of Willis (",
"    <a class=\"graphic graphic_figure graphicRef51410 \" href=\"mobipreview.htm?2/4/2122\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef65199 \" href=\"mobipreview.htm?41/34/42531\">",
"     figure 2",
"    </a>",
"    ). Occlusion of these small intracerebral penetrating vessels usually is due to lipohyalinosis from hypertension, but also may arise because of atheromatous disease at their origin. Occasionally, recurrent stereotyped TIAs occur; in this setting, the term lacunar or small vessel TIAs seems appropriate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The symptoms of a transient ischemic attack (TIA) depend upon the pathophysiologic subtype.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Low-flow TIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-flow TIAs usually are short-lived (minutes) and often recurrent. They may occur as little as several times per year but typically occur more often (once per week or up to several times per day).",
"   </p>",
"   <p>",
"    Low-flow TIAs are generally stereotyped, especially when they are due to hemodynamically significant stenotic lesions at the origin of the internal carotid artery, at the siphon portion of the internal carotid artery where collateral flow to the circle of Willis is inadequate, or in the middle cerebral artery stem. Symptoms due to ischemia from these lesions often include hand, arm, leg, face, tongue, or cheek numbness or weakness together, or a combination of one or more. Recurrent aphasic syndromes appear when there is focal ischemia in the dominant hemisphere, and recurrent neglect occurs in the presence of focal or nondominant hemisphere ischemia.",
"   </p>",
"   <p>",
"    In contrast, recurrent symptoms are often",
"    <strong>",
"     not",
"    </strong>",
"    stereotyped when the stenotic lesion that obstructs flow involves the vertebrobasilar junction or the basilar artery. The many closely packed neuronal structures in the brainstem preclude consistent manifestations of recurrent focal ischemia in this area.",
"   </p>",
"   <p>",
"    Nevertheless, certain generalizations about recurrent low-flow TIA symptoms in the posterior circulation can be made.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Obstructive lesions in the distal vertebral artery or at the vertebrobasilar junction usually cause disorganized dizziness that may or may not include spinning or vertigo. The patient may complain that the room is tilting or that the floor is coming up at them, rather than spinning dizziness. Patients most often use the word dizziness to describe a myriad of symptoms, not necessarily spinning. Other symptoms may include numbness of one side of the body or face, dysarthria, or diplopia.",
"     </li>",
"     <li>",
"      Ischemia in the pons from stenotic lesions in the proximal to midbasilar artery can cause bilateral leg and arm weakness or numbness and a feeling of heaviness in addition to dizziness. Patients often say it feels as though all of their energy has been drained. They may speak of a feeling of impending doom.",
"     </li>",
"     <li>",
"      Ischemia in the territory of the top of the basilar artery or proximal posterior cerebral artery may present with all of the above recurrent symptoms as well as overwhelming drowsiness, vertical diplopia, eyelid drooping, and an inability to look up. Transient ischemia at the top of the basilar artery is usually due to embolism rather than low-flow TIA.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Embolic TIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Embolic TIAs typically last hours rather than minutes as in low-flow TIAs. They may be infrequent since they are the result of emboli from a specific source (eg, a one, two, or three-time phenomenon). When the source of the embolus is in a proximal vessel, recurrent emboli can lodge in different branches of the parent vessel giving different symptoms.",
"   </p>",
"   <p>",
"    Emboli are subject to natural thrombolysis and migration since they typically break off of fresh thrombus. They may produce transient ischemia on many occasions, but an element of silent infarction remains. Emboli may be better referred to as acceptable minor embolism (ACME), a term coined by C Miller Fisher.",
"   </p>",
"   <p>",
"    Embolic TIAs are best divided into those in the anterior cerebral circulation (carotid, ACA, MCA territory) and those in the posterior cerebral circulation (vertebrobasilar, posterior cerebral artery territory). Symptoms in both circulations depend upon the size of the embolic fragment in relation to the size of the artery occluded.",
"   </p>",
"   <p>",
"    Embolic TIAs in the anterior circulation may be large enough to occlude the middle cerebral artery stem, producing a contralateral hemiplegia secondary to ischemia in the deep white matter and basal",
"    <span class=\"nowrap\">",
"     ganglion/internal",
"    </span>",
"    capsule lenticulostriate territory (",
"    <a class=\"graphic graphic_figure graphicRef60945 \" href=\"mobipreview.htm?28/23/29049\">",
"     figure 5",
"    </a>",
"    ). In addition, they may produce cortical surface symptoms when pial collateral flow is inadequate. These include aphasic syndromes in the dominant hemisphere and anosognosia or neglect in the nondominant hemisphere.",
"   </p>",
"   <p>",
"    Smaller emboli that occlude branches of the middle cerebral artery stem result in more focal symptoms, including hand alone or arm and hand numbness, weakness,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    heaviness induced by ischemia to the frontal area of the contralateral frontal lobe motor system (",
"    <a class=\"graphic graphic_figure graphicRef81813 \" href=\"mobipreview.htm?9/51/10042\">",
"     figure 3",
"    </a>",
"    ). The symptoms also may be as specific as thumb or hand numbness or a swollen feeling, suggesting focal ischemia in the hand area of the sensory strip or parietal association cortex. Transient unilateral visual obstruction often signifies atherothrombotic disease in the internal carotid artery proximal to the ophthalmic artery takeoff. Atherothrombotic disease is most often responsible for these syndromes, although carotid dissection and embolism from the aorta, heart, or an unknown source also should be considered.",
"   </p>",
"   <p>",
"    Posterior circulation territory embolic TIAs are generally produced by emboli arising from atherothrombotic disease at the origin or distal segment of one of the vertebral arteries or of the proximal basilar artery. Emboli arising from the aortic arch, the heart, an unknown source, or from a dissecting lesion in the vertebral artery should also be considered.",
"   </p>",
"   <p>",
"    Symptoms vary according to the vertebral or basilar artery branch in which the emboli lodges (",
"    <a class=\"graphic graphic_figure graphicRef60416 \" href=\"mobipreview.htm?21/17/21786\">",
"     figure 6",
"    </a>",
"    ). Emboli can produce transient ataxia, dizziness, diplopia, dysarthria, quadrantanopsia, hemianopsia, numbness, crossed face and body numbness, and focal hearing loss. When the top of the basilar artery is embolized, sudden, overwhelming stupor or coma may ensue due to bilateral medial thalamic, subthalamus, and medial rostral midbrain reticular activating system ischemia. Emboli in the more distal branches of the posterior cerebral artery may result in a homonymous field defect or in memory loss (inferior medial temporal lobe ischemia).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Lacunar or small vessel TIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lacunar or small vessel TIAs are thought to be caused by atherothrombotic obstructive lesions at the origin of the penetrating vessel or lipohyalinosis distally. Embolism is rarely proposed as the mechanism. These small vessel TIAs cause symptoms that are similar to the lacunar strokes that are likely to follow. Thus, face, arm, and leg weakness or numbness due to ischemia in the internal capsule, pons, or thalamus may occur, similar to the symptoms due to ischemia from embolism or large vessel atherothrombotic disease or dissection. As a result, serious disease in the parent vessel must be excluded before the diagnosis of lacunar or small vessel TIA can be established with confidence.",
"   </p>",
"   <p>",
"    Lacunar infarcts may be preceded by lacunar TIAs consisting of brief repetitive stereotyped clinical symptoms and signs, and lacunar stroke onset may be stepwise and progressive rather than abrupt [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40678/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. Such a pattern of TIAs, or nonsudden onset in association with a lacunar syndrome, is highly suggestive of small vessel lipohyalinotic etiology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40678/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     IMPORTANT PATHOLOGIC PROCESSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are four pathologic processes that give rise to low-flow \"true\" TIAs or embolic TIAs and that can produce sudden devastating stroke if not recognized and treated.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atherothrombotic stenotic lesions at the origin of the internal carotid artery that are narrowed more than 70 percent",
"     </li>",
"     <li>",
"      Intracranial atherothrombotic disease that produces low-flow or embolic TIA due to lesions at the distal vertebral",
"      <span class=\"nowrap\">",
"       artery/vertebrobasilar",
"      </span>",
"      <span class=\"nowrap\">",
"       junction/proximal",
"      </span>",
"      basilar artery",
"     </li>",
"     <li>",
"      Emboli to the top of the basilar artery or the middle cerebral artery stem that come from a source below, either arterial, aortic, or cardiac",
"     </li>",
"     <li>",
"      Dissection lesions at the origin of the petrous portion of the internal carotid artery or at the C1-2 level of the vertebral artery as it enters the foramen transversarium",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Internal carotid artery TIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;An atherothrombotic stenotic lesion at the origin of the internal carotid artery that is narrowed to more than 70 percent of its normal lumen diameter poses a threat of embolic or low-flow TIA or stroke [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40678/abstract/12-15\">",
"     12-15",
"    </a>",
"    ]. Even a 50 percent stenosis may be important when considering carotid endarterectomy for prevention of a secondary stroke or of a primary stroke when a TIA has occurred. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21530?source=see_link\">",
"     \"Management of symptomatic carotid atherosclerotic disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prospective natural history studies of asymptomatic atherothrombotic disease at the origin of the internal carotid artery (mostly asymptomatic carotid artery bruits) suggest that the rate of ipsilateral stroke increases dramatically when the residual lumen diameter narrows to greater than 70 percent stenosis (",
"    <a class=\"graphic graphic_figure graphicRef60048 \" href=\"mobipreview.htm?14/45/15069\">",
"     figure 7",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef66153 \" href=\"mobipreview.htm?38/17/39197\">",
"     figure 8",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40678/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. In one series of 500 patients, for example, the incidence of stroke was 1.7 percent per year overall but 5.5 percent per year in those with more than a 75 percent carotid artery stenosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40678/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This degree of stenosis corresponds to a residual lumen diameter of 1.5 mm, the precise point at which pressure drops across the stenotic lesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40678/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. When the pressure drops, flow to the ipsilateral middle cerebral artery stem is in part supplied by collateral circulation from the circle of Willis and from the external carotid to ophthalmic to distal internal carotid artery system (",
"    <a class=\"graphic graphic_figure graphicRef51410 \" href=\"mobipreview.htm?2/4/2122\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef65199 \" href=\"mobipreview.htm?41/34/42531\">",
"     figure 2",
"    </a>",
"    ). Less flow is provided by the internal carotid artery as the lesion further narrows. We believe that this provides a milieu for thrombus formation at the site of the stenosis and subsequent embolism. When the circle of Willis is compromised, low-flow \"true\" TIA ensues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Intracranial atherothrombotic disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracranial atherothrombotic disease that produces low-flow or embolic TIA most commonly occurs at the distal vertebral",
"    <span class=\"nowrap\">",
"     artery/vertebrobasilar",
"    </span>",
"    <span class=\"nowrap\">",
"     junction/proximal",
"    </span>",
"    basilar artery site. The potential of this lesion to precipitate a disastrous stroke by thrombosis, thrombus propagation, and embolism is extremely important. The other two most important, but less common, sites include the siphon portion of the internal carotid artery and the middle cerebral artery stem. The common carotid origin and the vertebral artery origin are much less problematic since they only rarely give rise to artery-to-artery emboli.",
"   </p>",
"   <p>",
"    The ability to noninvasively diagnose and follow these intracranial arterial lesions with precision through MRI angiography, duplex Doppler, and transcranial Doppler flow assessment allows for important preventive therapeutic considerations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/33/32281?source=see_link\">",
"     \"Secondary prevention for specific causes of ischemic stroke and transient ischemic attack\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Arterial, aortic, or cardiac sources of emboli",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emboli at the top of the basilar artery or in the middle cerebral artery stem that come from a source below &mdash; arterial, aortic, or cardiac &mdash; are extremely important to recognize since they may produce fluctuating symptoms or TIAs prior to a devastating stroke. Transient focal symptoms due to an embolus at these sites occur because blood flow reestablishes itself around the embolus.",
"   </p>",
"   <p>",
"    The symptoms may return in abundance and produce a stroke when the embolus itself causes a thrombus that further occludes the artery. This can occur hours or even days after the embolus has lodged at the site because it did not migrate or lyse. Acute antithrombotic therapy with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    may be highly effective in preventing this thrombus propagation and provide the time for spontaneous thrombolysis, although this has not been proven definitively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Dissection lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dissection lesions at the origin of the petrous portion of the internal carotid artery or at the C1-2 level of the vertebral artery as it enters the foramen transversarium cause symptoms of cerebral ischemia due to low flow or embolism, which occur within minutes, hours, or even days prior to a devastating stroke. Modern Doppler and neurologic imaging technology can establish the diagnosis noninvasively with the necessary precision to permit potentially stroke-saving therapeutic strategies (eg, intravenous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with transient ischemic attack (TIA) or minor stroke are at increased risk of recurrent stroke. Clinical TIAs associated with neuroimaging evidence of infarction (ie, transient symptoms with infarction or TSI) may be at particularly high risk of ischemic stroke. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18773?source=see_link&amp;anchor=H5#H5\">",
"     \"Definition of transient ischemic attack\", section on 'Transient symptoms with infarction'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Therefore, TIA is a neurologic emergency. Recognition of TIAs can identify patients who may benefit from preventive therapy or from revascularization of large vessels such as the carotid artery. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10426?source=see_link&amp;anchor=H15#H15\">",
"     \"Initial evaluation and management of transient ischemic attack and minor stroke\", section on 'Prognosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/22/35170?source=see_link\">",
"       \"Patient information: Transient ischemic attack (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/18/20772?source=see_link\">",
"       \"Patient information: Transient ischemic attack (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23478174\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Philip Kistler for his contributions to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40678/abstract/1\">",
"      Brown RD Jr, Petty GW, O'Fallon WM, et al. Incidence of transient ischemic attack in Rochester, Minnesota, 1985-1989. Stroke 1998; 29:2109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40678/abstract/2\">",
"      Kleindorfer D, Panagos P, Pancioli A, et al. Incidence and short-term prognosis of transient ischemic attack in a population-based study. Stroke 2005; 36:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40678/abstract/3\">",
"      Ueda K, Kiyohara Y, Hasuo Y, et al. Transient cerebral ischemic attacks in a Japanese community, Hisayama, Japan. Stroke 1987; 18:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40678/abstract/4\">",
"      Dennis MS, Bamford JM, Sandercock PA, Warlow CP. Incidence of transient ischemic attacks in Oxfordshire, England. Stroke 1989; 20:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40678/abstract/5\">",
"      Lemesle M, Milan C, Faivre J, et al. Incidence trends of ischemic stroke and transient ischemic attacks in a well-defined French population from 1985 through 1994. Stroke 1999; 30:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40678/abstract/6\">",
"      Feigin VL, Shishkin SV, Tzirkin GM, et al. A population-based study of transient ischemic attack incidence in Novosibirsk, Russia, 1987-1988 and 1996-1997. Stroke 2000; 31:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40678/abstract/7\">",
"      Kimura K, Minematsu K, Yasaka M, et al. The duration of symptoms in transient ischemic attack. Neurology 1999; 52:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40678/abstract/8\">",
"      Fisher CM. Lacunar strokes and infarcts: a review. Neurology 1982; 32:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40678/abstract/9\">",
"      Kappelle LJ, van Latum JC, Koudstaal PJ, van Gijn J. Transient ischaemic attacks and small-vessel disease. Dutch TIA Study Group. Lancet 1991; 337:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40678/abstract/10\">",
"      Donnan GA, O'Malley HM, Quang L, et al. The capsular warning syndrome: pathogenesis and clinical features. Neurology 1993; 43:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40678/abstract/11\">",
"      Herv&eacute; D, Gautier-Bertrand M, Labreuche J, et al. Predictive values of lacunar transient ischemic attacks. Stroke 2004; 35:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40678/abstract/12\">",
"      Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. North American Symptomatic Carotid Endarterectomy Trial Collaborators. N Engl J Med 1991; 325:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40678/abstract/13\">",
"      Kistler JP, Buonanno FS, Gress DR. Carotid endarterectomy--specific therapy based on pathophysiology. N Engl J Med 1991; 325:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40678/abstract/14\">",
"      MRC European Carotid Surgery Trial: interim results for symptomatic patients with severe (70-99%) or with mild (0-29%) carotid stenosis. European Carotid Surgery Trialists' Collaborative Group. Lancet 1991; 337:1235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40678/abstract/15\">",
"      Mayberg MR, Wilson SE, Yatsu F, et al. Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. Veterans Affairs Cooperative Studies Program 309 Trialist Group. JAMA 1991; 266:3289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40678/abstract/16\">",
"      Roederer GO, Langlois YE, Jager KA, et al. The natural history of carotid arterial disease in asymptomatic patients with cervical bruits. Stroke 1984; 15:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40678/abstract/17\">",
"      Chambers BR, Norris JW. Outcome in patients with asymptomatic neck bruits. N Engl J Med 1986; 315:860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40678/abstract/18\">",
"      Meissner I, Wiebers DO, Whisnant JP, O'Fallon WM. The natural history of asymptomatic carotid artery occlusive lesions. JAMA 1987; 258:2704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40678/abstract/19\">",
"      Suwanwela N, Can U, Furie KL, et al. Carotid Doppler ultrasound criteria for internal carotid artery stenosis based on residual lumen diameter calculated from en bloc carotid endarterectomy specimens. Stroke 1996; 27:1965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40678/abstract/20\">",
"      Can U, Furie KL, Suwanwela N, et al. Transcranial Doppler ultrasound criteria for hemodynamically significant internal carotid artery stenosis based on residual lumen diameter calculated from en bloc endarterectomy specimens. Stroke 1997; 28:1966.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1088 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-115.66.252.144-C3286EAA3D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_46_40678=[""].join("\n");
var outline_f39_46_40678=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOPHYSIOLOGIC MECHANISMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Large artery low flow TIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Embolic TIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lacunar TIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Low-flow TIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Embolic TIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Lacunar or small vessel TIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      IMPORTANT PATHOLOGIC PROCESSES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Internal carotid artery TIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Intracranial atherothrombotic disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Arterial, aortic, or cardiac sources of emboli",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Dissection lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23478174\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/1088\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/1088|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/4/2122\" title=\"figure 1\">",
"      Cerebral arterial circulation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?41/34/42531\" title=\"figure 2\">",
"      Cerebral vascular territories",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?9/51/10042\" title=\"figure 3\">",
"      Middle cerebral artery territory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/41/43673\" title=\"figure 4\">",
"      Superior pontine syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/23/29049\" title=\"figure 5\">",
"      Anterior cerebral artery territory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?21/17/21786\" title=\"figure 6\">",
"      Posterior cerebral artery territory",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/45/15069\" title=\"figure 7\">",
"      Stroke risk in carotid stenosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/17/39197\" title=\"figure 8\">",
"      Ischemic events with asymptomatic bruits",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/21/18773?source=related_link\">",
"      Definition of transient ischemic attack",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/11/10426?source=related_link\">",
"      Initial evaluation and management of transient ischemic attack and minor stroke",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/1/21530?source=related_link\">",
"      Management of symptomatic carotid atherosclerotic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?20/18/20772?source=related_link\">",
"      Patient information: Transient ischemic attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?34/22/35170?source=related_link\">",
"      Patient information: Transient ischemic attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/33/32281?source=related_link\">",
"      Secondary prevention for specific causes of ischemic stroke and transient ischemic attack",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_46_40679="Leg with filariasis";
var content_f39_46_40679=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F79016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F79016&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 494px\">",
"   <div class=\"ttl\">",
"    Leg with filariasis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 474px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Tish, DJ, Edwin, M, Kazura, JW. Mass chemotherapy options to control lymphatic filariasis: a systematic review. The Lancet Infectious Diseases 2005; 5: 514. Copyright &copy; 2005 Elsevier.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_46_40679=[""].join("\n");
var outline_f39_46_40679=null;
var title_f39_46_40680="Outcomes of renal transplantation in children";
var content_f39_46_40680=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Outcomes of renal transplantation in children",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/46/40680/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/46/40680/contributors\">",
"     Ruth A McDonald, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/46/40680/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/46/40680/contributors\">",
"     Patrick Niaudet, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/46/40680/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/46/40680/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/46/40680/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 4, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the estimated glomerular filtration rate declines to less than 30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    per 1.73m2 and the child is in Stage 4 chronic kidney disease, it is time to start preparing the child and the family for renal replacement therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/1\">",
"     1",
"    </a>",
"    ]. Although there have been many advances in chronic dialysis therapy in children, renal transplantation remains the best treatment for children with end-stage renal disease (ESRD) (",
"    <a class=\"graphic graphic_figure graphicRef54380 \" href=\"mobipreview.htm?36/13/37085\">",
"     figure 1",
"    </a>",
"    ). Over the last several years, renal allograft and patient survival have increased with improvements in the care of young patients and advances in immunosuppressive therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12774?source=see_link&amp;anchor=H363124528#H363124528\">",
"     \"Overview on renal replacement therapy (RRT) for children with chronic kidney disease\", section on 'Choice of RRT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Outcome of renal transplantation and the factors that affect allograft and patient survival in children will be reviewed here. General principles, immunosuppression and complications of renal transplantation in children are discussed separately. In addition, issues of renal transplantation survival and outcome that are common to both children and adults are presented in separate topic reviews. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23543?source=see_link\">",
"     \"General principles of kidney transplantation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38394?source=see_link\">",
"     \"Immunosuppression in renal transplantation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22154?source=see_link\">",
"     \"Complications of renal transplantation in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14170?source=see_link\">",
"     \"Risk factors for graft failure in kidney transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11159?source=see_link\">",
"     \"HLA matching and graft survival in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RISK FACTORS FOR ALLOGRAFT SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome of renal transplantation in children has improved over the last several decades primarily due to the introduction and widespread use of calcineurin inhibitors and other immunosuppressive agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/2-5\">",
"     2-5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38394?source=see_link\">",
"     \"Immunosuppression in renal transplantation in children\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H3\">",
"     'Effect of immunosuppressive regimens'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In addition to the efficacy of newer immunosuppressive regimens, other factors that affect allograft survival in children include the following [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/6-10\">",
"     6-10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Source of donor kidney",
"     </li>",
"     <li>",
"      HLA compatibility",
"     </li>",
"     <li>",
"      Age of the donor and recipient",
"     </li>",
"     <li>",
"      Presence of preformed anti-HLA antibodies (sensitization)",
"     </li>",
"     <li>",
"      Prolonged cold ischemia time",
"     </li>",
"     <li>",
"      Ethnicity of the recipient",
"     </li>",
"     <li>",
"      Delayed allograft function",
"     </li>",
"     <li>",
"      Acute rejection episodes",
"     </li>",
"     <li>",
"      Infections",
"     </li>",
"     <li>",
"      Adherence",
"     </li>",
"     <li>",
"      Underlying primary disease &ndash; Increased risk of recurrent disease is associated with focal glomerulosclerosis, atypical hemolytic uremic syndrome, and membranoproliferative glomerulonephritis. Obstructive uropathy with bladder dysfunction is associated with bladder complications, which may affect allograft function. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22154?source=see_link&amp;anchor=H6#H6\">",
"       \"Complications of renal transplantation in children\", section on 'Urologic complications'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22154?source=see_link&amp;anchor=H12#H12\">",
"       \"Complications of renal transplantation in children\", section on 'Recurrence of primary disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The effect of these risk factors was illustrated in a North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/9\">",
"     9",
"    </a>",
"    ]. In a cohort of patients who were less than 12 years of age when they received their transplants, children in whom allograft failure occurred within 10 years of transplant compared with those with continued allograft function 10 years post were more likely to be older, non-Caucasian, had a history of focal glomerulosclerosis, received a deceased donor kidney, and were less likely to have obstructive uropathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14170?source=see_link\">",
"     \"Risk factors for graft failure in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Similar results were seen in a multivariate analysis of the Organ Procurement and Transplant Network (OPTN) database of children who were transplanted from 1995 to 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/11\">",
"     11",
"    </a>",
"    ]. There was an increased risk of allograft failure in recipients who were older at the time of transplantation, black versus white ethnicity, female gender, received a deceased donor allograft, had delayed allograft function or a history of glomerular diseases (versus other categories), did not receive induction therapy, had an episode of acute rejection within the first year, or were transplanted in 1995 versus 2000.",
"   </p>",
"   <p>",
"    In the OPTN cohort, pretransplant dialysis had no effect on allograft survival for deceased donor allograft recipients. However, for living donor recipients, the use and duration of pretransplant hemodialysis but not pretransplant peritoneal dialysis adversely affected renal allograft survival. Improved allograft survival of preemptive transplantation was also reported in several studies, including one from the NAPRTCS registry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11224?source=see_link\">",
"     \"Dialysis issues prior to and after renal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Effect of immunosuppressive regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction of cyclosporin, the first calcineurin inhibitor, and other new immunosuppressive agents, such as",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/53/34640?source=see_link\">",
"     tacrolimus",
"    </a>",
"    , have improved allograft survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/7,10,15-18\">",
"     7,10,15-18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Based upon an OPTN analysis, rates were significantly higher for the period 1999 to 2002 versus 1994 to 1998 for both one year (95 and 88 percent) and three year allograft survival (79 and 76 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/7\">",
"       7",
"      </a>",
"      ]. This was thought to be due to the increased dosing of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      between these two time periods.",
"     </li>",
"     <li>",
"      In two earlier reports from NAPRTCS registry, a contributory factor for improved one year allograft survival rate and a decreased risk of chronic allograft rejection was increasing the dosing of",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"       cyclosporine",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/16,18\">",
"       16,18",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      From the 2010 NAPRTCS annual transplant report, the one, three, and five year allograft survival rates were 96.5, 91.5, and 84.3 percent for living donor recipients, and 95.1, 84.1, and 78 percent for deceased donor recipients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Allograft survival frequently exceeds 50 percent after 10 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. In a long-term Swedish study of children who received",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?33/24/34176?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?34/30/35296?source=see_link\">",
"     prednisolone",
"    </a>",
"    , and",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?2/10/2216?source=see_link\">",
"     azathioprine",
"    </a>",
"    , 5- and 10-year allograft survival rates were 77 and 66 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/21\">",
"     21",
"    </a>",
"    ]. In a report from the French pediatric kidney database, actuarial allograft survival was 86 and 78 percent at 5 and 10 years post transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Current immunosuppressive agents and their effects on graft survival are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38394?source=see_link\">",
"     \"Immunosuppression in renal transplantation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Donor source",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allograft survival is higher in children with living donor allografts compared with those with deceased donor allografts as illustrated by the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The five year allograft survival rates from the 2010 NAPRTCS annual report for living donor and deceased donor allografts were 83 and 70 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/10\">",
"       10",
"      </a>",
"      ]. Although the five year survival rates were higher in both living and deceased donor groups transplanted between 1996 and 2010, allograft survival remained higher in those receiving a living donor allograft (86 and 78 percent).",
"     </li>",
"     <li>",
"      Analysis of the OPTN database of children transplanted between January 1, 1994 and December 31, 2006 demonstrated a 9 percent adjusted five year allograft survival advantage using a living versus deceased donor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another analysis of the OPTN database found an approximate 35 percent improvement in seven year allograft survival in pediatric recipients who received a kidney from an 18- to 54-year-old living donor compared with a similar age range of deceased donors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/24\">",
"       24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite the general desirability of living donor allografts, a deceased donor may be preferred in settings in which there is a high risk of recurrent disease leading to loss of the allograft, as with rapidly progressive focal glomerulosclerosis Support for this exception is provided by the finding that five year allograft survival of living and deceased donor allografts was not significantly different for children with focal glomerulosclerosis (69 and 60 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/25\">",
"     25",
"    </a>",
"    ]. Other diseases with a high recurrence rate in the allograft include atypical hemolytic uremic syndrome and primary hyperoxaluria. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23543?source=see_link&amp;anchor=H5913747#H5913747\">",
"     \"General principles of kidney transplantation in children\", section on 'Donor choice'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     HLA matches",
"    </span>",
"    &nbsp;&mdash;&nbsp;Similar to adults, superior HLA matching between recipient and donor, whether deceased donor or living related, is associated with improved allograft outcomes in children. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11159?source=see_link\">",
"     \"HLA matching and graft survival in kidney transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Identical HLA matches result in the best outcomes. However, children rarely have brothers or sisters (some of whom are HLA identical) old enough to be an organ donor, as a result, most living donated allografts are from a parent, who is an obligate one haplotype match. Optimal HLA matching is also preferred to minimize sensitization, particularly for young recipients who will need retransplantations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11159?source=see_link&amp;anchor=H4#H4\">",
"     \"HLA matching and graft survival in kidney transplantation\", section on 'Long-term graft survival'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, maximization of HLA matching is not entirely beneficial for those awaiting a deceased donor allograft. Restricting deceased donor offers to only well HLA matched donors may significantly prolong the transplant candidate&rsquo;s wait time, increasing morbidities associated with ESRD and dialysis. In addition, improved matching may not prolong long-term graft survival as illustrated by the following studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an analysis from the OPTN database, there was no significant five year allograft survival advantage based on HLA-DR matching for primary pediatric renal recipients who received deceased donor allografts between 1996 and 2004 in the United States [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      An analysis of the International Collaborative Transplant Study database of 9209 pediatric renal transplant recipients also showed that two HLA-DR mismatches compared with 0 and 1 mismatches were not associated with significantly lower allograft survival in deceased donor transplants performed during 1998 to 2007, although they were associated with poorer allograft survival in the previous 10 year time period between 1988 and 1997 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/27\">",
"       27",
"      </a>",
"      ]. However, increasing numbers of combined HLA-A+B+DR mismatches correlated with poorer allograft survival during both time periods.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, a single center study that determined HLA-DR sensitization posttransplantation found that HLA-DR mismatching increased the risk of rejection in 178 patients (below 21 years of age) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/28\">",
"     28",
"    </a>",
"    ]. At a median follow-up of 4.1 years, patients with one or two mismatches had a 1.7 times greater chance of rejection than those patients without a mismatch. In addition, the study also reported that the probability of finding a zero mismatched ABO-identical donor was low. These results highlight the tension between the waiting time required to perform HLA matching that negatively impacts on allograft function and the benefit of finding a donor allograft without any mismatches.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Recipient age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The results of kidney transplantation in children appear to vary with the age of the recipient. Historically, younger recipients had poorer allograft survival but with the improvement in care of these patients, similar excellent long-term allograft survival to that of older children are seen in young children, especially those who receive living donor kidneys.",
"   </p>",
"   <p>",
"    In the 2004 Scientific Registry of Transplant Recipients, for example, five year allograft survival rates among living donor recipients for children 1 to 5 years of age and 6 to 10 years of age were 90 and 91 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/29\">",
"     29",
"    </a>",
"    ]. For deceased donor recipients, the survival rates at 5 years were 78 and 77 percent.",
"   </p>",
"   <p>",
"    Similar results were observed in the NAPRTCS registry with five year survival rates based on donor source and recipient age as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Living-related donor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      0 to 1 year of age &ndash; 84 percent",
"     </li>",
"     <li>",
"      2 to 5 years of age &ndash; 85 percent",
"     </li>",
"     <li>",
"      6 to 12 years of age &ndash; 85 percent",
"     </li>",
"     <li>",
"      &gt;12 years of age &ndash; 79 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deceased donor",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      0 to 1 year of age &ndash; 61 percent",
"     </li>",
"     <li>",
"      2 to 5 years of age &ndash; 74 percent",
"     </li>",
"     <li>",
"      6 to 12 years of age &ndash; 72 percent",
"     </li>",
"     <li>",
"      &gt;12 years of age &ndash; 66 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As these data demonstrate, adolescents represent an age group at increased risk of allograft failure. Contributory factors include nonadherence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/29\">",
"     29",
"    </a>",
"    ] and transition to adult care during this vulnerable period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/30,31\">",
"     30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Donor age",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poorer allograft survival is associated with the transplantation of renal allografts from deceased donors younger than 2 years of age or older than 50 years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. In the former, poorer allograft survival may be due to a higher incidence of primary nonfunction and allograft thrombosis.",
"   </p>",
"   <p>",
"    In the NAPRTCS registry, the five year allograft survival of kidneys from deceased donors based on donor ages was as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      &lt;2 years of age &ndash; 50 percent",
"     </li>",
"     <li>",
"      2 to 17 years of age &ndash; 67 percent",
"     </li>",
"     <li>",
"      18 to 49 years of age &ndash; 72 percent",
"     </li>",
"     <li>",
"      &ge; 50 years of age &ndash; 58 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the previously mentioned analysis from the International Collaborative Transplant Study, allograft survival rates were similar for patients who received kidneys from deceased donors aged 11 to 17, 18 to 34, or 35 to 49 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/27\">",
"     27",
"    </a>",
"    ]. It is unclear whether younger donors were used in this study.",
"   </p>",
"   <p>",
"    In a study based on UNOS data from 1987 to 2003, en-bloc kidney transplantation compared with single kidney had a lower rate of delayed allograft function and better five year allograft survival when deceased donors were less than five years of age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Delayed graft function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed allograft function (DGF), defined by the need of dialysis during the first week following transplantation, is associated with poor outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/11,35\">",
"     11,35",
"    </a>",
"    ]. It occurs more frequently in patients who receive deceased donor allograft, and the incidence of DGF increases with cold ischemia time. In the NAPRTCS cohort, the five year allograft survival was lower in patients receiving a deceased donor allograft with a cold ischemic time greater than 24 hours compared with those with a lower cold ischemic time (62 versus 71 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/10\">",
"     10",
"    </a>",
"    ]. Intraoperative vascular volume maintenance is most important to prevent DGF, especially in young recipients. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22154?source=see_link&amp;anchor=H3#H3\">",
"     \"Complications of renal transplantation in children\", section on 'Delayed graft function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Acute rejection episodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 2010 NAPRTCS report, the rate of allograft failure or death due to acute rejection was 5 percent in children who received living donor kidneys, and 7 percent in those with decreased donor kidneys [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/10\">",
"     10",
"    </a>",
"    ]. In another cohort of children who received deceased donor allografts, the estimated allograft half-life was shorter in patients who had acute rejection episodes than those who did not (6.6 versus 12.5 years ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/36\">",
"     36",
"    </a>",
"    ]. An analysis of OPTN data also showed an increased relative risk of allograft failure for pediatric recipients who were treated for acute rejection in the first years post transplant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/11\">",
"     11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22154?source=see_link&amp;anchor=H8#H8\">",
"     \"Complications of renal transplantation in children\", section on 'Acute rejection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to acutely threatening survival of the allograft, acute rejection episodes markedly increase the risk of developing chronic rejection, thereby enhancing possible allograft loss over time. In one study of nearly 3500 children, multivariate analyses found that the relative risks of chronic rejection increased with an acute rejection episode and were even greater with two such episodes (RR, 3.1 and 4.3, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/37\">",
"     37",
"    </a>",
"    ]. Given this association, the prevention of such events by providing optimal immunosuppressive therapy is extremely important. The beneficial effects of improved immunosuppressive regimens and optimal HLA matching on allograft survival are in part because of their role in lowering the risk of acute rejection. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=see_link&amp;anchor=H12#H12\">",
"     \"Chronic renal allograft nephropathy\", section on 'Importance of acute rejection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22154?source=see_link&amp;anchor=H9#H9\">",
"     \"Complications of renal transplantation in children\", section on 'Chronic allograft injury'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38394?source=see_link\">",
"     \"Immunosuppression in renal transplantation in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infections are a permanent risk in patients receiving immunosuppressive treatment and may impact on allograft survival. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22154?source=see_link&amp;anchor=H23#H23\">",
"     \"Complications of renal transplantation in children\", section on 'Infections'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytomegalovirus (CMV) infection is associated with increased mortality and morbidity. Prophylaxis of CMV infection may be associated with improved patient and allograft survival. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29738?source=see_link\">",
"       \"Cytomegalovirus infection in renal transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Polyomavirus, mainly BK virus, affects 3 to 8 percent of children with renal allografts and may be responsible for allograft nephropathy and allograft failure. Risk factors for BKV infection are intense immunosuppression and acute rejection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/7/6266?source=see_link\">",
"       \"Clinical manifestations and diagnosis of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/45/42712?source=see_link\">",
"       \"Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In contrast, there appears to be no correlation between a history of urinary tract infection (either before or after transplant) and decreased allograft survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Nonadherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonadherence to immunosuppressive treatment contributes to both acute and chronic rejection. An analysis of the United States Renal Data System showed that among pediatric renal transplant recipients, greater adherence was significantly associated with improved long term allograft survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 16 studies included in a systematic review of the literature, the rate of nonadherence ranged from 5 to 70 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/40\">",
"     40",
"    </a>",
"    ]. Amongst these studies, there was variability on how adherence was assessed ranging from drug level assays, pill counting to patient self-reporting. Factors associated with nonadherence included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Poor socioeconomic status",
"     </li>",
"     <li>",
"      Family stress and conflicts",
"     </li>",
"     <li>",
"      Lack of parental supervision",
"     </li>",
"     <li>",
"      Patient depression",
"     </li>",
"     <li>",
"      Cosmetic side effects of medications",
"     </li>",
"     <li>",
"      Large number of medications",
"     </li>",
"     <li>",
"      Size of tablets and difficulty swallowing tablets",
"     </li>",
"     <li>",
"      Taste of medication",
"     </li>",
"     <li>",
"      Poor patient knowledge",
"     </li>",
"     <li>",
"      Striving for increase autonomy and independence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Nonadherence is a risk factor for graft loss [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/14,23,40\">",
"     14,23,40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the 2010 NAPRTCS transplant report, 5 percent of primary allograft loss was due to patient discontinuation of medications.",
"     </li>",
"     <li>",
"      In a study based on OPTN data, 3.4 percent of allografts in pediatric African American recipients were lost due to nonadherence as a contributory factor compared with 1.5 percent among other races [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/23\">",
"       23",
"      </a>",
"      ]. Significantly lower incidence of nonadherence was observed in children under the age of 10 (0.9 percent) when compared with early adolescents aged 10 to 14 (2.2 percent) and older teens aged 15 to 20 (2.0 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although it is clear from the above evidence that increasing adherence would improve renal transplantation outcome, data on interventions to improve adherence are lacking. One study conducted in adult transplant recipients showed a multidimensional program that included home visits, follow-up calls, and educational material resulted in a lower adherence in the intervention group compared with the control group over the three month study period [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/41\">",
"     41",
"    </a>",
"    ]. However, the differences between the two groups faded after nine months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     PATIENT SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient survival is better in pediatric renal transplant recipients than adults, and mortality has decreased in recent years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/5,19,21,29,42-45\">",
"     5,19,21,29,42-45",
"    </a>",
"    ]. Data from the NAPRTCS 2010 annual report showed that for those transplanted since 1996, the three year patient survival exceeded 90 percent in all recipients of living related or deceased donors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/10\">",
"     10",
"    </a>",
"    ]. The three year survival rate has significantly improved for infants who received deceased donor allograft from 78.6 percent for those transplanted between 1987 and 1995 to 93.4 percent in the cohort transplanted after 1996 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, mortality remains higher for infants compared with older children, especially for those who are deceased donor recipients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/5,10\">",
"     5,10",
"    </a>",
"    ]. This was illustrated by the following three year survival rates of 10,552 children registered in the NAPRTCS database who were transplanted between 1996 and 2010 as follows [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Living donor (n = 5581)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All patients &ndash; 97.9 percent",
"     </li>",
"     <li>",
"      Patients &le;1 year of age &ndash; 95.9",
"     </li>",
"     <li>",
"      Patients between 2 and 5 years of age &ndash; 97.4 percent",
"     </li>",
"     <li>",
"      Patients between 6 and 12 years of age &ndash; 98.3 percent",
"     </li>",
"     <li>",
"      Patients &gt;12 years of age &ndash; 98.1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deceased donor (n = 4971)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      All patients &ndash; 97.8 percent",
"     </li>",
"     <li>",
"      Patients &le;1 year of age &ndash; 93.4",
"     </li>",
"     <li>",
"      Patients between 2 and 5 years of age &ndash; 96.3 percent",
"     </li>",
"     <li>",
"      Patients between 6 and 12 years of age &ndash; 98.9 percent",
"     </li>",
"     <li>",
"      Patients &gt;12 years of age &ndash; 97.6 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As with adults, survival is superior among children with a kidney allograft compared with those who remain on dialysis. This was best shown in an observational study of nearly 6000 patients under 19 years of age who were placed on the kidney transplant waiting list [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/46\">",
"     46",
"    </a>",
"    ]. Compared to those who remained on the list, a significantly lower mortality rate was noted in those who underwent transplantation (13.1 versus 17.6",
"    <span class=\"nowrap\">",
"     deaths/1000",
"    </span>",
"    patient-years). This survival benefit was observed beginning six months post transplant.",
"   </p>",
"   <p>",
"    Overall, the major causes of death are cardiopulmonary disease and infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/47\">",
"     47",
"    </a>",
"    ]. The main causes of death during the first three months are infections (principally CMV infection) and hemorrhage. However, the incidence of malignancies and cardiovascular lower when compared with those reported for adults. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22154?source=see_link&amp;anchor=H8#H8\">",
"     \"Complications of renal transplantation in children\", section on 'Acute rejection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Non-renal manifestations of the underlying disease also may have an effect upon patient survival. In one study comparing patient survival rates of children with and without autosomal recessive polycystic kidney disease (ARPKD), death resulting from sepsis due to cholangitis and liver involvement was a factor in those with ARPKD [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Mortality after transplantation is also affected by the underlying renal disease, with higher mortality rates observed for oxalosis, congenital nephrotic syndrome, and Drash syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     GROWTH AFTER RENAL TRANSPLANTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children have improved statural growth after successful renal transplantation; however, complete catch-up growth is dependent on a variety of factors that include renal allograft function, corticosteroid therapy, age of transplant, and donor source:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5262288\">",
"    <span class=\"h2\">",
"     Age of recipient",
"    </span>",
"    &nbsp;&mdash;&nbsp;Catch-up growth is generally only observed in children &lt;5 years. After five years of age, children may grow at a normal rate but rarely with catch-up growth.",
"   </p>",
"   <p>",
"    This was best illustrated by a study using data from the NAPRTCS registry that included 300 children with a functioning graft who received conventional steroid-based immunosuppressive therapy. In this report, catch-up growth was observed in patients younger than one year of age at the time of transplantation (mean increase of 1 standard deviation [SD] in height) and those between two and five years of age (mean increase of 0.5 SD in height) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/50\">",
"     50",
"    </a>",
"    ]. In contrast, there was no catch-up growth seen in patients between 6 and 17 years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5262313\">",
"    <span class=\"h2\">",
"     Allograft function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Normal growth rate requires normal or nearly normal allograft function.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the above NAPRTCS report, an increase in the serum creatinine level by 1.0",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      was associated with a decrease in relative height of 0.15 SD [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/50\">",
"       50",
"      </a>",
"      ]. However, in this study, it was difficult to determine the independent impact of glomerular filtration rate (GFR) on growth, because patients with poor graft function also received higher amounts of glucocorticoids to suppress chronic graft rejection.",
"     </li>",
"     <li>",
"      In a single center study of 70 prepubertal Dutch children with renal allografts, multivariate analysis demonstrated a negative correlation between a GFR below 50",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per 1.73 m",
"      <sup>",
"       2",
"      </sup>",
"      and catch-up growth [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5262320\">",
"    <span class=\"h2\">",
"     Immunosuppressive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticosteroid therapy, particularly daily steroid therapy, is an important contributor to poor growth in children following renal transplantation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/51\">",
"     51",
"    </a>",
"    ]. Growth is impaired when the dose of corticosteroids is above 5",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    per day. These agents interact with the growth hormone insulin-like growth hormone axis, and are therefore associated with decreased levels of growth hormone and insulin-like growth hormone activity.",
"   </p>",
"   <p>",
"    <br/>",
"    Because of the significant adverse effects of corticosteroids, ongoing trials are focused on identifying regimens that successfully withdraw or minimize the use of these drugs to avoid or reduce their adverse effects (eg, growth impairment) without increasing the risk of acute rejection. Immunosuppression with corticosteroid withdrawal and the use of alternate-day steroid therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38394?source=see_link&amp;anchor=H533861718#H533861718\">",
"     \"Immunosuppression in renal transplantation in children\", section on 'Corticosteroid withdrawal'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/53/17240?source=see_link&amp;anchor=H359697803#H359697803\">",
"     \"Prevention and management of growth failure in children with chronic kidney disease\", section on 'Corticosteroid therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5262332\">",
"    <span class=\"h2\">",
"     Donor source",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children who receive living donor allografts have better growth outcome compared with those who receive deceased donor allografts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40680/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12074525\">",
"    <span class=\"h2\">",
"     Growth hormone therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recombinant growth hormone therapy may be beneficial in improving growth in prepubertal children with growth impairment after renal transplantation. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/14/27881?source=see_link\">",
"     \"Growth hormone treatment in children with chronic kidney disease and postrenal transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6257820\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Patrick Niaudet, who contributed to an earlier version of this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The outcome of renal transplantation in children has improved over the last several decades, a period that coincides with the introduction and widespread use of calcineurin inhibitors and other immunosuppressive agents. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Effect of immunosuppressive regimens'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Other factors that affect renal allograft survival include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Donor source &ndash; Allograft survival is better with kidneys from living versus deceased donors. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Donor source'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Better histocompatibility matching between donor and recipient improves allograft survival with the possible exception of deceased donor allografts. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'HLA matches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recipient &ndash; Although the overall allograft survival is excellent for recipients of all ages, infants and adolescent recipients have a lower allograft survival rate. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Recipient age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Donor age &ndash; Poorer allograft survival is associated with renal allografts from deceased donors younger than 2 years of age or older than 50 years of age. In the former, poorer allograft survival may be due to a higher incidence of primary nonfunction and allograft thrombosis. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Donor age'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute rejection episodes and subsequent infection with either cytomegalovirus or BK virus are associated with decreased allograft survival time. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Acute rejection episodes'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Infections'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patient survival is better in pediatric renal transplant recipients than in adults and has increased in recent years. The major causes of death are infection and cardiopulmonary disease. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Patient survival'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most children have improved statural growth after successful renal transplantation. Catch-up growth is only observed with normal or nearly normal allograft function. The most important factors limiting growth after renal transplantation are poor renal allograft function and corticosteroid therapy. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Growth after renal transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/1\">",
"      National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39:S1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/2\">",
"      Benfield MR, McDonald RA, Bartosh S, et al. Changing trends in pediatric transplantation: 2001 Annual Report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2003; 7:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/3\">",
"      Englund MS, Berg UB, Bohlin AB, et al. Ten years' experience of renal transplantation in children in the cyclosporine era. Transplantation 1993; 56:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/4\">",
"      Melter M, Briscoe DM. Challenges after pediatric transplantation. Semin Nephrol 2000; 20:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/5\">",
"      Harmon WE, McDonald RA, Reyes JD, et al. Pediatric transplantation, 1994-2003. Am J Transplant 2005; 5:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/6\">",
"      Warady BA, H&eacute;bert D, Sullivan EK, et al. Renal transplantation, chronic dialysis, and chronic renal insufficiency in children and adolescents. The 1995 Annual Report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Nephrol 1997; 11:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/7\">",
"      Hwang AH, Cho YW, Cicciarelli J, et al. Risk factors for short- and long-term survival of primary cadaveric renal allografts in pediatric recipients: a UNOS analysis. Transplantation 2005; 80:466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/8\">",
"      Omoloja A, Mitsnefes M, Talley L, et al. Racial differences in graft survival: a report from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS). Clin J Am Soc Nephrol 2007; 2:524.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/9\">",
"      Ellis EN, Martz K, Talley L, et al. Factors related to long-term renal transplant function in children. Pediatr Nephrol 2008; 23:1149.",
"     </a>",
"    </li>",
"    <li>",
"     The North American Pediatric Renal Trials and Collaborative Studies 2010 Annual Report. Available at: www.naprtcs.org (Accessed on May 04, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/11\">",
"      Butani L, Perez RV. Effect of pretransplant dialysis modality and duration on long-term outcomes of children receiving renal transplants. Transplantation 2011; 91:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/12\">",
"      Schurman SJ, McEnery PT. Factors influencing short-term and long-term pediatric renal transplant survival. J Pediatr 1997; 130:455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/13\">",
"      Mahmoud A, Sa&iuml;d MH, Dawahra M, et al. Outcome of preemptive renal transplantation and pretransplantation dialysis in children. Pediatr Nephrol 1997; 11:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/14\">",
"      Vats AN, Donaldson L, Fine RN, Chavers BM. Pretransplant dialysis status and outcome of renal transplantation in North American children: a NAPRTCS Study. North American Pediatric Renal Transplant Cooperative Study. Transplantation 2000; 69:1414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/15\">",
"      Broyer M, Ehrich J, Jones E, Selwood N. Five year survival of kidney transplantation in children: data from the European (EDTA-ERA) Registry. Kidney Int Suppl 1993; 43:S22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/16\">",
"      Tejani A, Stablein DM, Donaldson L, et al. Steady improvement in short-term graft survival of pediatric renal transplants: the NAPRTCS experience. Clin Transpl 1999; :95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/17\">",
"      Colombani PM, Dunn SP, Harmon WE, et al. Pediatric transplantation. Am J Transplant 2003; 3 Suppl 4:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/18\">",
"      Tejani A, Ho PL, Emmett L, et al. Reduction in acute rejections decreases chronic rejection graft failure in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Am J Transplant 2002; 2:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/19\">",
"      Najarian JS, So SK, Simmons RL, et al. The outcome of 304 primary renal transplants in children (1968-1985). Ann Surg 1986; 204:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/20\">",
"      Broyer M, Gagnadoux MF, Guest G, et al. Kidney transplantation in children: results of 383 grafts performed at Enfants Malades Hospital from 1973 to 1984. Adv Nephrol Necker Hosp 1987; 16:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/21\">",
"      Englund M, Berg U, Tyd&eacute;n G. A longitudinal study of children who received renal transplants 10-20 years ago. Transplantation 2003; 76:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/22\">",
"      Allain-Launay E, Roussey-Kesler G, Ranchin B, et al. Mortality in pediatric renal transplantation: a study of the French pediatric kidney database. Pediatr Transplant 2009; 13:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/23\">",
"      Hardy BE, Shah T, Cicciarelli J, et al. Kidney transplantation in children and adolescents: an analysis of United Network for Organ Sharing Database. Transplant Proc 2009; 41:1533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/24\">",
"      Dale-Shall AW, Smith JM, McBride MA, et al. The relationship of donor source and age on short- and long-term allograft survival in pediatric renal transplantation. Pediatr Transplant 2009; 13:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/25\">",
"      Baum MA, Stablein DM, Panzarino VM, et al. Loss of living donor renal allograft survival advantage in children with focal segmental glomerulosclerosis. Kidney Int 2001; 59:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/26\">",
"      Gritsch HA, Veale JL, Leichtman AB, et al. Should pediatric patients wait for HLA-DR-matched renal transplants? Am J Transplant 2008; 8:2056.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/27\">",
"      Opelz G, D&ouml;hler B. Pediatric kidney transplantation: analysis of donor age, HLA match, and posttransplant non-Hodgkin lymphoma: a collaborative transplant study report. Transplantation 2010; 90:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/28\">",
"      Vu LT, Baxter-Lowe LA, Garcia J, et al. HLA-DR matching in organ allocation: balance between waiting time and rejection in pediatric kidney transplantation. Arch Surg 2011; 146:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/29\">",
"      Port FK, Dykstra DM, Merion RM, Wolfe RA. Trends and results for organ donation and transplantation in the United States, 2004. Am J Transplant 2005; 5:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/30\">",
"      Smith JM, Ho PL, McDonald RA, North American Pediatric Renal Transplant Cooperative Study. Renal transplant outcomes in adolescents: a report of the North American Pediatric Renal Transplant Cooperative Study. Pediatr Transplant 2002; 6:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/31\">",
"      Koshy SM, Hebert D, Lam K, et al. Renal allograft loss during transition to adult healthcare services among pediatric renal transplant patients. Transplantation 2009; 87:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/32\">",
"      Harmon WE, Stablein D, Alexander SR, Tejani A. Graft thrombosis in pediatric renal transplant recipients. A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 1991; 51:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/33\">",
"      Rao KV, Kasiske BL, Odlund MD, et al. Influence of cadaver donor age on posttransplant renal function and graft outcome. Transplantation 1990; 49:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/34\">",
"      Dharnidharka VR, Stevens G, Howard RJ. En-bloc kidney transplantation in the United states: an analysis of united network of organ sharing (UNOS) data from 1987 to 2003. Am J Transplant 2005; 5:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/35\">",
"      Tejani AH, Sullivan EK, Alexander SR, et al. Predictive factors for delayed graft function (DGF) and its impact on renal graft survival in children: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Pediatr Transplant 1999; 3:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/36\">",
"      Lindholm A, Ohlman S, Albrechtsen D, et al. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens. Transplantation 1993; 56:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/37\">",
"      Tejani A, Cortes L, Stablein D. Clinical correlates of chronic rejection in pediatric renal transplantation. A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 1996; 61:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/38\">",
"      Silva A, Rodig N, Passerotti CP, et al. Risk factors for urinary tract infection after renal transplantation and its impact on graft function in children and young adults. J Urol 2010; 184:1462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/39\">",
"      Chisholm-Burns MA, Spivey CA, Rehfeld R, et al. Immunosuppressant therapy adherence and graft failure among pediatric renal transplant recipients. Am J Transplant 2009; 9:2497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/40\">",
"      Dobbels F, Ruppar T, De Geest S, et al. Adherence to the immunosuppressive regimen in pediatric kidney transplant recipients: a systematic review. Pediatr Transplant 2010; 14:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/41\">",
"      De Geest S, Sch&auml;fer-Keller P, Denhaerynck K, et al. Supporting medication adherence in renal transplantation (SMART): a pilot RCT to improve adherence to immunosuppressive regimens. Clin Transplant 2006; 20:359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/42\">",
"      Potter DE, Najarian J, Belzer F, et al. Long-term results of renal transplantation in children. Kidney Int 1991; 40:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/43\">",
"      Broyer M. Kidney transplantation in children--data from the EDTA registry. The EDTA Registry Committee. Transplant Proc 1989; 21:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/44\">",
"      Churchill BM, Sheldon CA, McLorie GA, Arbus GS. Factors influencing patient and graft survival in 300 cadaveric pediatric renal transplants. J Urol 1988; 140:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/45\">",
"      Rigden SPA, Bewick M, Koffman G, et al. Twenty years experience of renal transplantation in children. Pediatr Nephrol 1989; 3:C229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/46\">",
"      Gillen DL, Stehman-Breen CO, Smith JM, et al. Survival advantage of pediatric recipients of a first kidney transplant among children awaiting kidney transplantation. Am J Transplant 2008; 8:2600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/47\">",
"      Neu AM. Special issues in pediatric kidney transplantation. Adv Chronic Kidney Dis 2006; 13:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/48\">",
"      Davis ID, Ho M, Hupertz V, Avner ED. Survival of childhood polycystic kidney disease following renal transplantation: the impact of advanced hepatobiliary disease. Pediatr Transplant 2003; 7:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/49\">",
"      Tejani A, Sullivan EK, Alexander S, et al. Posttransplant deaths and factors that influence the mortality rate in North American children. Transplantation 1994; 57:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/50\">",
"      Tejani A, Fine R, Alexander S, et al. Factors predictive of sustained growth in children after renal transplantation. The North American Pediatric Renal Transplant Cooperative Study. J Pediatr 1993; 122:397.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/51\">",
"      Hokken-Koelega AC, Van Zaal MA, de Ridder MA, et al. Growth after renal transplantation in prepubertal children: impact of various treatment modalities. Pediatr Res 1994; 35:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40680/abstract/52\">",
"      Pape L, Ehrich JH, Zivicnjak M, Offner G. Growth in children after kidney transplantation with living related donor graft or cadaveric graft. Lancet 2005; 366:151.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6135 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_46_40680=[""].join("\n");
var outline_f39_46_40680=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RISK FACTORS FOR ALLOGRAFT SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Effect of immunosuppressive regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Donor source",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HLA matches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Recipient age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Donor age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Delayed graft function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Acute rejection episodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Nonadherence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      PATIENT SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      GROWTH AFTER RENAL TRANSPLANTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5262288\">",
"      Age of recipient",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5262313\">",
"      Allograft function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5262320\">",
"      Immunosuppressive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5262332\">",
"      Donor source",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12074525\">",
"      Growth hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6257820\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6135\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6135|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?36/13/37085\" title=\"figure 1\">",
"      Expected lifetime based on renal replacement therapy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/61/34778?source=related_link\">",
"      Chronic renal allograft nephropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/7/6266?source=related_link\">",
"      Clinical manifestations and diagnosis of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/40/22154?source=related_link\">",
"      Complications of renal transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/61/11224?source=related_link\">",
"      Dialysis issues prior to and after renal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/63/23543?source=related_link\">",
"      General principles of kidney transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/14/27881?source=related_link\">",
"      Growth hormone treatment in children with chronic kidney disease and postrenal transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/57/11159?source=related_link\">",
"      HLA matching and graft survival in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/31/38394?source=related_link\">",
"      Immunosuppression in renal transplantation in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/45/42712?source=related_link\">",
"      Management of BK virus-induced (polyomavirus-induced) nephropathy in kidney transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12774?source=related_link\">",
"      Overview on renal replacement therapy (RRT) for children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/53/17240?source=related_link\">",
"      Prevention and management of growth failure in children with chronic kidney disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14170?source=related_link\">",
"      Risk factors for graft failure in kidney transplantation",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_46_40681="Allergic and asthmatic reactions to food additives";
var content_f39_46_40681=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Allergic and asthmatic reactions to food additives",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/46/40681/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/46/40681/contributors\">",
"     Ronald A Simon, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/46/40681/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/46/40681/contributors\">",
"     Scott H Sicherer, MD, FAAAAI",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/46/40681/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/46/40681/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/46/40681/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 15, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The list of additives used in the food industry is extensive and includes thousands of natural and synthetic substances used as flavorings, coloring substances, preservatives, sweeteners, antioxidants, thickeners, etc. However, only a small number of additives have been implicated in IgE-mediated or other (immunological or nonimmunological) adverse reactions.",
"   </p>",
"   <p>",
"    Food additives that have been linked to",
"    <span class=\"nowrap\">",
"     urticaria/angioedema,",
"    </span>",
"    asthma, and anaphylaxis will be discussed here. Food additives that cause",
"    <span class=\"nowrap\">",
"     asthma/rhinitis",
"    </span>",
"    in food industry workers, and testing and challenge procedures for food additives are mentioned briefly here and reviewed in more detail elsewhere (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38903?source=see_link\">",
"     \"Occupational asthma: Pathogenesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/48/7945?source=see_link\">",
"     \"Occupational rhinitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/12/2248?source=see_link\">",
"     \"Testing and challenge procedures to evaluate allergic and asthmatic reactions to food additives\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Issues surrounding food additives that are",
"    <strong>",
"     not",
"    </strong>",
"    discussed in this topic review include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperactivity and behavioral changes in children (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32730?source=see_link\">",
"       \"Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Oncogenic potential of food additives (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/618?source=see_link\">",
"       \"Risk factors for gastric cancer\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Dietary factors and headache (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=see_link&amp;anchor=H3#H3\">",
"       \"Evaluation of headache in adults\", section on 'Headache triggers'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10180362\">",
"    <span class=\"h1\">",
"     OVERVIEW",
"    </span>",
"    &nbsp;&mdash;&nbsp;Food additives may be classified by function. Additives that affect the chemical or structural characteristics of foods include emulsifiers, acidulants, buffers, raising agents, and enzymes. Shelf-life extenders include preservatives, antioxidants, and",
"    <span class=\"nowrap\">",
"     curing/pickling",
"    </span>",
"    agents. Thickeners, colors, gelling agents, and non-nutritive sweeteners are added to alter the sensory characteristics of foods. Food additives are identified in the United States by their English names, or in the European Union, by a unique identifying number, the \"E number\" [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213672\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients and parents of young children suspect allergy and intolerance to food additives far more often than it can be verified [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/3\">",
"     3",
"    </a>",
"    ]. The prevalence of a reaction to food additives was only 0.23 percent in a population-based study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Many of the cases of adverse reactions attributed to food additives that are reported in the medical literature are either anecdotal or characterized by poorly controlled challenge procedures. In reality, relatively few food additives have been convincingly demonstrated to cause reactions such as urticaria, angioedema, asthmatic reactions, and anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/5-9\">",
"     5-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Allergic reactions to nutritive foods (eg, tree nuts or seafood) are far more prevalent than reactions to food additives, and food allergy must always be considered first in the differential diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14808?source=see_link\">",
"     \"Clinical manifestations of food allergy: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10180518\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Food additives should be considered as a possible cause of allergic or asthmatic reactions when reactions occur in association with meals or other ingestions (candy, etc).",
"   </p>",
"   <p>",
"    Clues that the patient may be reacting to a food additive include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Allergic or asthmatic reactions that occur in timely association with meals or other ingestions (ie, usually within minutes to a few hours of eating)",
"     </li>",
"     <li>",
"      A convincing history of symptoms to several apparently unrelated foods",
"     </li>",
"     <li>",
"      Reactions to commercially prepared forms of foods that are tolerated when prepared at home",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following types of allergic and asthmatic reactions to food additives have been reported:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anaphylaxis - Classic IgE-mediated allergic reactions most commonly involve one or more of the following signs and symptoms: Flushing, urticaria, pruritus, angioedema, bronchospasm, nausea, vomiting, throat tightness (",
"      <a class=\"graphic graphic_table graphicRef79448 \" href=\"mobipreview.htm?19/49/20251\">",
"       table 1",
"      </a>",
"      ). Anaphylaxis is the most severe form of an IgE-mediated allergy. Diagnostic criteria for anaphylaxis are shown in the figure (",
"      <a class=\"graphic graphic_figure graphicRef82831 \" href=\"mobipreview.htm?32/46/33514\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Isolated asthmatic reactions in people known to have asthma.",
"     </li>",
"     <li>",
"      Urticaria and angioedema, alone or in combination.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast, there are no known associations between food additives and other chronic atopic conditions, such as atopic dermatitis or eosinophilic esophagitis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1752738\">",
"    <span class=\"h3\">",
"     Reactions to multiple additives",
"    </span>",
"    &nbsp;&mdash;&nbsp;When patients do have a true adverse or allergic reaction to a food additive, it is generally caused by a single agent. The medical literature does not support the notion of patients being broadly &ldquo;chemically sensitive.&rdquo; The evaluation of patients with apparent &ldquo;multiple chemical sensitivity&rdquo; is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27242?source=see_link\">",
"     \"Overview of idiopathic environmental intolerance (multiple chemical sensitivity)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1213920\">",
"    <span class=\"h3\">",
"     Other types of reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are many nonallergic reactions that also need to be considered in the patient presenting with reactions related to food ingestion (",
"    <a class=\"graphic graphic_table graphicRef51225 \" href=\"mobipreview.htm?7/26/7597\">",
"     table 2",
"    </a>",
"    ). These are mentioned separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14808?source=see_link&amp;anchor=H6555155#H6555155\">",
"     \"Clinical manifestations of food allergy: An overview\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     URTICARIA/ANGIOEDEMA",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10181207\">",
"    <span class=\"h2\">",
"     Patients with chronic urticaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic urticaria (CU) is defined as the presence of urticaria (hives) most days of the week for a period of six weeks or longer. CU is inherently variable and when the disorder first develops, many patients will try to make an association with specific foods or food additives. However, clinically relevant allergies to foods or food additives are rare in patients with chronic urticaria.",
"   </p>",
"   <p>",
"    Although allergies rarely cause this disorder, a subset of patients with chronic urticaria will notice that symptoms are exacerbated by foods that have high levels of natural histamine-like chemicals. The relationship between diet and symptom severity in chronic urticaria is reviewed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/7/117?source=see_link&amp;anchor=H7#H7\">",
"     \"Chronic urticaria: Standard management and patient education\", section on 'Dietary manipulations'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most accurate means to assess a possible adverse reaction is to utilize double-blind placebo-controlled challenge protocols, as is done with food challenges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. However, challenges are difficult to perform in patients with CU, because withdrawal of antihistamines can result in increased symptoms that can be misinterpreted as a positive challenge. On the other hand, the patient is unlikely to react to challenge if full doses of antihistamine are continued, yielding false negative results.",
"   </p>",
"   <p>",
"    In one extensively-controlled study of patients with chronic urticaria, antihistamines were tapered to the \"minimal effective dose\" to keep patients comfortable but not hive free [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/13\">",
"     13",
"    </a>",
"    ]. Double-blind placebo-controlled challenges were performed with the following additives:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      MSG",
"     </li>",
"     <li>",
"      Benzoates",
"     </li>",
"     <li>",
"      Parabens",
"     </li>",
"     <li>",
"      Sulfites",
"     </li>",
"     <li>",
"      BHA",
"     </li>",
"     <li>",
"      BHT",
"     </li>",
"     <li>",
"      Tartrazine (FD&amp;C Yellow #5, E102)",
"     </li>",
"     <li>",
"      Sunset yellow (FD&amp;C Yellow #6, E110)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Criteria for a positive challenge were both objective and semi-quantitative and utilized \"skin scores\" of urticaria lesions. Challenge scores were compared to scores after full-day single-blind administration of placebo. This study concluded that reactivity to the following food additives in patients with chronic",
"    <span class=\"nowrap\">",
"     urticaria/angioedema",
"    </span>",
"    is rare, if it occurs at all.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Additives implicated in case reports",
"    </span>",
"    &nbsp;&mdash;&nbsp;Case reports exist for a few of the additives listed above in which reactions were convincingly demonstrated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     BHA and BHT",
"    </span>",
"    &nbsp;&mdash;&nbsp;BHA (butylated hydroxyanisole) (E320) and BHT (butylated hydroxytoluene) (E321) are antioxidants commonly used in breakfast cereals and other grain products to maintain crispness and prevent rancidity. There is one well-documented report of chronic urticaria, confirmed by double-blind, placebo-controlled challenges, exacerbated by these agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/14\">",
"     14",
"    </a>",
"    ]. Sensitive subjects exhibited improvement in urticaria after elimination of BHA and BHT from the diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Aspartame (NutraSweet&reg;)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aspartame (NutraSweet&reg;), a dipeptide, is a low calorie artificial sweetener [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/15\">",
"     15",
"    </a>",
"    ]. Two cases of aspartame-induced urticaria, confirmed by placebo-controlled double-blind challenge, have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/16\">",
"     16",
"    </a>",
"    ], and additional cases by the same author have also been described [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/17\">",
"     17",
"    </a>",
"    ]. However, other investigators have encountered difficulty recruiting subjects with adverse reactions to aspartame and have found that such subjects do not have reproducible reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Lysozyme",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lysozyme in egg, aged cheeses, and pharmaceuticals, was implicated in a case report of recurrent angioedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ASTHMATIC SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A subset of individuals with asthma appears to be susceptible to provocation of bronchospasm following ingestion of sulfites. The evidence that other additives can provoke asthma, especially benzoate, MSG, and tartrazine, is limited to case reports and has not been supported by rigorous double-blind placebo-controlled challenges.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Sulfites and related compounds",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sulfites have been widely used for centuries to freshen and prevent oxidative discoloration (browning) of foods. Sulfites are also used as sanitizers and to inhibit the growth of undesirable microorganisms in the fermentation industry. Sulfiting agents include sulfur dioxide, sodium potassium sulfite, bisulfite, and metabisulfite. Foods containing sulfites are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef66943 \" href=\"mobipreview.htm?11/18/11565\">",
"     table 3",
"    </a>",
"    ). Currently, the highest levels of sulfites are found in commercially prepared dried fruits (such as apricots), potatoes, wines, and some seafood items [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sulfiting agents can cause serious and potentially life-threatening asthmatic reactions in patients with asthma, as demonstrated in double-blind controlled studies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. As many as 5 percent of the asthmatic population may experience adverse reactions from mild wheezing to severe bronchospasm following ingestion of sulfite-containing foods or beverages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/23,25,26\">",
"     23,25,26",
"    </a>",
"    ]. Asthmatic reactions in patients without underlying asthma appear to be uncommon.",
"   </p>",
"   <p>",
"    While any asthmatic may develop sulfite sensitivity, many sulfite sensitive asthmatics have more severe asthma and are steroid dependent. Therefore, one should consider sulfite sensitivity in",
"    <span class=\"nowrap\">",
"     moderate/severe",
"    </span>",
"    or steroid-dependent asthmatics who give a history of reacting to",
"    <span class=\"nowrap\">",
"     foods/beverages",
"    </span>",
"    likely to contain moderate to high levels of sulfites (",
"    <a class=\"graphic graphic_table graphicRef66943 \" href=\"mobipreview.htm?11/18/11565\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Tartrazine (FD&amp;C Yellow 5)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tartrazine (FD&amp;C Yellow #5 or E102) is an acidic dye derived from",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/43/44724?source=see_link\">",
"     coal tar",
"    </a>",
"    that is used as a colorant in foods and medications. It has been reported to provoke asthmatic reactions. A 40 to 50 percent incidence of tartrazine sensitivity in",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -sensitive asthmatics was described in some early reports, and the notion took hold that tartrazine \"cross-reacts\" with nonsteroidal antiinflammatory drugs (NSAIDs) and should be avoided by patients with aspirin-sensitive asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/27-30\">",
"     27-30",
"    </a>",
"    ]. However, these early studies lacked adequate controls and the design features that are used in studies of this nature today. Based upon subsequent studies, tartrazine-sensitivity in asthmatic patients appears to be rare.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Two double-blind placebo-controlled studies each found no tartrazine-sensitive subjects among approximately 50 adult and pediatric subjects with chronic, frequently steroid dependent asthma [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/31,32\">",
"       31,32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Double-blind placebo-controlled challenge protocols in",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      -sensitive asthmatics found no adverse reactions in 165 patients challenged to a dose of 50 mg of tartrazine [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/33\">",
"       33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A 2001 systematic review identified six randomized trials examining the effects of tartrazine in patients with asthma, both with and without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    sensitivity. Only three included analyzable data and these were not comparable, so no formal conclusions were drawn [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/34\">",
"     34",
"    </a>",
"    ]. However, tartrazine challenges or tartrazine avoidance were not found to affect asthma symptoms in any of the six trials. Therefore, based on the available evidence, routine avoidance of tartrazine in patients with asthma is not justified.",
"   </p>",
"   <p>",
"    Finally, in a study of 26 atopic patients with either asthma, allergic rhinitis, urticaria, or pseudoallergic reactions to NSAIDs, subjects underwent double-blind placebo-controlled challenge with 25 mg of tartrazine and demonstrated no increase in symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Sodium benzoate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/6/32866?source=see_link\">",
"     Sodium benzoate",
"    </a>",
"    (E211) is used as an antimicrobial preservative in foods. There has been only one subject in the medical literature shown to have benzoate-provoked asthma, as reported in a double-blind, placebo-controlled study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/36\">",
"     36",
"    </a>",
"    ]; this patient was not",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -sensitive, and did not experience amelioration of asthma symptoms while on a benzoate-free diet.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Spearmint, peppermint, and menthol",
"    </span>",
"    &nbsp;&mdash;&nbsp;The flavorings spearmint (Mentha spicata), peppermint (Mentha piperita), and menthol (Mentha labiatae), used in chewing gum and toothpaste, have been confirmed by challenges in two cases to have triggered asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. Anaphylaxis was described in another case report [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ANAPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis to several chemical food additives has been reported. In response to consumer preference for products containing only \"natural\" ingredients, food manufacturers have been replacing synthetic food additives with compounds derived from plant, insect, and animal products. Because most IgE-mediated allergy is caused by proteins from other living organisms, this switch to natural agents has been associated with an increase in IgE-mediated allergies to these substances. As examples, case reports have described the potential for anaphylaxis with annatto, carmine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/26/8614?source=see_link\">",
"     psyllium",
"    </a>",
"    , and guar gum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/40-43\">",
"     40-43",
"    </a>",
"    ]. IgE-mediated allergy to spices is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11082?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)\", section on 'Pollen-food associations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Sulfites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two cases of anaphylaxis related to sulfite ingestion with positive skin tests have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/40,44\">",
"     40,44",
"    </a>",
"    ]. In addition, three reports assessed sulfite sensitivity in subjects with idiopathic anaphylaxis. In one, one subject among 130 challenged was found to be sulfite-sensitive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/45\">",
"     45",
"    </a>",
"    ]; in another, one subject experienced a systemic reaction following a sulfite skin test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/46\">",
"     46",
"    </a>",
"    ]; a third found no sulfite sensitivity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Epinephrine autoinjectors contain small amounts of sulfite. This is discussed below. (See",
"    <a class=\"local\" href=\"#H1214102\">",
"     'Patients with anaphylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Annatto (E160b)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Annatto (E160b) is a yellow food coloring used to color a variety of foods including cereal, cheese, ice cream, margarine, oils, and beverages. Annatto dye extract is produced from the pericarp of the fruit of the annatto tree, Bixa Orellana. Anaphylaxis to annatto has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/42,48\">",
"     42,48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Carmine (E120)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carmine (E120), or cochineal extract, is a red food dye derived from the dried bodies of female Dactylopius coccus costa insects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/49\">",
"     49",
"    </a>",
"    ]. Carmine is used in foodstuffs such as candy, ice cream, yogurt, cookies, pastries, syrups, liqueurs, vinegar, cheese, butter, delicatessen meats, jam, and caviar, as well as in cosmetics. It has been implicated in anaphylaxis as well as occupational asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/43,50\">",
"     43,50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38903?source=see_link\">",
"     \"Occupational asthma: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Allergic symptoms following carmine ingestion appear rapidly in some individuals, but are delayed by several hours in others, for reasons which are not clear [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/49\">",
"     49",
"    </a>",
"    ]. Skin testing is informative, although positive results may appear after 30 minutes, rather than the usual 15 minutes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Erythritol",
"    </span>",
"    &nbsp;&mdash;&nbsp;Erythritol (ERT; 1,2,3,4-butanetetrol) is a 4-carbon sugar alcohol prepared from glucose by fermentation that is used as a sweetener [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/41\">",
"     41",
"    </a>",
"    ]. It may occur naturally in foods such as wine, beer, soy, cheese, mushroom, grape, and watermelon. Anaphylaxis has been reported after ingestion of ERT-containing foods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Guar gum (E412)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guar gum is a galactomannan derived from the guar bean, which is used as an emulsifier and binder in foods and pharmaceuticals. Guar gum has been implicated in severe anaphylaxis, as well as occupational",
"    <span class=\"nowrap\">",
"     rhinitis/asthma",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/52-55\">",
"     52-55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Psyllium",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/26/8614?source=see_link\">",
"     Psyllium",
"    </a>",
"    is a source of soluble dietary fiber derived from the husks of Plantago ovata seeds. Psyllium is commonly used in bulk laxatives, and fiber-enriched breakfast cereals. Allergic reactions, including severe anaphylaxis, have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/56\">",
"     56",
"    </a>",
"    ]. Psyllium can also be a source of occupational",
"    <span class=\"nowrap\">",
"     asthma/rhinitis",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/57-59\">",
"     57-59",
"    </a>",
"    ]. Healthcare workers who have prepared and handled psyllium-containing bulk laxatives appear to be at particular risk [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other additives",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several other additives have been implicated in anaphylaxis, including the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Carrageenan is a gelatinous polysaccharide derived from seaweed which is used as a stabilizer and thickener. It has been implicated in anaphylaxis caused by a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"       barium",
"      </a>",
"      enema solution [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Lupine flour is an inexpensive flour extender that has been implicated in allergic reactions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/61,62\">",
"       61,62",
"      </a>",
"      ]. Lupine may have some cross-reactivity with peanut. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2042?source=see_link&amp;anchor=H6#H6\">",
"       \"Food allergens: Overview of clinical features and cross-reactivity\", section on 'Peanut'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pectin, a jelling agent and thickener, has been reported to cause anaphylaxis upon ingestion and occupational asthma upon inhalation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/63\">",
"       63",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Gelatin in gummy candies and fruit chews has caused anaphylaxis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/64,65\">",
"       64,65",
"      </a>",
"      ]. Gelatin in vaccines (particularly in Japan) has been more frequently implicated in anaphylaxis. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43097?source=see_link\">",
"       \"Allergic reactions to vaccines\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mycoprotein is fermented fungus (Fusarium venenatum) bound with egg albumin. It shares common allergenic determinants with other molds. Mycoprotein is used as a meat substitute (marketed as Quorn&reg; in the United States). Allergic reactions, including anaphylaxis, have been reported, mainly in patients with inhalant mold allergy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/66-68\">",
"       66-68",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1001422\">",
"    <span class=\"h2\">",
"     Spices",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"spice\" is often used to describe a variety of flavoring agents. Items that can be considered spices include allspice (a type of pepper), basil, cardamom, celery, chives, cinnamon, coriander, cumin, dill, fennel, garlic, ginger, marjoram, nutmeg, onion, oregano, parsley, pepper, peppermint, rosemary, saffron, sage, savory, star anise, tarragon, tumeric and vanilla. Seeds (eg, poppy, sesame, caraway, mustard) are sometimes considered spices within the food industry.",
"   </p>",
"   <p>",
"    Many types of pepper are used for spice (eg, bell, red, cayenne). In addition, many spices that are \"hot\" or \"spicy\" contain a chemical,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/44/14022?source=see_link\">",
"     capsaicin",
"    </a>",
"    , that triggers burning sensations in normal individuals that could be misinterpreted as an allergic reaction, especially in a child.",
"   </p>",
"   <p>",
"    Allergic reactions and anaphylaxis to a variety of spices have been reported and usually affect adults. In a French study, allergy to spices was estimated to account for approximately 2 percent of adults with food allergic reactions, and was rare in children [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/69\">",
"     69",
"    </a>",
"    ]. The most allergenic groups of spices were those of the Apiaceae family (coriander, caraway, fennel, celery, chervil, and dill) and Liliaceae family (garlic, onion, chive, shallot, and saffron). Most individuals allergic to spices have concomitant allergy to inhaled pollens (especially birch and mugwort), and experience allergic reactions upon ingesting spices that contain proteins with homology to pollen proteins. Spice allergy is discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5785?source=see_link\">",
"     \"Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7548074\">",
"    <span class=\"h1\">",
"     REACTIONS TO MSG",
"    </span>",
"    &nbsp;&mdash;&nbsp;MSG (monosodium glutamate) is a nonessential dicarboxylic amino acid that is a normal constituent of food protein. Additional MSG is added to food as a flavor enhancer, particularly in Asian food. A variety of nonallergic symptoms have been attributed to MSG, while allergic and asthmatic reactions are only rarely reported and generally not well-substantiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10181006\">",
"    <span class=\"h2\">",
"     MSG symptom complex",
"    </span>",
"    &nbsp;&mdash;&nbsp;Perhaps the best known adverse reaction to a food additive is the monosodium glutamate (MSG) symptom complex. This is not an allergic reaction.",
"   </p>",
"   <p>",
"    The MSG symptom complex typically appears 1 to 14 hours after ingestion. Reported symptoms include headache, myalgia, backache, neck pain, nausea, diaphoresis, tingling, flushing, palpitations, and chest heaviness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/70\">",
"     70",
"    </a>",
"    ]. Children have been reported with shivering, chills, irritability, screaming, and delirium.",
"   </p>",
"   <p>",
"    The mechanism of these reactions has been proposed to involve an exaggerated sensitivity to this compound, which is metabolized after ingestion to glutamate, a major excitatory amino acid neurotransmitter.",
"   </p>",
"   <p>",
"    The MSG symptom complex has not been reproduced in controlled challenges, and symptoms were not consistently inducible in 130 patients who were self-identified as sensitive to MSG and challenged in a double-blind manner. Those patients who inconsistently experienced symptoms most often did so only when MSG was ingested in quantities larger than those that would be encountered in a normal diet, and without accompanying food [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/71\">",
"     71",
"    </a>",
"    ]. Thus, MSG is currently regarded as a safe food additive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/72,73\">",
"     72,73",
"    </a>",
"    ]. Still, a patient suffering from these symptoms who believes that MSG is the cause can be advised to avoid foods containing added MSG, since this is relatively simple to do. Such patients should particularly avoid liquid foods (such as wonton soup), from which high levels of MSG can be rapidly absorbed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10181021\">",
"    <span class=\"h2\">",
"     Allergic and asthmatic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small number of case reports have implicated MSG in causing urticaria and angioedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/72,74,75\">",
"     72,74,75",
"    </a>",
"    ]. As an example, one case described angioedema beginning 16 hours after ingestion of 250 mg MSG, which was reproduced by single-blind, placebo-controlled challenge [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although MSG has been implicated in provoking asthma [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/76,77\">",
"     76,77",
"    </a>",
"    ], this association has not been supported in studies characterized by double-blind, placebo-controlled MSG challenges in high-risk asthmatic subjects (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    -sensitive or history-positive) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/78-80\">",
"     78-80",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One group of researchers reported a small number of subjects with perennial rhinitis attributed to MSG ingestion and positive responses to double-blind placebo-controlled oral challenges [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/81,82\">",
"     81,82",
"    </a>",
"    ]. However, this hypothesis requires further investigation, as MSG could aggravate rhinitis through its vasoactive properties, and the implication that it is a cause of rhinitis has not been established [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1752493\">",
"    <span class=\"h1\">",
"     EVALUATION AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An evaluation for allergy to a food additive involves a detailed and focused clinical history, a physical examination, possibly skin testing with foods or isolated food additives, and possibly a supervised challenge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1752505\">",
"    <span class=\"h2\">",
"     Clinical history",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinician should review each reaction that the patient can clearly recall in detail. (See",
"    <a class=\"local\" href=\"#H10180518\">",
"     'Clinical manifestations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22881236\">",
"    <span class=\"h2\">",
"     Analysis of causative foods",
"    </span>",
"    &nbsp;&mdash;&nbsp;Allergic reactions to nutritive foods (such as tree nuts or seafood) are far more prevalent than reactions to food additives and thus, food allergy must always be considered first in differential diagnosis. Ingredient lists of food items that caused adverse reactions should be carefully compared to determine if there is a nutritive food that is present in each item. If not, then food additives should be considered.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In the patient with a suggestive history, in whom a suspect additive",
"      <strong>",
"       can",
"      </strong>",
"      be identified, a trial of avoidance of the suspected additive would be reasonable. If no further reaction occurs, then this may be sufficiently confirmatory and no further testing may be needed.",
"     </li>",
"     <li>",
"      In the patient with a suggestive history, in whom a suspect additive",
"      <strong>",
"       cannot",
"      </strong>",
"      be identified, it is not useful or safe to advise patients to &ldquo;avoid all additives,&rdquo; particularly if the patient experienced anaphylaxis. (See",
"      <a class=\"local\" href=\"#H7548108\">",
"       'Pitfalls of additive-free diets'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      In patients with history of repeated anaphylaxis in association with eating that cannot be linked to a food or food additive, differential diagnosis should also include other disorders such as indolent systemic mastocytosis, clonal mast cell disorder, or mast cell activation syndrome. In addition, allergy to galactose-&alpha;-1,3-galactose (alpha-gal), a carbohydrate allergen which can cause delayed anaphylaxis several hours after ingestion of red meat, can evade diagnosis because the reactions occur much later after ingestion than is typical of most food allergies. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6170?source=see_link\">",
"       \"Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20937?source=see_link\">",
"       \"Mast cell activation disorders\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36072?source=see_link&amp;anchor=H11265746#H11265746\">",
"       \"Allergy to meats\", section on 'Carbohydrate allergens'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22881089\">",
"    <span class=\"h2\">",
"     Indications for allergy referral",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain groups of patients suspected to have an allergic or asthmatic reaction to a food additive require further evaluation and should be referred to an allergy expert with knowledge about appropriate testing and challenge procedures:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have experienced anaphylaxis.",
"     </li>",
"     <li>",
"      Patients with recurrent idiopathic",
"      <span class=\"nowrap\">",
"       urticaria/angioedema",
"      </span>",
"      who have refractory or severe symptoms or are dependent upon glucocorticoids to control symptoms.",
"     </li>",
"     <li>",
"      Patients with chronic persistent asthma or life-threatening asthmatic exacerbations.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Skin testing and challenge procedures may be needed to make the diagnosis and should be carried out by an allergy expert because these techniques require training and experience to interpret properly. In addition, allergic reactions during these procedures are possible (although uncommon). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/12/2248?source=see_link\">",
"     \"Testing and challenge procedures to evaluate allergic and asthmatic reactions to food additives\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Common goals of allergy evaluation are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Proving that a food additive is causing a specific acute reaction, particularly in patients with anaphylaxis.",
"     </li>",
"     <li>",
"      Excluding reactions to food additives and normalizing the diet in people who are avoiding multiple foods because of concerns about possible reactions to food additives.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7548108\">",
"    <span class=\"h2\">",
"     Pitfalls of additive-free diets",
"    </span>",
"    &nbsp;&mdash;&nbsp;Additive-free diets are usually not helpful. These diets are sometimes proposed as an initial means of determining that the patient is sensitive to some additive, without implicating a specific one. As an example, patients may be advised to eat a limited number of specified meats, grains, fruits and vegetables for three weeks, and if the symptoms improve, then it is concluded that the patient is allergic to some additive. However, this approach has several drawbacks. Patients' symptoms often improve initially, but then gradual re-introduction of commercially prepared foods does not lead to identification of a specific culprit. Sometimes patients remain well for a while despite resuming a normal diet and then their symptoms eventually return and begin to wax and wane again. In addition, it is difficult to adhere to an additive-free diet for any significant period of time, so most people cannot maintain the exercise for very long.",
"   </p>",
"   <p>",
"    For patients who experienced anaphylaxis, and who normally eat commercially prepared or processed foods, additive-free diets are difficult to maintain over time and the patient is likely to resume their prior eating habits over time. This approach puts the patient at risk for future recurrences of anaphylaxis. Whenever possible, patients with anaphylaxis should be referred to an allergy specialist so that the chances of identifying the culprit allergen are maximized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10180860\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management usually consists of avoidance of commercially prepared foods that are likely to contain the additive in question. The patient should be informed of common foodstuffs that contain the additive as well as all relevant chemical nomenclature and alternative names for that additive. For patients with asthma, good asthma control is an important aspect of care.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1214102\">",
"    <span class=\"h2\">",
"     Patients with anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Any patient who has suffered anaphylaxis should be supplied with an epinephrine autoinjector, accompanied by verbal and written instruction on how and when to self-administer the drug. Referral to an allergy expert should be arranged when possible. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23832?source=see_link\">",
"     \"Prescribing epinephrine for anaphylaxis self-treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Epinephrine autoinjectors contain metabisulfite. However, the injection of the amount of metabisulfite contained in an epinephrine autoinjector did not trigger any symptoms or change in lung function in a small group of sulfite-sensitive asthmatics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40681/abstract/83\">",
"     83",
"    </a>",
"    ], and there are no case reports to suggest that autoinjectors are unsafe for sulfite-sensitive patients.",
"   </p>",
"   <p>",
"    A personalized anaphylaxis action plan is helpful for providing specific instructions to patients about when and how to treat recurrent episodes (",
"    <a class=\"graphic graphic_form graphicRef60439 \" href=\"mobipreview.htm?2/42/2722\">",
"     form 1",
"    </a>",
"    ). These materials are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link&amp;anchor=H39#H39\">",
"     \"Anaphylaxis: Rapid recognition and treatment\", section on 'Discharge care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/57/29586?source=see_link\">",
"       \"Patient information: Epinephrine auto-injectors (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/30/28134?source=see_link\">",
"       \"Patient information: Use of an epinephrine autoinjector (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Of the thousands of food additives currently in use, only a small number have been implicated in allergic or allergic-like reactions. Symptoms include urticaria",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angioedema, asthmatic reactions, and anaphylaxis. (See",
"      <a class=\"local\" href=\"#H10180362\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clues that a patient may be reacting to a food additive include reactions that occur within minutes to a few hours of eating, a convincing history of similar reactions to several apparently unrelated foods, and reactions to commercially prepared forms of foods that are tolerated when prepared at home. However, allergy to a nutritive food is far more likely than allergy to an additive, so this must be considered first in the differential diagnosis. (See",
"      <a class=\"local\" href=\"#H10180518\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Large series of patients with chronic",
"      <span class=\"nowrap\">",
"       urticaria/angioedema",
"      </span>",
"      support the conclusion that symptoms are not caused by food additives, although foods and food additives can aggravate the condition in a minority of patients. Patients with recurrent idiopathic",
"      <span class=\"nowrap\">",
"       urticaria/angioedema",
"      </span>",
"      who have refractory or severe symptoms or are dependent upon glucocorticoids to control symptoms AND appear to have flares in their symptoms after eating should be referred to an allergy specialist for further evaluation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Urticaria/angioedema'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sulfites can cause potentially serious asthmatic reactions in as many as 5 percent of patients with asthma, whereas individuals without asthma are rarely affected. Sulfite-sensitive patients more often have severe",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      steroid dependent asthma. Patients with asthma who experience exacerbations after apparent exposure to sulfites should be counseled to avoid sulfite-containing foods (",
"      <a class=\"graphic graphic_table graphicRef66943 \" href=\"mobipreview.htm?11/18/11565\">",
"       table 3",
"      </a>",
"      ) and (if possible) referred to an allergy specialist with experience in evaluating for sulfite sensitivity. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Sulfites and related compounds'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"       aspirin",
"      </a>",
"      -exacerbated asthma were advised in the past to avoid foods and medications containing tartrazine (FD&amp;C Yellow #5 or E102), because of a notion that tartrazine was cross-reactive with aspirin, although there is no convincing evidence to support this conclusion. Tartrazine avoidance is not necessary in patients with asthma. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Tartrazine (FD&amp;C Yellow 5)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preservative",
"      <a class=\"drug drug_pediatric\" href=\"mobipreview.htm?32/6/32866?source=see_link\">",
"       sodium benzoate",
"      </a>",
"      (E211) and the flavorings spearmint, peppermint, and menthol, have each been implicated in causing asthmatic symptoms in one or two case reports supported by challenge procedures. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Asthmatic symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anaphylaxis has been reported to annatto (E160b), carmine (E120), saffron, erythritol, guar gum (E412),",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/26/8614?source=see_link\">",
"       psyllium",
"      </a>",
"      , carrageenan, lupine flour, gelatin, and pectin. These \"natural\" additives are derived from plants, insects, or animals and the reactions are believed to be IgE-mediated. Sulfites have been implicated in a very small number of cases of anaphylaxis. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Anaphylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An evaluation for allergy to a food additive involves a detailed and focused clinical history, a physical examination, possibly skin testing with foods or isolated food additives, and possibly a supervised challenge. Testing and challenge procedures should be done by an allergy expert, since these techniques require training and experience to interpret correctly and have the potential to cause allergic reactions in very sensitive patients. (See",
"      <a class=\"local\" href=\"#H1752493\">",
"       'Evaluation and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Any patient who has experienced anaphylaxis should be supplied with an epinephrine autoinjector. If the history suggests that a food additive may have been responsible, the patient should be referred to an allergy specialist with experience in performing testing and challenges to food additives. (See",
"      <a class=\"local\" href=\"#H1214102\">",
"       'Patients with anaphylaxis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     An alphabetical list of food additives approved for use in the United States is available online at www.fda.gov/Food/FoodIngredientsPackaging/FoodAdditives/FoodAdditiveListings/ucm091048.htm (Accessed on August 08, 2011).",
"    </li>",
"    <li>",
"     A complete list of food additives by E number is available online at www.food.gov.uk/safereating/chemsafe/additivesbranch/enumberlist (Accessed on August 08, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/3\">",
"      Turner PJ, Kemp AS. Intolerance to food additives - does it exist? J Paediatr Child Health 2012; 48:E10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/4\">",
"      Young E, Patel S, Stoneham M, et al. The prevalence of reaction to food additives in a survey population. J R Coll Physicians Lond 1987; 21:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/5\">",
"      Simon RA. Adverse reactions to food and drug additives. Immunol Allergy Clin North Am 1996; 16:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/6\">",
"      Wilson BG, Bahna SL. Adverse reactions to food additives. Ann Allergy Asthma Immunol 2005; 95:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/7\">",
"      Ortolani C, Pastorello E, Fontana A, et al. Chemicals and drugs as triggers of food-associated disorder. Ann Allergy 1988; 60:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/8\">",
"      Genton C, Frei PC, P&eacute;coud A. Value of oral provocation tests to aspirin and food additives in the routine investigation of asthma and chronic urticaria. J Allergy Clin Immunol 1985; 76:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/9\">",
"      Asero R. Multiple intolerance to food additives. J Allergy Clin Immunol 2002; 110:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/10\">",
"      Worm M, Ehlers I, Sterry W, Zuberbier T. Clinical relevance of food additives in adult patients with atopic dermatitis. Clin Exp Allergy 2000; 30:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/11\">",
"      Bock SA, Sampson HA, Atkins FM, et al. Double-blind, placebo-controlled food challenge (DBPCFC) as an office procedure: a manual. J Allergy Clin Immunol 1988; 82:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/12\">",
"      Sampson HA. Food allergy. Part 2: diagnosis and management. J Allergy Clin Immunol 1999; 103:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/13\">",
"      Simon RA, Bosso JV, Daffern PD, Ward B. Prevalence of sensitivity to food/drug additives in patients with chronic idiopathic urticaria (CIUA). J Clin Immunol 1998; 101:S154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/14\">",
"      Goodman DL, McDonnell JT, Nelson HS, et al. Chronic urticaria exacerbated by the antioxidant food preservatives, butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT). J Allergy Clin Immunol 1990; 86:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/15\">",
"      Aspinall RL, Saunders RN, Pautsch WF, Nutting EF. The biological properties of aspartame. V. Effects on a variety of physiological parameters related to inflammation and metabolism. J Environ Pathol Toxicol 1980; 3:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/16\">",
"      Kulczycki A Jr. Aspartame-induced urticaria. Ann Intern Med 1986; 104:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/17\">",
"      Kulczycki A Jr. Aspartame-induced hives. J Allergy Clin Immunol 1995; 95:639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/18\">",
"      Garriga MM, Berkebile C, Metcalfe DD. A combined single-blind, double-blind, placebo-controlled study to determine the reproducibility of hypersensitivity reactions to aspartame. J Allergy Clin Immunol 1991; 87:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/19\">",
"      Geha R, Buckley CE, Greenberger P, et al. Aspartame is no more likely than placebo to cause urticaria/angioedema: results of a multicenter, randomized, double-blind, placebo-controlled, crossover study. J Allergy Clin Immunol 1993; 92:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/20\">",
"      P&eacute;rez-Calder&oacute;n R, Gonzalo-Garijo MA, Lamilla-Yerga A, et al. Recurrent angioedema due to lysozyme allergy. J Investig Allergol Clin Immunol 2007; 17:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/21\">",
"      Simon RA. Update on sulfite sensitivity. Allergy 1998; 53:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/22\">",
"      Stevenson DD, Simon RA. Sensitivity to ingested metabisulfites in asthmatic subjects. J Allergy Clin Immunol 1981; 68:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/23\">",
"      Bush RK, Taylor SL, Holden K, et al. Prevalence of sensitivity to sulfiting agents in asthmatic patients. Am J Med 1986; 81:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/24\">",
"      Baker GJ, Collett P, Allen DH. Bronchospasm induced by metabisulphite-containing foods and drugs. Med J Aust 1981; 2:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/25\">",
"      Simon RA, Green L, Stevenson DD. The incidence of metabisulfite sensitivity in an asthmatic population. J Allergy Clin Immunol 1982; 69:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/26\">",
"      Buckley R, Saltzman HA, Sieker HO. The prevalence and degree of sensitivity to ingested sulfites. J Allergy Clin Immunol 1985; 77:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/27\">",
"      Samter M, Beers RF Jr. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 1968; 68:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/28\">",
"      Settipane GA, Pudupakkam RK. Aspirin intolerance. III. Subtypes, familial occurence, and cross-reactivity with tartarazine. J Allergy Clin Immunol 1975; 56:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/29\">",
"      Spector SL, Wangaard CH, Farr RS. Aspirin and concomitant idiosyncrasies in adult asthmatic patients. J Allergy Clin Immunol 1979; 64:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/30\">",
"      Stenius BS, Lemola M. Hypersensitivity to acetylsalicylic acid (ASA) and tartrazine in patients with asthma. Clin Allergy 1976; 6:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/31\">",
"      Weber RW, Hoffman M, Raine DA Jr, Nelson HS. Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes, and preservatives in a population of perennial asthmatics. J Allergy Clin Immunol 1979; 64:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/32\">",
"      Vedanthan PK, Menon MM, Bell TD, Bergin D. Aspirin and tartrazine oral challenge: incidence of adverse response in chronic childhood asthma. J Allergy Clin Immunol 1977; 60:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/33\">",
"      Stevenson DD, Simon RA, Lumry WR, Mathison DA. Adverse reactions to tartrazine. J Allergy Clin Immunol 1986; 78:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/34\">",
"      Ardern KD, Ram FS. Tartrazine exclusion for allergic asthma. Cochrane Database Syst Rev 2001; :CD000460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/35\">",
"      Pestana S, Moreira M, Olej B. Safety of ingestion of yellow tartrazine by double-blind placebo controlled challenge in 26 atopic adults. Allergol Immunopathol (Madr) 2010; 38:142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/36\">",
"      Tarlo SM, Broder I. Tartrazine and benzoate challenge and dietary avoidance in chronic asthma. Clin Allergy 1982; 12:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/37\">",
"      Spurlock BW, Dailey TM. Shortness of (fresh) breath--toothpaste-induced bronchospasm. N Engl J Med 1990; 323:1845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/38\">",
"      Subiza J, Subiza JL, Valdivieso R, et al. Toothpaste flavor-induced asthma. J Allergy Clin Immunol 1992; 90:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/39\">",
"      Paiva M, Piedade S, Gaspar A. Toothpaste-induced anaphylaxis caused by mint (Mentha) allergy. Allergy 2010; 65:1201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/40\">",
"      Prenner BM, Stevens JJ. Anaphylaxis after ingestion of sodium bisulfite. Ann Allergy 1976; 37:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/41\">",
"      Yunginger JW, Jones RT, Kita H, et al. Allergic reactions after ingestion of erythritol-containing foods and beverages. J Allergy Clin Immunol 2001; 108:650.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/42\">",
"      Nish WA, Whisman BA, Goetz DW, Ramirez DA. Anaphylaxis to annatto dye: a case report. Ann Allergy 1991; 66:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/43\">",
"      Beaudouin E, Kanny G, Lambert H, et al. Food anaphylaxis following ingestion of carmine. Ann Allergy Asthma Immunol 1995; 74:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/44\">",
"      Yang WH, Purchase EC, Rivington RN. Positive skin tests and Prausnitz-K&uuml;stner reactions in metabisulfite-sensitive subjects. J Allergy Clin Immunol 1986; 78:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/45\">",
"      Meggs WJ, Atkins FM, Wright R, et al. Failure of sulfites to produce clinical responses in patients with systemic mastocytosis or recurrent anaphylaxis: results of a single-blind study. J Allergy Clin Immunol 1985; 76:840.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/46\">",
"      Stricker WE, Anorve-Lopez E, Reed CE. Food skin testing in patients with idiopathic anaphylaxis. J Allergy Clin Immunol 1986; 77:516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/47\">",
"      Sonin L, Patterson R. Metabisulfite challenge in patients with idiopathic anaphylaxis. J Allergy Clin Immunol 1985; 75:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/48\">",
"      Ebo DG, Ingelbrecht S, Bridts CH, Stevens WJ. Allergy for cheese: evidence for an IgE-mediated reaction from the natural dye annatto. Allergy 2009; 64:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/49\">",
"      Greenhawt MJ, Baldwin JL. Carmine dye and cochineal extract: hidden allergens no more. Ann Allergy Asthma Immunol 2009; 103:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/50\">",
"      DiCello MC, Myc A, Baker JR Jr, Baldwin JL. Anaphylaxis after ingestion of carmine colored foods: two case reports and a review of the literature. Allergy Asthma Proc 1999; 20:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/51\">",
"      Greenhawt M, McMorris M, Baldwin J. Carmine hypersensitivity masquerading as azithromycin hypersensitivity. Allergy Asthma Proc 2009; 30:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/52\">",
"      Roesch A, Haegele T, Vogt T, et al. Severe contact urticaria to guar gum included as gelling agent in a local anaesthetic. Contact Dermatitis 2005; 52:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/53\">",
"      Papanikolaou I, Stenger R, Bessot JC, et al. Anaphylactic shock to guar gum (food additive E412) contained in a meal substitute. Allergy 2007; 62:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/54\">",
"      Lemi&egrave;re C, Cartier A, Malo JL, Lehrer SB. Persistent specific bronchial reactivity to occupational agents in workers with normal nonspecific bronchial reactivity. Am J Respir Crit Care Med 2000; 162:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/55\">",
"      Malo JL, Cartier A, L'Archev&ecirc;que J, et al. Prevalence of occupational asthma and immunologic sensitization to guar gum among employees at a carpet-manufacturing plant. J Allergy Clin Immunol 1990; 86:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/56\">",
"      James JM, Cooke SK, Barnett A, Sampson HA. Anaphylactic reactions to a psyllium-containing cereal. J Allergy Clin Immunol 1991; 88:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/57\">",
"      Malo JL, Cartier A, L'Archev&ecirc;que J, et al. Prevalence of occupational asthma and immunologic sensitization to psyllium among health personnel in chronic care hospitals. Am Rev Respir Dis 1990; 142:1359.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/58\">",
"      Schwartz HJ, Arnold JL, Strohl KP. Occupational allergic rhinitis reaction to psyllium. J Occup Med 1989; 31:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/59\">",
"      Cartier A, Malo JL, Dolovich J. Occupational asthma in nurses handling psyllium. Clin Allergy 1987; 17:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/60\">",
"      Tarlo SM, Dolovich J, Listgarten C. Anaphylaxis to carrageenan: a pseudo-latex allergy. J Allergy Clin Immunol 1995; 95:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/61\">",
"      Peeters KA, Nordlee JA, Penninks AH, et al. Lupine allergy: not simply cross-reactivity with peanut or soy. J Allergy Clin Immunol 2007; 120:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/62\">",
"      De las Marinas D, Cojocariu Z, Escudero R, et al. Anaphylaxis induced by lupine as a hidden allergen. J Investig Allergol Clin Immunol 2007; 17:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/63\">",
"      Ferdman RM, Ong PY, Church JA. Pectin anaphylaxis and possible association with cashew allergy. Ann Allergy Asthma Immunol 2006; 97:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/64\">",
"      Wang J, Sicherer SH. Anaphylaxis following ingestion of candy fruit chews. Ann Allergy Asthma Immunol 2005; 94:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/65\">",
"      Scurlock AM, Althage KA, Christie L, et al. Anaphylaxis after ingestion of gummy bears. J Allergy Clin Immunol 2002; 110:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/66\">",
"      Sandhu MS, Hopp RJ. Type I hypersensitivity reaction to ingestion of mycoprotein (quorn) in a patient with mold allergy. Pediatric Asthma Allergy and Immunology 2009; 22:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/67\">",
"      Tee RD, Gordon DJ, Welch JA, Newman Taylor AJ. Investigation of possible adverse allergic reactions to mycoprotein ('Quorn'). Clin Exp Allergy 1993; 23:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/68\">",
"      Hoff M, Tr&uuml;eb RM, Ballmer-Weber BK, et al. Immediate-type hypersensitivity reaction to ingestion of mycoprotein (Quorn) in a patient allergic to molds caused by acidic ribosomal protein P2. J Allergy Clin Immunol 2003; 111:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/69\">",
"      Moneret-Vautrin DA, Morisset M, Lemerdy P, et al. Food allergy and IgE sensitization caused by spices: CICBAA data (based on 589 cases of food allergy). Allerg Immunol (Paris) 2002; 34:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/70\">",
"      Yang WH, Drouin MA, Herbert M, et al. The monosodium glutamate symptom complex: assessment in a double-blind, placebo-controlled, randomized study. J Allergy Clin Immunol 1997; 99:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/71\">",
"      Geha RS, Beiser A, Ren C, et al. Review of alleged reaction to monosodium glutamate and outcome of a multicenter double-blind placebo-controlled study. J Nutr 2000; 130:1058S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/72\">",
"      Williams AN, Woessner KM. Monosodium glutamate 'allergy': menace or myth? Clin Exp Allergy 2009; 39:640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/73\">",
"      Walker R, Lupien JR. The safety evaluation of monosodium glutamate. J Nutr 2000; 130:1049S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/74\">",
"      RANDOLPH TG, ROLLINS JP. Beet sensitivity: allergic reactions from the ingestion of beet sugar (sucrose) and monosodium glutamate of beet origin. J Lab Clin Med 1950; 36:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/75\">",
"      Squire EN Jr. Angio-oedema and monosodium glutamate. Lancet 1987; 1:988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/76\">",
"      Allen DH, Baker GJ. Chinese-restaurant asthma. N Engl J Med 1981; 305:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/77\">",
"      Allen DH, Baker GJ. Asthma and MSG. Med J Aust 1981; 2:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/78\">",
"      Woessner KM, Simon RA, Stevenson DD. Monosodium glutamate sensitivity in asthma. J Allergy Clin Immunol 1999; 104:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/79\">",
"      Woods RK, Weiner JM, Thien F, et al. The effects of monosodium glutamate in adults with asthma who perceive themselves to be monosodium glutamate-intolerant. J Allergy Clin Immunol 1998; 101:762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/80\">",
"      Zhou Y, Yang M, Dong BR. Monosodium glutamate avoidance for chronic asthma in adults and children. Cochrane Database Syst Rev 2012; 6:CD004357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/81\">",
"      Asero R. Food additives intolerance: a possible cause of perennial rhinitis. J Allergy Clin Immunol 2002; 110:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40681/abstract/82\">",
"      Asero R, Bottazzi G. Chronic rhinitis with nasal polyposis associated with sodium glutamate intolerance. Int Arch Allergy Immunol 2007; 144:159.",
"     </a>",
"    </li>",
"    <li>",
"     Simon R, unpublished data. (These challenges were performed subcutaneously because that was the recommended route of epinephrine injection at the time).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2405 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-125.39.66.147-BCDCD7344F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_46_40681=[""].join("\n");
var outline_f39_46_40681=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H25\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10180362\">",
"      OVERVIEW",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1213672\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10180518\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1752738\">",
"      - Reactions to multiple additives",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1213920\">",
"      - Other types of reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      URTICARIA/ANGIOEDEMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10181207\">",
"      Patients with chronic urticaria",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Additives implicated in case reports",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - BHA and BHT",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Aspartame (NutraSweet&reg;)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Lysozyme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ASTHMATIC SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Sulfites and related compounds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Tartrazine (FD&amp;C Yellow 5)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Sodium benzoate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Spearmint, peppermint, and menthol",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ANAPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Sulfites",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Annatto (E160b)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Carmine (E120)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Erythritol",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Guar gum (E412)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Psyllium",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other additives",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1001422\">",
"      Spices",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7548074\">",
"      REACTIONS TO MSG",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10181006\">",
"      MSG symptom complex",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10181021\">",
"      Allergic and asthmatic reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1752493\">",
"      EVALUATION AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1752505\">",
"      Clinical history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22881236\">",
"      Analysis of causative foods",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22881089\">",
"      Indications for allergy referral",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7548108\">",
"      Pitfalls of additive-free diets",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10180860\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1214102\">",
"      Patients with anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/2405\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2405|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?32/46/33514\" title=\"figure 1\">",
"      Clinical criteria for diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2405|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"mobipreview.htm?2/42/2722\" title=\"form 1\">",
"      Anaphylaxis action plan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/2405|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?19/49/20251\" title=\"table 1\">",
"      Manifestations of IgE rxns",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?7/26/7597\" title=\"table 2\">",
"      Differential dx food reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/18/11565\" title=\"table 3\">",
"      Sulfite-containing foods",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/5/43097?source=related_link\">",
"      Allergic reactions to vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36072?source=related_link\">",
"      Allergy to meats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/61/32730?source=related_link\">",
"      Attention deficit hyperactivity disorder in children and adolescents: Overview of treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/7/117?source=related_link\">",
"      Chronic urticaria: Standard management and patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/52/11082?source=related_link\">",
"      Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/29/14808?source=related_link\">",
"      Clinical manifestations of food allergy: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/1/6170?source=related_link\">",
"      Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/51/34615?source=related_link\">",
"      Evaluation of headache in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/63/2042?source=related_link\">",
"      Food allergens: Overview of clinical features and cross-reactivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/28/20937?source=related_link\">",
"      Mast cell activation disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/63/38903?source=related_link\">",
"      Occupational asthma: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/48/7945?source=related_link\">",
"      Occupational rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/38/27242?source=related_link\">",
"      Overview of idiopathic environmental intolerance (multiple chemical sensitivity)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/41/5785?source=related_link\">",
"      Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?28/57/29586?source=related_link\">",
"      Patient information: Epinephrine auto-injectors (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?27/30/28134?source=related_link\">",
"      Patient information: Use of an epinephrine autoinjector (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/17/23832?source=related_link\">",
"      Prescribing epinephrine for anaphylaxis self-treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/38/618?source=related_link\">",
"      Risk factors for gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/12/2248?source=related_link\">",
"      Testing and challenge procedures to evaluate allergic and asthmatic reactions to food additives",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_46_40682="Twin pregnancy: Prenatal issues";
var content_f39_46_40682=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Twin pregnancy: Prenatal issues",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/46/40682/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/46/40682/contributors\">",
"     Stephen T Chasen, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/46/40682/contributors\">",
"     Frank A Chervenak, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/46/40682/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/46/40682/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?39/46/40682/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?39/46/40682/contributors\">",
"     Vanessa A Barss, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?39/46/40682/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twin pregnancies comprise an increasing proportion of the total pregnancies in the developed world due to the expanded use of fertility treatments and older maternal age at childbirth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In the United States, twin births accounted for 3.3 percent of live births in 2010 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple gestation is associated with higher rates of almost every potential complication of pregnancy, with the exceptions of postterm pregnancy and macrosomia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. The most serious risk is spontaneous preterm delivery, which plays a major role in the increased perinatal mortality and short-term and long-term morbidity observed in these infants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/6\">",
"     6",
"    </a>",
"    ]. Higher rates of fetal growth restriction and congenital anomalies also contribute to adverse outcome in twin births. In addition, monochorionic twins are at risk for complications unique to these pregnancies, such as twin-twin transfusion syndrome, which can be lethal or associated with serious morbidity.",
"   </p>",
"   <p>",
"    Appropriate decisions regarding antepartum assessment and delivery are essential to ensure optimal perinatal outcomes. However, there is no consensus as to what constitutes optimal care. Specialized antenatal clinics for women with multiple gestations have not been proven to improve birth outcomes compared with standard care, although data from randomized trials are sparse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An overview of the antepartum care of women with twin pregnancy will be presented here. Intrapartum management is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/11/5306?source=see_link\">",
"     \"Twin pregnancy: Labor and delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ZYGOSITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dizygotic or &ldquo;fraternal&rdquo; twins occur from ovulation and fertilization of two oocytes, which almost always results in dichorionic placentation, usually with two separate placentas. Monozygotic or &ldquo;identical&rdquo; twins result from ovulation and fertilization of a single oocyte, with subsequent division of the zygote; placentation may be dichorionic or monochorionic. There are rare reports of twins that do not conform to the traditionally accepted classification of dizygotic and monozygotic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/8\">",
"     8",
"    </a>",
"    ]. Various hypotheses for this phenomenon have been proposed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INCIDENCE AND EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twins account for 96 percent of multiple births in the United States. Dizygotic twins are more common than monozygotic twins, 69 and 31 percent of twins, respectively (in the absence of use of assisted reproductive techniques [ART]) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/10\">",
"     10",
"    </a>",
"    ]. The incidence of monozygotic twins is relatively stable worldwide at 3 to 5 per 1000 births. The major factors influencing the incidence of dizygotic twins are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Use of fertility stimulating drugs",
"      </strong>",
"      &mdash; Use of fertility enhancing treatment (ART and non-ART) increases the incidence of twin pregnancy 20-fold higher than with natural conception. These therapies account for most of the increase in twin births in recent years (twin births increased from",
"      <span class=\"nowrap\">",
"       1/53",
"      </span>",
"      infants in 1980 to",
"      <span class=\"nowrap\">",
"       1/30",
"      </span>",
"      infants in 2009 [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/11\">",
"       11",
"      </a>",
"      ]). In the United States, ART accounts for about 1 percent of all births and 8 to 16 percent of twin births; non-ART fertility treatment (ovulation induction, superovulation) accounts for 3 to 7 percent of all births and 21 to 32 percent of multiple (primarily twin) births; and 60 percent of twin births result from natural conception [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/11-13\">",
"       11-13",
"      </a>",
"      ]. Worldwide, about 25 percent of pregnancies conceived by ART are twins [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/14\">",
"       14",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Given that ART often involves transfer of more than one embryo, dizygotic multiples are far more common than monozygotic multiples in pregnancies conceived with ART compared with naturally conceived pregnancies: at least 95 percent of twins conceived via ART are dizygotic versus about 70 percent of those conceived naturally [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/10,15\">",
"       10,15",
"      </a>",
"      ]. Interestingly, ART also appears to increase the risk of embryo cleavage resulting in monozygotic twins. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?2/6/2154?source=see_link&amp;anchor=H8#H8\">",
"       \"Pregnancy outcome after assisted reproductive technology\", section on 'Monozygotic multiples'",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      Twin pregnancy after non-ART ovarian stimulation generally results from ovulation and fertilization of multiple oocytes, thus usually leading to dizygoticity.",
"     </li>",
"     <li>",
"      <strong>",
"       Maternal age",
"      </strong>",
"      &mdash; Advancing age is associated with an increased prevalence of twin births. Naturally conceived dizygotic twinning increases four-fold between age 15 and age 35; this may be related to rising follicle stimulating hormone (FSH) concentration with age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/16\">",
"       16",
"      </a>",
"      ]. Older women are also more likely to use fertility treatments. One-third of the increase in multiple births in recent decades has been attributed to increasing age at childbirth.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        Race/geographic",
"       </strong>",
"      </span>",
"      area",
"      &mdash; There are significant ethnic variations in the incidence of dizygotic twinning:",
"      <span class=\"nowrap\">",
"       1.3/1000",
"      </span>",
"      Japan,",
"      <span class=\"nowrap\">",
"       8/1000",
"      </span>",
"      United States and Europe,",
"      <span class=\"nowrap\">",
"       50/1000",
"      </span>",
"      Nigeria [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Parity",
"      </strong>",
"      &mdash; Increasing parity correlates with an increased likelihood of twin birth, even after adjustment for maternal age [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Family history",
"      </strong>",
"      &mdash; Twinning appears to have a genetic component that is expressed in women, but can be inherited from either parent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/17\">",
"       17",
"      </a>",
"      ]. Thus, a woman is at increased risk of having twins if she has a family history of twin births, while the family history of the biologic father appears to have little or no effect on his partner's risk of having twins. However, if he has a positive family history of twinning, he could pass this trait to his daughter. This theory is supported by gene mapping studies in animals and humans that found specific genetic mutations expressed by oocytes or ovarian cells were at least partly responsible for twinning [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/17,18\">",
"       17,18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <strong>",
"       Maternal weight and height",
"      </strong>",
"      &mdash; Obese (BMI &ge;30",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      and tall women (&ge;65 inches [164 cm]) are at greater risk for twin birth than underweight (BMI &lt;20",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"       )",
"      </span>",
"      and short women (&lt;61 inches [155 cm]) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/19-21\">",
"       19-21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Diet may be an important factor affecting the twinning rate in some geographic areas, among certain races, and in women of particular body habitus [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/16,22,23\">",
"     16,22,23",
"    </a>",
"    ]. As an example, some studies have reported that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation increased the rate of twinning [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/24-27\">",
"     24-27",
"    </a>",
"    ]. However, there were several limitations to these studies, which could have biased the results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     RECOGNITION OF TWIN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound examination is the only safe and reliable method of definitive diagnosis of multiple gestation. Ultrasound assessment also provides accurate estimation of gestational age, which is important in all pregnancies, but is critical in management of twin pregnancies because of the higher risk of preterm delivery, growth abnormalities, and twin-specific complications (discussed below).",
"   </p>",
"   <p>",
"    Most pregnant women in developed countries undergo routine ultrasound screening examination. Randomized clinical trials comparing routine ultrasound examination with ultrasound performed only for clinical indications have shown that a significant number of twin pregnancies are not recognized until the third trimester or delivery in women who do not undergo routine ultrasound examination [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. As an example, the RADIUS (Routine Antenatal Diagnostic Imaging with Ultrasound Study) study of over 15,000 gravidas reported that 38 percent of twin pregnancies remained unrecognized until after 26 weeks of gestation in women who did not have a routine second trimester ultrasound examination, and 13 percent of twins were not diagnosed until delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/28\">",
"     28",
"    </a>",
"    ]. The Helsinki Ultrasound Trial reported similar findings, as about 25 percent of twin pregnancies were not identified until after 21 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/29\">",
"     29",
"    </a>",
"    ]. In both trials, no twin pregnancies were missed on ultrasound examination.",
"   </p>",
"   <p>",
"    A policy of routine first or second trimester ultrasound would diagnose all twin gestations at a time when amnionicity and chorionicity are easily determined (discussed below) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/31\">",
"     31",
"    </a>",
"    ]. However, the American College of Obstetricians and Gynecologists (ACOG) does not recommend routine ultrasound examination because, in a population of women with low-risk pregnancy, neither a reduction in perinatal morbidity and mortality, nor a lower rate of unnecessary interventions, have been demonstrated from routine diagnostic sonography [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/28-30,32\">",
"     28-30,32",
"    </a>",
"    ]. This may be related to the small numbers of twins in these trials and a lack of a standardized protocol for management of the multiple gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/33\">",
"     33",
"    </a>",
"    ]. ACOG does recommend that ultrasound be performed when there are specific indications for the examination, such as when twins are suspected because uterine size is greater than expected for menstrual dates.",
"   </p>",
"   <p>",
"    Prenatal ultrasound screening guidelines vary worldwide. The Royal College of Obstetricians and Gynaecologists recommend that all women with a twin pregnancy be offered an ultrasound examination at 10 to 13 weeks of gestation to assess viability, chorionicity, major congenital malformation, and nuchal translucency [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EARLY AND LATE LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early spontaneous reduction from twin to singleton pregnancy is common. In one study of 549 twin pregnancies, an initial ultrasound examination was performed 3.5 to 4.5 weeks after ovulation and repeated every two weeks until 12 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/35\">",
"     35",
"    </a>",
"    ]. Spontaneous reduction of one sac (&ldquo;vanishing twin&rdquo;) occurred in 27 percent of pregnancies diagnosed as twins prior to 7 weeks of gestation; both sacs were lost in 9 percent. A vanishing twin may have implications for the remainder of the pregnancy. For example, maternal analyte levels for Down syndrome screening may be affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Additional risks to the survivor are discussed below. (See",
"    <a class=\"local\" href=\"#H24\">",
"     'Death of one twin'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Rates of late fetal and infant death are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef66305 \" href=\"mobipreview.htm?11/51/12091\">",
"     table 1",
"    </a>",
"    ). Infant mortality in twins is five-fold higher than that of singletons (37 versus 7 per 1000 live births) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/38\">",
"     38",
"    </a>",
"    ], and twins account for 12 to 15 percent of neonatal deaths [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Comparative outcomes of twin versus singleton pregnancies are shown in the table (",
"    <a class=\"graphic graphic_table graphicRef75320 graphicRef60676 \" href=\"mobipreview.htm?16/25/16797\">",
"     table 2A-B",
"    </a>",
"    ). Interestingly, studies have consistently shown that, in pregnancies conceived using ART, the rate of early loss of the entire pregnancy is significantly lower for twin than singleton gestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NUTRITION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H215418\">",
"    <span class=\"h2\">",
"     Weight gain",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women carrying multiple gestations should increase their daily dietary intake by about 300 kcal above that for a singleton pregnancy, or 600 kcal over that of a nonpregnant woman [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/32\">",
"     32",
"    </a>",
"    ]. The Institute of Medicine recommends the following cumulative weight gain by term for women carrying twins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/41\">",
"     41",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      BMI &lt;18.5",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (underweight) &mdash; no recommendation due to insufficient data",
"     </li>",
"     <li>",
"      BMI 18.5 to 24.9",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (normal weight) &mdash; weight gain 37 to 54 lbs (16.8 to 24.5 kg)",
"     </li>",
"     <li>",
"      BMI 25.0 to 29.9",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (overweight) &mdash; weight gain 31 to 50 lbs (14.1 to 22.7 kg)",
"     </li>",
"     <li>",
"      BMI &ge;30.0",
"      <span class=\"nowrap\">",
"       kg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      (obese) &mdash; weight gain 25 to 42 lbs (11.4 to 19.1 kg)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These thresholds represent the 25th through 75th percentile weight gains in women who gave birth to twins weighing at least 2500 g [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/41\">",
"     41",
"    </a>",
"    ]. Women with normal prepregnancy BMIs who met or exceeded these guidelines had fewer preterm births and higher birth weights compared with women who did not meet the minimum weight gain suggested by the guidelines [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. Other guidelines have also been developed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H215425\">",
"    <span class=\"h2\">",
"     Vitamins and minerals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dietary or",
"    <span class=\"nowrap\">",
"     vitamin/mineral",
"    </span>",
"    supplementation should include adequate iron and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    . Women with twins are at increased risk of developing anemia. The Society of Maternal-Fetal Medicine recommendations for daily total intake of vitamins and minerals in twin pregnancy include [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?8/61/9174?source=see_link\">",
"       Folic acid",
"      </a>",
"      - 1 mg throughout pregnancy",
"     </li>",
"     <li>",
"      Iron - 30 mg in the first trimester, then 60 mg until delivery",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     AMNIONICITY AND CHORIONICITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Relationship with timing of egg division",
"    </span>",
"    &nbsp;&mdash;&nbsp;Timing of egg division determines placentation in monozygotic twins (",
"    <a class=\"graphic graphic_figure graphicRef53594 \" href=\"mobipreview.htm?12/44/12992\">",
"     figure 1",
"    </a>",
"    ); the factors responsible for timing of egg division are not known:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diamniotic, dichorionic",
"      <span class=\"nowrap\">",
"       (DA/DC)",
"      </span>",
"      placentation occurs with division prior to the morula stage (within three days post fertilization). Essentially all dizygotic and one third of monozygotic twins are",
"      <span class=\"nowrap\">",
"       DA/DC",
"      </span>",
"      (alternatively, for DC gestations, 80 to 90 percent are dizygotic and 10 to 20 percent are monozygotic).",
"     </li>",
"     <li>",
"      Diamniotic, monochorionic",
"      <span class=\"nowrap\">",
"       (DA/MC)",
"      </span>",
"      placentation occurs with division between days 4 and 8 post fertilization. Essentially, all MC twins are monozygotic and two-thirds of monozygotic twins are MC.",
"     </li>",
"     <li>",
"      Monoamniotic, monochorionic",
"      <span class=\"nowrap\">",
"       (MA/MC)",
"      </span>",
"      placentation occurs with division between days 8 and 12 post fertilization. All are monozygotic and may be mirror image twins (ie, they exhibit characteristics with reversed asymmetry [eg, one twin is left-handed and the other is right-handed, opposite hair whorl directions]).",
"     </li>",
"     <li>",
"      Division at or after day 13 results in conjoined twins. (See",
"      <a class=\"local\" href=\"#H180876174\">",
"       'Conjoined twins'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are at least six case reports of dizygotic twins with MC placentation, all involving assisted reproductive technology [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/46-48\">",
"     46-48",
"    </a>",
"    ]. The mechanism has not been explained, but may have been related to assisted reproductive technology.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Clinical significance of monochorionicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;An accurate diagnosis of chorionicity is important, and may be more important than zygosity. MC twins share the placental mass and fetoplacental circulation. Because of this, MC twins are at risk of specific pregnancy complications, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/49-53\">",
"     49-53",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Twin-twin transfusion syndrome",
"      </strong>",
"      <strong>",
"       (TTTS)",
"      </strong>",
"      , which develops in 10 to 15 percent of MC twins. It is characterized by oligohydramnios-polyhydramnios sequence, and progresses to more severe complications. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28039?source=see_link\">",
"       \"Pathogenesis and diagnosis of twin-twin transfusion syndrome\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?9/43/9913?source=see_link\">",
"       \"Management of twin-twin transfusion syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Twin anemia-polycythemia sequence (TAPS),",
"      </strong>",
"      which is a variant of TTTS in which amniotic fluid volumes are normal. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28039?source=see_link&amp;anchor=H276251225#H276251225\">",
"       \"Pathogenesis and diagnosis of twin-twin transfusion syndrome\", section on 'TAPS'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Twin reversed arterial perfusion sequence (TRAP),",
"      </strong>",
"      which is a rare complication of MC twins. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/10/165?source=see_link\">",
"       \"Diagnosis and management of twin reversed arterial perfusion (TRAP) sequence\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Selective intrauterine growth restriction",
"      </strong>",
"      . (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Growth restriction and discordance'",
"      </a>",
"      below.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These complications increase the risk of neurologic morbidity and perinatal mortality in MC twins compared to DC twins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/50,51,54-57\">",
"     50,51,54-57",
"    </a>",
"    ]. In a population-based study including over 9000 twins, stillbirth rates were significantly higher in MC than DC twins: 44.4 versus 12.2 per 1000 births (RR 3.6; 95% CI: 2.6&ndash;5.1); neonatal death rates were also significantly higher: 32.4 versus 21.4 per 1000 live births (RR 1.5; 95% CI 1.04&ndash;2.2) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/56\">",
"     56",
"    </a>",
"    ]. In other series of",
"    <span class=\"nowrap\">",
"     MC/DA",
"    </span>",
"    twin pregnancies, fetal mortality ranged from 6 to 13 percent; most deaths occurred before 24 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/50,54,55,58\">",
"     50,54,55,58",
"    </a>",
"    ]. After this stage, the rate of perinatal loss is lower (2 percent), but remains higher in MC than DC pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/59\">",
"     59",
"    </a>",
"    ]. For these reasons, management protocols for",
"    <span class=\"nowrap\">",
"     MC/DA",
"    </span>",
"    twins have involved more intensive surveillance of fetal growth and amniotic fluid volume than protocols for DC twins.",
"    <br/>",
"   </p>",
"   <p>",
"    Selective termination of one twin (eg, anomalous fetus) with intracardiac injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is not considered in MC twins because feticide using these methods can result in death of the cotwin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/60\">",
"     60",
"    </a>",
"    ]; however, radiofrequency ablation can be considered for management of the TRAP sequence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39065?source=see_link\">",
"     \"Multifetal pregnancy reduction and selective termination\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/45/1750?source=see_link\">",
"     \"Induced fetal demise\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348913022\">",
"    <span class=\"h2\">",
"     Monoamnionicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monoamniotic twins are at especially high risk of fetal death; therefore, they are managed with more intensive fetal surveillance, antenatal glucocorticoids, earlier delivery, and cesarean birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/61,62\">",
"     61,62",
"    </a>",
"    ]. Diagnosis, management, and outcome of these pregnancies are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/31/43511?source=see_link\">",
"     \"Monoamniotic twin pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Ultrasonographic assessment of chorionicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasonography is an effective prenatal tool for determining amnionicity and chorionicity. The optimal time for performing the ultrasound examination is in the first or early second trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. Sonographic assessment of the fetal membranes is more difficult in the third trimester, especially in the setting of oligohydramnios.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     DC twins",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most reliable indicator of DC twins in early pregnancy is identification of two separate placentas (sensitivity &gt;97 percent, specificity 100 percent). Identification of two placentas is generally a useful sign only in early pregnancy since separate placentas often fuse later in gestation. Rarely, an MC placenta that is bilobed or has a succenturiate lobe may give the appearance of two separate placentas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If there is only one placental mass, the best means of establishing a diagnosis of DC twins in early pregnancy is presence of a \"twin peak\" or \"lambda\" sign, which refers to a triangular projection of chorionic tissue projecting from fused dichorionic placentas and extending between layers of the intertwin membrane (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79928 \" href=\"mobipreview.htm?35/46/36577\">",
"     image 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/68\">",
"     68",
"    </a>",
"    ]. This landmark is most useful early in pregnancy because, after 20 weeks of gestation, it becomes less prominent and may disappear.",
"   </p>",
"   <p>",
"    After the first trimester, identification of fetuses of different sex is a highly reliable means of confirming a DC pregnancy.",
"   </p>",
"   <p>",
"    Another method for diagnosis of DC placentation involves identifying more than two layers in the interfetal membrane, which is best accomplished between 16 and 24 weeks of gestation using high resolution, magnified images with the membrane perpendicular to the ultrasound beam. This is technically difficult; therefore, this method is not commonly employed.",
"   </p>",
"   <p>",
"    An additional clue that twins are DC is that the intertwin membrane is thicker with DC than MC twins since the",
"    <span class=\"nowrap\">",
"     DC/DA",
"    </span>",
"    membrane consists of four layers (ie, two layers of both amnion and chorion) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75595 \" href=\"mobipreview.htm?2/38/2657\">",
"     image 2",
"    </a>",
"    ), whereas the intertwin membrane in a",
"    <span class=\"nowrap\">",
"     MC/DA",
"    </span>",
"    pregnancy is comprised of just two layers of amnion (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef56124 \" href=\"mobipreview.htm?10/29/10706\">",
"     image 3",
"    </a>",
"    ) and there is no intervening membrane in an",
"    <span class=\"nowrap\">",
"     MC/MA",
"    </span>",
"    pregnancy. There is no consensus for the cut-off between thin and thick membranes; thresholds of 1.5 to 2 mm in the first trimester have been used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. The differences in membrane thickness are less obvious later in pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/71,72\">",
"     71,72",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     MC twins",
"    </span>",
"    &nbsp;&mdash;&nbsp;MC twins are best identified by presence of the \"T\" sign, which refers to the appearance of the thin intertwin membrane as it takes-off from the placenta at a 90 degree angle. The \"T\" sign has 100 percent sensitivity and &gt;98 percent specificity for predicting MC.",
"   </p>",
"   <p>",
"    In MC twins, amnionicity is determined based upon visualization or nonvisualization of an intertwin membrane. Visualizing the membrane becomes more difficult with advancing gestation because of fetal crowding, progressive thinning of the membrane, and, in some cases, development of oligohydramnios in one or both sacs. These factors may lead to a false diagnosis of",
"    <span class=\"nowrap\">",
"     MC/MA",
"    </span>",
"    twins. On the other hand,",
"    <span class=\"nowrap\">",
"     MC/MA",
"    </span>",
"    twins may be misdiagnosed as",
"    <span class=\"nowrap\">",
"     MC/DA",
"    </span>",
"    twins when separation of the amnion and chorion is mistaken for an intertwin membrane. Early knowledge of amnionicity from first or early second trimester ultrasound examination helps to eliminate these errors.",
"   </p>",
"   <p>",
"    In a study including over 600 twin pregnancies at 11 to 14 weeks of gestation at a tertiary referral center, use of the T sign, lambda sign, and number of placentas for determining monochorionicity had sensitivity of 100 percent and specificity of 99.8 percent, with only one dichorionic pregnancy incorrectly assigned as monochorionic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/73\">",
"     73",
"    </a>",
"    ]. In this pregnancy a placental hematoma precluded diagnosis of the T or lambda sign. &nbsp;Other smaller studies have reported sensitivity of 90-100 percent and specificity of 97.4-99.5 percent using these markers and fetal sex. The lower sensitivities in some of these studies may be related to assessment very early in the first trimester.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     PRENATAL DIAGNOSIS OF DOWN SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;We suggest offering Down syndrome screening with the first-trimester combined test, which can provide fetus-specific risk assessment when chorionic villus sampling (CVS) is available. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/22/7529?source=see_link&amp;anchor=H2#H2\">",
"     \"First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18\", section on 'First trimester combined test'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Each fetus of a multiple gestation is at the same risk of having trisomy 21 as a singleton fetus; this risk is based upon maternal age and family history. Since there are two fetuses at risk in twin pregnancy, the risk that one fetus of a dizygotic pregnancy is affected is twice that of a singleton pregnancy (if zygosity is unknown, multiply singleton risk by",
"    <span class=\"nowrap\">",
"     5/3).",
"    </span>",
"    The risk of an affected pregnancy is about the same for women age 31 to 33 carrying twins as for women age 35 carrying a singleton [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/74,75\">",
"     74,75",
"    </a>",
"    ]. Age-based cutoffs for offering invasive testing are no longer recommended in singleton pregnancies, and should not be used in twin pregnancies either. All women should be offered the options of risk assessment (screening) and invasive testing.",
"   </p>",
"   <p>",
"    Determination of each fetus' risk also depends upon zygosity. As discussed above, this cannot always be determined with certainty before birth. For dizygotic twins, the pregnancy specific risk is calculated by summing the individual estimates of risk. By comparison, both twins in a monozygotic pair would be expected to be either affected or unaffected so their risk estimate is calculated differently [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/76\">",
"     76",
"    </a>",
"    ]. The method and calculations involved for prenatal screening of Down syndrome and neural tube defects in twin pregnancies were described by Wald [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/76\">",
"     76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Maternal serum analyte interpretation is problematic in twin pregnancies since both twins contribute to the analyte concentration, thus a fetus&rsquo; specific risk cannot be calculated. Maternal analyte levels can be adjusted for twin pregnancy; however, the detection rate for Down syndrome is lower than in singleton pregnancy (eg, integrated test: 93 percent detection in MC twins, 78 percent detection in DC twins, 95 percent detection in singletons; for the combined test detection rates are 84, 70, and 85 percent, respectively) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/76\">",
"     76",
"    </a>",
"    ]. In addition, maternal analyte levels for Down syndrome screening in twin pregnancy may be affected by early loss of one embryo of a triplet gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/36,37\">",
"     36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Measurement of nuchal thickness can improve the detection rate and help identify which fetus is affected [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. Using first trimester combined risk assessment (nuchal translucency and analytes), a study by the Fetal Medicine Foundation identified three of four fetuses with Down syndrome in dizygotic pregnancies discordant for the abnormality (detection rate 75 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/77\">",
"     77",
"    </a>",
"    ]; by comparison, the detection rate was 90 percent in singleton pregnancies (5 percent false-positive rate) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In our institution, first-trimester combined risk assessment identified all six affected pregnancies (five discordant and one concordant for Down syndrome) at a screen-positive rate of 5 percent, while nuchal translucency alone detected five of six affected fetuses. Although biochemical testing enhanced risk assessment, serum analyte levels in affected twin pregnancies were closer to the median levels than in affected singleton pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of note, the false-positive rate of nuchal translucency screening is higher in MC than in DC twins because increased nuchal translucency can be an early manifestation of twin-to-twin-transfusion syndrome, as well as a marker of chromosomal abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/80\">",
"     80",
"    </a>",
"    ]. Also, in vitro fertilization affects analyte values used in Down syndrome screening and may be considered by some laboratories when interpreting screening results in twins conceived by this method [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/81\">",
"     81",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/39/27257?source=see_link&amp;anchor=H28#H28\">",
"     \"Laboratory issues related to maternal serum screening for Down syndrome\", section on 'In vitro fertilization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An additional factor complicating prenatal diagnosis of monozygotic twins is that rarely these twins have different genotypes due to fetal mosaicism or confined placental mosaicism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/82-87\">",
"     82-87",
"    </a>",
"    ]. Moreover, fetuses with the same genotype may have different phenotypes; as an example, only one fetus of twins with Down syndrome may have increased nuchal translucency. In a series of eight MC twin pairs discordant for nuchal translucency who were karyotyped, the discordance was a marker for concordant chromosome abnormalities in one twin pair and discordant chromosomal abnormalities in two twin pairs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/87\">",
"     87",
"    </a>",
"    ]. For these reasons, both fetuses of a monozygotic pair should undergo karyotyping when karyotyping is performed, although this may not be possible when CVS is performed. In some cases, amniocytes, as well as fetal blood, may be needed to make an accurate diagnosis.",
"   </p>",
"   <p>",
"    Invasive testing is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16570?source=see_link\">",
"     \"Diagnostic amniocentesis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28169?source=see_link&amp;anchor=H8#H8\">",
"     \"Chorionic villus sampling: Risks, complications, and techniques\", section on 'Multiple gestations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     DIAGNOSIS AND MANAGEMENT OF CONGENITAL ANOMALIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of congenital anomalies is three to five fold higher in monozygotic twins than in singletons or dizygotic twins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/10,88-93\">",
"     10,88-93",
"    </a>",
"    ]. The concordance rate of major congenital malformations in monozygotic twins is about 20 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/89\">",
"     89",
"    </a>",
"    ]. Malformations in dizygotic twins occur at a similar rate to that in singletons and without a high risk of concordance.",
"   </p>",
"   <p>",
"    Twins are not predisposed to any specific type of congenital anomaly, although congenital heart disease is more prevalent in MC twins with twin to twin transfusion syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/91\">",
"     91",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reported accuracy of ultrasound for detection of fetal anomalies in twins varies because of differences in ascertainment postnatally and at pregnancy termination, the criteria for defining an anomaly, and operator capability. Ultrasound examination can detect the majority of major malformations in twins, but should be performed by sonographers experienced in both anomaly detection and assessment of multiple gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/94\">",
"     94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of a congenital anomaly in one twin is especially problematic since decisions regarding monitoring, therapy, and delivery affect both fetuses. Expectant management, pregnancy termination, and selective feticide should all be discussed, if appropriate by gestational age. Women who choose to continue the pregnancy should understand how the anomalous fetus might affect the cotwin's outcome (eg, preterm birth, organ damage), including the role of chorionicity. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39065?source=see_link\">",
"     \"Multifetal pregnancy reduction and selective termination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H180876174\">",
"    <span class=\"h2\">",
"     Conjoined twins",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conjoined twins are classified according to the anatomical site of union (eg, chest, head) with the suffix \"pagus\" (meaning fixed, eg thoracopagus). Findings on ultrasound include monoamnionicity, contiguous skin, twins that stay in the same orientation to one another, fetal scoliosis, unusual limb positioning, and more than three vessels in the cord [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/95\">",
"     95",
"    </a>",
"    ]. Associated congenital defects unrelated to the area of fusion are common, as is stillbirth. Detailed ultrasonography and echocardiography, possibly with additional magnetic resonance imaging, are essential to determine the extent of deformity, to counsel the parents about prognosis, and to prepare for possible postnatal surgical management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/95-98\">",
"     95-98",
"    </a>",
"    ]. Delivery of potentially viable infants is always by cesarean. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/60/27594?source=see_link&amp;anchor=H29#H29\">",
"     \"Neonatal outcome, complications, and management of multiple births\", section on 'Conjoined twins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Selective fetal termination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The timely diagnosis of a fetal anomaly allows the patient to consider selective termination of the anomalous fetus. This is a safe and effective option in expert hands, although there is a risk of miscarriage or preterm delivery of the normal co-twin. Because of these risks, expectant management may be a safer option if the twin with the anomaly is not expected to have prolonged survival or a favorable outcome (eg, trisomy 18) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anencephaly is an exception since it is associated with polyhydramnios and preterm birth. If polyhydramnios develops in the anencephalic twin's sac of a DC twin pair, selective feticide or amniodrainage appears to result in longer gestation and higher birthweight in the viable twin than expectant management [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. In our practice, we suggest selective termination whenever a fetal anomaly incompatible with survival is identified in one twin if this anomaly is associated with polyhydramnios. We do not recommend amnioreduction unless maternal respiratory compromise is present.",
"   </p>",
"   <p>",
"    As discussed above, selective termination of one twin (eg, anomalous fetus) with intracardiac injection of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/57/34711?source=see_link\">",
"     potassium chloride",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29113?source=see_link\">",
"     digoxin",
"    </a>",
"    is not considered in MC twins because feticide can result in death of the cotwin. Selective cord coagulation is an alternative approach in this setting, and avoids the intertwin risks associated with shared circulations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/102\">",
"     102",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39065?source=see_link&amp;anchor=H15#H15\">",
"     \"Multifetal pregnancy reduction and selective termination\", section on 'Selective termination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348913135\">",
"    <span class=\"h1\">",
"     MONITORING DURING THE SECOND TRIMESTER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Each twin&rsquo;s growth and amniotic fluid volume is monitored during the second and third trimesters to look for abnormalities and intertwin discordancy. Although it is critical to accurately identify each twin consistently over serial examinations, this can be difficult in same sex twins since they move around. The relative orientation of the twins to each other can be defined as lateral",
"    <span class=\"nowrap\">",
"     (left/right)",
"    </span>",
"    or vertical",
"    <span class=\"nowrap\">",
"     (top/bottom",
"    </span>",
"    <span class=\"nowrap\">",
"     [fundus/lower",
"    </span>",
"    uterine segment]). The presenting twin in laterally oriented twins may change over time, but the bottom twin of vertically oriented twins is likely to remain the presenting twin throughout pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/103\">",
"     103",
"    </a>",
"    ]. Documentation of the sites of placental implantation (anterior, posterior, lateral) and of the sites and types of placental cord insertion (eg, marginal versus central; normal versus velamentous) is also useful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H276251595\">",
"    <span class=\"h2\">",
"     Evaluation for TTTS and TAPS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The monitoring of",
"    <span class=\"nowrap\">",
"     MC/DA",
"    </span>",
"    pregnancies should include assessment of amniotic fluid volume and fetal bladder in both twins for early detection of TTTS and measurement of MCA-PSV in both fetuses for early detection of TAPS [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/104\">",
"     104",
"    </a>",
"    ]. There are inadequate data to determine the optimal frequency of monitoring, but measurement every two to three weeks after 16 weeks is reasonable. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28039?source=see_link&amp;anchor=H276251225#H276251225\">",
"     \"Pathogenesis and diagnosis of twin-twin transfusion syndrome\", section on 'TAPS'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28039?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogenesis and diagnosis of twin-twin transfusion syndrome\", section on 'Monitoring for TTTS'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Evaluation of fetal growth",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of fetal growth is particularly important in twin pregnancy because growth restriction and prematurity are major causes of the higher",
"    <span class=\"nowrap\">",
"     morbidity/mortality",
"    </span>",
"    rates in twins compared with singleton gestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/51,105-113\">",
"     51,105-113",
"    </a>",
"    ]. In the first and second trimesters, the growth rate of twins is not significantly different from that of singletons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/114-116\">",
"     114-116",
"    </a>",
"    ]. In the third trimester, particularly after 30 to 32 weeks of gestation, most studies have described slower fetal growth in uncomplicated twin pregnancies than in uncomplicated singleton gestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/115,116\">",
"     115,116",
"    </a>",
"    ]. The slower growth rate has been attributed to placental crowding and anomalous umbilical cord insertion.",
"   </p>",
"   <p>",
"    Growth curves have been derived specifically for twins, but are of limited usefulness since they were derived from small populations and did not consider chorionicity or outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/106,117\">",
"     106,117",
"    </a>",
"    ]. We, and others, feel that singleton growth curves are the best predictor of adverse outcome in twin pregnancies and should be used for evaluating twins for growth abnormalities [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/106\">",
"     106",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Twin growth should be monitored with serial ultrasound examinations, as described below for MC and DC twins (see",
"    <a class=\"local\" href=\"#H348913278\">",
"     'Frequency'",
"    </a>",
"    below). If there is evidence of growth discordance or growth restriction in either twin, then more intensive fetal monitoring is initiated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Growth restriction and discordance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Growth abnormalities manifest in three ways: (1) one twin can be small for gestational age, (2) both twins can be small for gestational age, or (3) one twin can be significantly smaller than the other twin (ie, growth discordance). In almost two-thirds of discordant twin pairs, the smaller twin has a birth weight &lt;10th percentile [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no consensus regarding the optimum threshold for defining discordance in twins. Discordance in birth weight ranging from 15 to 40 percent has been considered predictive of adverse outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/107,109-111,118,119\">",
"     107,109-111,118,119",
"    </a>",
"    ]. The most commonly used definitions are discordance &ge;20 percent or &ge;25 percent. Approximately 15 percent of twins are &ge;20 percent discordant in weight [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/112\">",
"     112",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A population based series with 128,168 twin sets reported fetal growth less than the 10th percentile was significantly more common among highly discordant twins than nondiscordant twins, 60 versus 5 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/110\">",
"       110",
"      </a>",
"      ]. In addition, the neonatal mortality rate of the smaller twin increased with increasing discordance: no discordance",
"      <span class=\"nowrap\">",
"       (3.8/1000",
"      </span>",
"      live births), 15 to 19 percent discordance",
"      <span class=\"nowrap\">",
"       (5.6/1000),",
"      </span>",
"      20 to 24 percent discordance",
"      <span class=\"nowrap\">",
"       (8.5/1000),",
"      </span>",
"      25 to 30 percent",
"      <span class=\"nowrap\">",
"       (18.4/1000),",
"      </span>",
"      and 30 percent or more",
"      <span class=\"nowrap\">",
"       (43.4/1000).",
"      </span>",
"      Large twins of discordant pairs were also at increased risk of neonatal mortality.",
"     </li>",
"     <li>",
"      Another population based series with 269,287 twin births found a significantly increased risk of neonatal death with birth weight discordancy &ge;15 percent for same sex twins (assume 30 percent are MC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/118\">",
"       118",
"      </a>",
"      ]) and &ge;30 percent for those with different sexes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/120\">",
"       120",
"      </a>",
"      ]. The lower threshold for risk with same sex twins may be related to complications in MC twinning, whereas opposite sex twins are, with very rare exception, DC.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The ability of ultrasound to accurately identify discordant twins is limited (sensitivity 23 to 93 percent, specificity 60 to 98 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/121\">",
"     121",
"    </a>",
"    ]. MC placentation is a significant risk factor for discordant growth due to unequal sharing of the placenta or twin-twin transfusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/54,122-124\">",
"     54,122-124",
"    </a>",
"    ]. MC placentation also appears to have a small independent adverse effect on intrauterine growth compared with DC placentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/125,126\">",
"     125,126",
"    </a>",
"    ]. Preeclampsia and antepartum bleeding are also associated with growth discordance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Sonographic assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Discordance in crown rump length may be observed as early as the first trimester and predicts later weight discordance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/127-130\">",
"     127-130",
"    </a>",
"    ]. We recommend serial ultrasound examinations of twin pregnancies in the second and third trimesters to screen for fetal growth restriction and growth discordance, given the risk of adverse outcome associated with these conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/131-133\">",
"     131-133",
"    </a>",
"    ]. Fundal height determination is not sensitive for identifying fetal growth abnormalities in twins. However, the effectiveness of ultrasound in predicting discordance at birth is controversial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/74,134,135\">",
"     74,134,135",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of 192 twin pregnancies that delivered within 16 days of ultrasound examination, sonographic prediction of intertwin birth weight discordance of &ge;25 percent had sensitivity, specificity, and positive and negative predictive values of 55, 97, 82, and 91 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/74\">",
"       74",
"      </a>",
"      ]. Estimation of fetal weight was calculated by applying the Hadlock formula using composite measures of fetal biometry.",
"     </li>",
"     <li>",
"      In contrast, a study of 242 twin pairs found that estimation of fetal weight and intertwin difference in abdominal circumference of &ge;20 mm were not accurate in predicting a 25 percent discordancy in birth weight [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/134\">",
"       134",
"      </a>",
"      ]. Both estimation of fetal weight (EFW) and AC difference had low sensitivity in predicting birth weight differences of 25 percent or more (sensitivity EFW 33 percent, sensitivity AC 43 percent); the positive predictive value was 33 percent for fetal weight and 11 percent for abdominal circumference.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H348913278\">",
"    <span class=\"h4\">",
"     Frequency",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monochorionic twins &mdash; Starting in the second trimester, we perform an ultrasound examination of MC twins every two to three weeks to look for evidence of growth delay or discordance. At the same time, we monitor amniotic fluid and fetal bladder volume for signs of TTTS (oligohydramnios-polyhydramnios). Starting in the third trimester, we measure MCA-PSV for signs of TAPS. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28039?source=see_link&amp;anchor=H6#H6\">",
"       \"Pathogenesis and diagnosis of twin-twin transfusion syndrome\", section on 'Clinical manifestations and diagnosis'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28039?source=see_link&amp;anchor=H276251225#H276251225\">",
"       \"Pathogenesis and diagnosis of twin-twin transfusion syndrome\", section on 'TAPS'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Dichorionic twins &mdash; In DC twin pregnancies, we perform an ultrasound examination every four to six weeks after 20 weeks of gestation, as fetal growth deceleration leading to discordancy is optimally detected between 20 and 28 weeks of gestation [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/122\">",
"       122",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Many infants with growth abnormalities can be identified at the time of a baseline exam at 20 to 24 weeks, so if there is no evidence of growth abnormality at that time, then frequent routine scanning might not be necessary [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/136\">",
"     136",
"    </a>",
"    ]; however, we continue serial ultrasound assessment until delivery.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Doppler velocimetry",
"    </span>",
"    &nbsp;&mdash;&nbsp;Doppler velocimetry of the umbilical artery may improve the performance of ultrasound in detecting growth restriction or discordance because inequality of the two fetal-placental circulations can cause intertwin differences in growth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/137\">",
"     137",
"    </a>",
"    ]. The available data do not show a clear benefit of Doppler velocimetry over the use of ultrasound alone; therefore, routine use of Doppler velocimetry in twin gestations cannot be recommended at this time.",
"   </p>",
"   <p>",
"    The largest trial of Doppler assessment of twin pregnancy randomly assigned 568 women to receive standard biometric ultrasound assessment at 25, 30, and 35 weeks of gestation or standard assessment plus Doppler velocimetry of the umbilical artery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/138\">",
"     138",
"    </a>",
"    ]. Chorionicity was not documented. All examination results were provided to the patient's physician with recommendations for close fetal surveillance if findings were abnormal. There were no differences between groups in any antenatal, intrapartum, or neonatal outcome, although there was a trend toward fewer unexplained fetal deaths in the Doppler group (0 versus 3, RR 0.14, 95% CI 0.01-1.31). This study was limited by insufficient power (over 6000 subjects would be required to show a 50 percent reduction in perinatal mortality) and because MC pregnancies were not analyzed separately, even though this placentation is associated with more complications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Management of growth abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of growth abnormalities is similar to the management of growth abnormalities in singleton pregnancies, but complicated by the possibility of twin-twin transfusion syndrome in MC twin pregnancies and the need to balance the risk of continuing pregnancy for the small twin versus the risk of preterm delivery for the unaffected twin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/113\">",
"     113",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23994?source=see_link\">",
"     \"Fetal growth restriction: Evaluation and management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28039?source=see_link\">",
"     \"Pathogenesis and diagnosis of twin-twin transfusion syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/43/9913?source=see_link\">",
"     \"Management of twin-twin transfusion syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     ASSESSMENT OF FETAL WELL-BEING",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no proven benefit from routine use of antepartum testing (nonstress test [NST], biophysical profile [BPP], amniotic fluid volume determination, or Doppler velocimetry) in uncomplicated twin pregnancies. Although some obstetricians routinely obtain one or more of these tests in the third trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/139\">",
"     139",
"    </a>",
"    ], prospective studies have not validated the effectiveness of this approach.",
"   </p>",
"   <p>",
"    Fetal assessment is probably indicated in higher risk situations, including fetal growth restriction, discordant growth, abnormal amniotic fluid volume, monoamnionicity, and preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/32\">",
"     32",
"    </a>",
"    ]. Some experts consider any MC pregnancy as high risk since there are some data showing that uncomplicated",
"    <span class=\"nowrap\">",
"     MC/DA",
"    </span>",
"    twins are at increased risk of in-utero death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/140\">",
"     140",
"    </a>",
"    ]. NSTs or BPPs performed once or twice weekly may identify those fetuses that would benefit from early delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We begin weekly testing routinely at 32 weeks of gestation, and earlier if complications are identified. Both NSTs and BPPs are as reliable in twin gestations as in singleton pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/141,142\">",
"     141,142",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2232?source=see_link\">",
"     \"Antepartum fetal heart rate assessment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11928?source=see_link\">",
"     \"The fetal biophysical profile\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The best technique to assess amniotic fluid volume in DA twin gestations is uncertain. Subjective assessment of the volume of amniotic fluid in each sac appears to be as accurate as quantitative assessment. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31558?source=see_link&amp;anchor=H10#H10\">",
"     \"Assessment of amniotic fluid volume\", section on 'AFV assessment in twins'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     DEATH OF ONE TWIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single fetal death after 20 weeks of gestation occurs in about 5 percent of twin pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/143\">",
"     143",
"    </a>",
"    ], most often before 25 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/57\">",
"     57",
"    </a>",
"    ]. Because of the presence of placental vascular anastomoses between MC twins, the intrauterine death of one twin in an MC pregnancy can cause acute hypotension, anemia, and ischemia in the cotwin, resulting in morbidity or death of that twin. In a DC pregnancy, death of one twin may reflect an adverse intrauterine environment that could also place the cotwin at risk, but the risk is much lower.",
"   </p>",
"   <p>",
"    The type and magnitude of these risks were illustrated in a systematic review of 22 studies that evaluated the prognosis of the cotwin following a single twin death in various clinical settings [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/144\">",
"     144",
"    </a>",
"    ]. Following intrauterine demise of one twin:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The rates of fetal demise of the cotwin in MC and DC pregnancies were 15 and 3 percent, respectively (OR 5.24, 95% CI 1.75-15.73).",
"     </li>",
"     <li>",
"      The rates of preterm birth in MC and DC pregnancies were 68 and 54 percent, respectively (OR 1.10, 95% CI 0.34-3.51).",
"     </li>",
"     <li>",
"      The rates of abnormal postnatal cranial imaging in MC and DC pregnancies were 34 and 16 percent, respectively (OR 3.25, 95% CI 0.66-16.1).",
"     </li>",
"     <li>",
"      The rates of neurodevelopmental impairment of the cotwin in MC and DC pregnancies were 26 and 2 percent, respectively (OR 4.81, 95% CI 1.39-16.64).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the high risk of neurologic impairment in a surviving MC cotwin, prompt delivery of MC twins should be considered if fetal assessment suggests impending death of one twin.",
"   </p>",
"   <p>",
"    While the risk to the surviving cotwin in a MC pregnancy is clear when death of one twin occurs late in pregnancy, the risk with death of one twin in the first trimester is unclear. It has been hypothesized that congenital anomalies and cerebral palsy may be attributable to early fetal loss of one conceptus in a twin gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/145\">",
"     145",
"    </a>",
"    ]. A retrospective study using data from the UK population-based Northern Multiple Pregnancy Register and Northern Congenital Abnormality Survey provided support for this theory. The risk of a congenital anomaly in the survivor following loss of a co-conceptus before 16 weeks of gestation was more than twice that in twin births from twin pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/146\">",
"     146",
"    </a>",
"    ]. These data may reflect, at least in part, the known increased risk of concordant and discordant congenital anomalies in monozygotic twins, which may lead to early in utero death of one twin if the anomaly is severe. Prospective studies are needed to clarify these relationships.",
"   </p>",
"   <p>",
"    Compared with pregnancies conceived as singletons, additional risks to the survivor after demise of one twin include a 120 gram reduction in mean birth weight, an increased risk of small for gestational age birth, and an increased risk of preterm birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal management of these pregnancies is unclear.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DC twins &mdash; In DC twins, death of one twin is not, by itself, a strong indication for intervention to deliver the surviving twin. However, if a condition affecting both twins is present (eg, preeclampsia, chorioamnionitis), then close surveillance and timely intervention for the surviving twin are indicated to prevent a second fetal loss.",
"     </li>",
"     <li>",
"      MC twins &mdash; In a MC pregnancy, there is a potential for direct harmful effects to the survivor because of intertwin vascular anastomoses [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/147\">",
"       147",
"      </a>",
"      ]. The hemodynamic changes that occur upon death of one twin are immediate; therefore, intervention to prevent damage to the survivor appears to be futile [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/148\">",
"       148",
"      </a>",
"      ]. Conservative management is probably the best option in the absence of fetal lung maturity. For gestations at 32 to 34 weeks, administering a course of corticosteroids to enhance fetal maturity and delivery 48 hours later is an option; however, there are no data showing that this is beneficial to the survivor. Before 32 weeks, it is probably best to allow the pregnancy to continue. The risk of cerebral palsy in the surviving cotwin may be as high as 20 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/149\">",
"       149",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Ultrasound and magnetic resonance evaluation of the surviving cotwin can identify signs of brain injury, such as white matter lesions or intracranial hemorrhage, which develop over time. However, the ability of imaging studies to predict or exclude fetal brain injury in this setting is unknown. Our practice is to discuss pregnancy termination when one twin dies prior to viability, although, as stated above, the risk to the cotwin is not clear when the death occurs in the first trimester.",
"   </p>",
"   <p>",
"    It is not necessary to monitor for maternal coagulopathy since it is rare, although a platelet count and fibrinogen level are desirable prior to delivery. Maternal hypofibrinogenemia or disseminated intravascular coagulation following death of one fetus of a multiple gestation has been described in only a few case reports [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/150-154\">",
"     150-154",
"    </a>",
"    ]. Although some experts have treated these women with a short course of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , spontaneous resolution of hypofibrinogenemia occurs without therapy. We only consider heparin therapy if there is active hypofibrinogemia-related bleeding or hypofibrinogemia-related risk of active bleeding (eg, placenta previa, impending labor), or if there are thrombotic complications. We have not seen clinical bleeding with hypofibrinogenemia in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25929?source=see_link\">",
"     \"Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anti-D immune globulin prophylaxis is recommended for Rh(D)-negative women. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40648?source=see_link&amp;anchor=H8#H8\">",
"     \"Prevention of Rh(D) alloimmunization\", section on 'Additional indications'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     PRETERM BIRTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major source of perinatal morbidity and mortality in twin gestations is spontaneous preterm birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/6\">",
"     6",
"    </a>",
"    ]. The rate of preterm twin delivery in the United States for 2009 was 58.8 percent before 37 completed weeks of gestation and 11.4 percent before 32 completed weeks (56.6 percent of twins were low birth weight [&lt;2500 g] and 9.9 percent were very low birth weight [&lt;1500 g]), although not all of the preterm deliveries were spontaneous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/155\">",
"     155",
"    </a>",
"    ]. Interestingly, male-male twin pairs seem to be at highest risk of preterm birth [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/156-158\">",
"     156-158",
"    </a>",
"    ]. Other risk factors for preterm birth, including the relationship between prior preterm birth and preterm birth in the current pregnancy, are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/3/35898?source=see_link&amp;anchor=H3#H3\">",
"     \"Risk factors for preterm labor and delivery\", section on 'History of preterm birth'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several studies have shown that neonatal outcome is similar for singletons, twins, and triplets who are matched for gestational age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/159,160\">",
"     159,160",
"    </a>",
"    ]. However, actual outcomes are not equivalent because the average length of gestation for singletons, twins, and triplets is about 39, 35, and 32 weeks of gestation, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/155\">",
"     155",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Multiple pregnancies that experience spontaneous reduction deliver earlier than unreduced pregnancies with the same number of fetuses. In one large series, triplet pregnancies that spontaneously reduced to twins had a significantly higher risk of preterm birth &lt;32 weeks than twins that did not originate from a triplet pregnancy (27 versus 12 percent; OR 3.09, 95% CI 1.63&ndash;5.87), and the length of gestation was on average 1.5 weeks shorter [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/161\">",
"     161",
"    </a>",
"    ]. The difference between groups in delivery &lt;37 weeks was not statistically significant (83 percent versus 73 percent in twins without spontaneous reduction).",
"   </p>",
"   <p>",
"    A variety of interventions has been recommended to prevent preterm birth or to predict women at highest risk of developing preterm labor. Although the following tests can predict pregnancies at particularly increased risk of preterm delivery, no intervention has been proven effective in reducing preterm birth rates.",
"   </p>",
"   <p>",
"    In our institution, we do not perform fetal fibronectin or cervical length screening in twin pregnancies with no symptoms of preterm labor, although a short cervix may be incidentally noted at the time of ultrasound to evaluate fetal anatomy or growth. If fetal fibronectin or cervical length measurement, or both, are performed, we consider a course of antenatal corticosteroids in symptomatic women who test positive (fetal fibronectin &ge; 50",
"    <span class=\"nowrap\">",
"     ng/mL,",
"    </span>",
"    cervical length &lt;20 mm) at 24 to 34 weeks of gestation (see",
"    <a class=\"local\" href=\"#H38\">",
"     'Antenatal corticosteroids'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Tests for predicting increased risk of preterm birth",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Fetal fibronectin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fetal fibronectin (fFN) is used as a marker for preterm birth in singleton pregnancies and may have some predictive value in twin gestations, but published reports have been too small to allow clear conclusions about the utility of this approach [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/162-165\">",
"     162-165",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?14/51/15159?source=see_link&amp;anchor=H2#H2\">",
"     \"Fetal fibronectin for prediction of preterm labor and delivery\", section on 'Fetal fibronectin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The largest prospective series included 147 women with twin pregnancies who underwent fFN testing at two-week intervals between 24 and 30 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/164\">",
"     164",
"    </a>",
"    ]. Approximately 30 percent of women with a positive test (&ge;50",
"    <span class=\"nowrap\">",
"     ng/mL)",
"    </span>",
"    at 28 weeks delivered before 32 weeks of gestation, compared with 4 percent of women with a negative result. When the fibronectin test was done at 30 weeks, the rates of delivery before 32 weeks after positive or negative test results were 38 and 1 percent, respectively. However, there were too few preterm births to reliably assess test performance; only 13 of the 147 women (8.8 percent) delivered before 32 weeks.",
"   </p>",
"   <p>",
"    Although these data suggest that fFN has some ability to predict preterm birth in twin pregnancies, we do not recommend routine fFN testing of asymptomatic twin pregnancies in the absence of additional risk factors for preterm birth (other than twin pregnancy). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Measurement of cervical length",
"    </span>",
"    &nbsp;&mdash;&nbsp;Meta-analyses have found that cervical shortening on transvaginal ultrasound examination identifies twin pregnancies at high risk for preterm birth, but the positive predictive value for preterm birth is low (",
"    <a class=\"graphic graphic_table graphicRef68816 \" href=\"mobipreview.htm?14/8/14476\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/166,167\">",
"     166,167",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of studies that measured cervical length by transvaginal ultrasound to predict spontaneous preterm birth in twin pregnancies found that the test was most useful when performed in asymptomatic women at 20 to 24 weeks of gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/166\">",
"     166",
"    </a>",
"    ]. A cut-off of 20 mm identified 35 percent of pregnancies that delivered before 28 weeks and 39 percent of pregnancies that delivered before 32 weeks; the positive likelihood ratios were 5.2 and 10.1, respectively. At a cut-off of 25 mm, 64 percent of pregnancies delivering before 28 weeks and 54 percent of those delivering before 32 weeks were identified; the positive likelihood ratios were 9.6 and 6.0, respectively. The high frequency of short cervices in women who are not at imminent risk of delivery and the lack of effective interventions to prevent preterm birth limit the usefulness of screening cervical length. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21017?source=see_link\">",
"     \"Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A long cervical length is reassuring to patients and clinicians that the risk of preterm delivery is not high, and is particularly reassuring in symptomatic women. In one small study, none of 21 women with twin pregnancies, contractions, and cervical length &ge;25 mm delivered within seven days, whereas 19 of 66 women with cervical length &lt;25 mm delivered during this interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/168\">",
"     168",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     fFN and cervical length",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic patients with both positive fFN and short cervical length at 22 to 32 weeks of gestation appear to be at high risk of preterm birth. In one study, more than 50 percent of these women delivered before 32 weeks, whereas only 4 percent of those with both tests negative delivered this early in gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/169\">",
"     169",
"    </a>",
"    ]. However, only 13 of the 155 women in this study delivered before 32 weeks, with a similar number coming from the groups with two positive and two negative results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Home uterine monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Home uterine activity monitoring (HUAM) has been proposed as a means for the early diagnosis and treatment of preterm labor. It effectively detects contractions predictive of preterm labor. However, there are no data that it improves any measure of neonatal outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/170\">",
"     170",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Interventions",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Supplemental progesterone",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no evidence to support the effectiveness of routine progesterone supplementation for decreasing the incidence of preterm delivery or death in twin pregnancies. Progesterone supplementation does not appear to prevent early preterm birth even in those twin pregnancies with previous spontaneous preterm delivery or previous late miscarriage; however, there may be a benefit in twin pregnancies with cervical shortening. These data are discussed separately (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?5/33/5657?source=see_link&amp;anchor=H31324701#H31324701\">",
"     \"Progesterone supplementation to reduce the risk of spontaneous preterm birth\", section on 'Twin pregnancy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h3\">",
"     Bedrest",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although bedrest or reduced activity is often recommended for prevention of preterm labor and birth, randomized trials of hospitalization or bedrest in twin pregnancies failed to show a prolongation of gestational age at delivery [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/171,172\">",
"     171,172",
"    </a>",
"    ]. A prospective cohort study from Denmark observed a trend toward decreased preterm births in women with multiple gestations who engaged in limited (up to two",
"    <span class=\"nowrap\">",
"     hours/week)",
"    </span>",
"    amounts of exercise in late pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/173\">",
"     173",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h3\">",
"     Cerclage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only randomized trial that evaluated use of prophylactic cerclage in twin pregnancies did not find a benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/174\">",
"     174",
"    </a>",
"    ]. A prospective cohort study of cerclage in twin pregnancies with sonographically detected shortened cervical length also did not find a benefit [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/175\">",
"     175",
"    </a>",
"    ]. A meta-analysis of randomized trials of ultrasound-indicated cerclage in singletons and twins suggested higher rates of delivery at &lt;35 weeks following cerclage placement in twins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/176\">",
"     176",
"    </a>",
"    ]. We do not recommend cerclage placement following detection of a short cervix in twins.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h3\">",
"     Tocolytic drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;A systematic review of randomized, placebo controlled trials concluded there was insufficient evidence that tocolytic drugs administered to asymptomatic women for prevention of preterm labor and birth significantly reduced preterm birth (&lt;37 weeks: RR 0.85, 95% CI 0.65-1.10; &lt;34 weeks: RR 0.47, 95% CI 0.15-1.50) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/177\">",
"     177",
"    </a>",
"    ]. Most trials involved beta-mimetics.",
"   </p>",
"   <p>",
"    Use of tocolytic drugs is indicated for inhibition of symptomatic preterm labor and is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35674?source=see_link\">",
"     \"Inhibition of acute preterm labor\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Women with twin pregnancies appear to be at higher risk of pulmonary edema after administration of beta-adrenergic agents because these women have a higher blood volume and lower colloid osmotic pressure than women carrying singletons. Therefore, these drugs should be used judiciously in women with multiple gestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/178\">",
"     178",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h1\">",
"     PRETERM PREMATURE RUPTURE OF MEMBRANES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature rupture of membranes typically occurs in the presenting sac, but can develop in the nonpresenting twin, especially after invasive procedures (eg, amniocentesis). Several studies have looked at perinatal outcome after preterm premature rupture of membranes (PPROM) in twin versus singleton gestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/179-181\">",
"     179-181",
"    </a>",
"    ]. The largest of these was a retrospective cohort study of 116 twin pregnancies with PPROM at less than or equal to 36 weeks of gestation and 116 matched singleton pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/179\">",
"     179",
"    </a>",
"    ]. Perinatal and neonatal outcomes were similar in the two groups; however, the median latency period was statistically shorter in twins (11.4 versus 19.5 hours). In our series of twin pregnancies with PPROM, 53 percent of twins with PPROM at &ge;30 weeks of gestation delivered within two days, compared to only 29 percent of patients with PPROM at &lt;30 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/182\">",
"     182",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study compared the frequency of chorioamnionitis in the nonpresenting and presenting twins and by placentation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/183\">",
"     183",
"    </a>",
"    ]. Chorioamnionitis in the nonpresenting twin was significantly less common in DC than in MC twins. Advanced inflammation (defined as chorioamnionitis with funisitis) was significantly less common in the nonpresenting twin than in the presenting twin, but only when the placentas were DC and separate.",
"   </p>",
"   <p>",
"    General issues in management of PPROM and PROM are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15866?source=see_link\">",
"     \"Preterm premature rupture of membranes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4407?source=see_link\">",
"     \"Management of premature rupture of the fetal membranes at term\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h1\">",
"     ANTENATAL CORTICOSTEROIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The small number of twin pregnancies included in randomized trials of antenatal glucocorticoid therapy precludes a definite conclusion about the effectiveness of this therapy or the optimum dose in multiple gestation. Observational data suggest some benefits, although these have not consistently approached the benefits achieved in singletons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/184-187\">",
"     184-187",
"    </a>",
"    ]. The National Institutes of Health consensus statement on use of antenatal corticosteroids for fetal maturation in preterm infants stated it was reasonable to treat women with multiple gestation as one would treat women with threatened premature delivery carrying a singleton. This therapy should be reserved for women with preterm labor or otherwise at increased risk for preterm birth within seven days; routine prophylactic administration to all twin pregnancies should be avoided and may have adverse effects [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/188\">",
"     188",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=see_link\">",
"     \"Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     POTENTIAL MATERNAL COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Twin pregnancy results in greater maternal hemodynamic changes than singleton pregnancy. Women carrying twins have a 20 percent higher cardiac output and 10 to 20 percent greater increase in plasma volume than women with singleton pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/189,190\">",
"     189,190",
"    </a>",
"    ]. Although there is also a larger rise in red cell mass in twin pregnancy, physiological anemia is common.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h2\">",
"     Gestational hypertension and preeclampsia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gestational hypertension and preeclampsia are more common in women carrying twins. This was best illustrated in a secondary analysis of prospective data from women with twin (n = 684) and singleton (n = 2946) gestations enrolled in multicenter trials of low-dose",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    for prevention of preeclampsia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/191\">",
"     191",
"    </a>",
"    ]. Rates of gestational hypertension and preeclampsia were twice as high in twin compared with singleton pregnancies (13 percent in twins versus 5 to 6 percent in singletons for both disorders). Early severe preeclampsia and HELLP syndrome tended to occur more frequently in multiple gestations.",
"   </p>",
"   <p>",
"    The diagnosis, management, and course of",
"    <span class=\"nowrap\">",
"     preeclampsia/gestational",
"    </span>",
"    hypertension are not usually affected by the multiple gestation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/192\">",
"     192",
"    </a>",
"    ], with some exceptions. A number of studies have shown that maternal uric acid concentration increases with the number of fetuses in both normotensive and preeclamptic pregnancies, with typical values of 5.2 and 6.4",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    respectively, in twin pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/193-196\">",
"     193-196",
"    </a>",
"    ]. In addition, there have been case reports of resolution of early severe preeclampsia upon death of one twin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/197-199\">",
"     197-199",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=see_link\">",
"     \"Preeclampsia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=see_link\">",
"     \"Preeclampsia: Management and prognosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29383?source=see_link\">",
"     \"Gestational hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13434?source=see_link\">",
"     \"Management of hypertension in pregnant and postpartum women\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Acute fatty liver",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute fatty liver is rare, but occurs more frequently in multiple than singleton gestations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/178\">",
"     178",
"    </a>",
"    ]. This disorder is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24166?source=see_link\">",
"     \"Acute fatty liver of pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Gestational diabetes",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data as to whether gestational diabetes is more common in twin pregnancies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/178,200-205\">",
"     178,200-205",
"    </a>",
"    ]. Diagnosis and management are similar to that in singleton pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9210?source=see_link\">",
"     \"Screening and diagnosis of diabetes mellitus during pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37866?source=see_link\">",
"     \"Medical management and follow-up of gestational diabetes mellitus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other maternal disorders observed more often in women with multiple gestations include pruritic urticarial papules and plaques of pregnancy (PUPPP), cholestasis, iron deficiency anemia, hyperemesis gravidarum, and thromboembolism [",
"    <a class=\"abstract\" href=\"mobipreview.htm?39/46/40682/abstract/178,206,207\">",
"     178,206,207",
"    </a>",
"    ]. The increased risk of thrombosis relates, at least in part, to the increased prevalence of cesarean delivery and bedrest in these gestations. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/61/29657?source=see_link\">",
"     \"Dermatoses of pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39353?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H115954197\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;National organizations that provide guidelines for management of multiple gestation include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"external\" href=\"file://publications.nice.org.uk/multiple-pregnancy-cg129\">",
"       National Institute for Health and Clinical Excellence (NICE)",
"      </a>",
"     </li>",
"     <li>",
"      <a class=\"external\" href=\"file://www.acog.org/\">",
"       American College of Obstetricians and Gynecologists",
"      </a>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/44/1732?source=see_link\">",
"       \"Patient information: Having twins (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Routine ultrasound examination performed in the first or second trimester is the best method to ensure the timely diagnosis of a twin pregnancy and establish gestational age. Early loss of one twin is common. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Recognition of twin pregnancy'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5\">",
"       'Early and late loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chorionicity should be determined early in gestation. This information affects pregnancy management and is crucial before fetal reduction. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Amnionicity and chorionicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monochorionic (MC) twins have a significantly higher risk of adverse perinatal outcome than dichorionic (DC) twins. They are also at risk for unique pregnancy complications (twin-twin transfusion syndrome, twin anemia-polycythemia sequence, twin reversed arterial perfusion sequence, selective intrauterine growth restriction). (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Clinical significance of monochorionicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Institute of Medicine recommends a 35 to 45 pound total weight gain at term for women carrying twins, or about 1.75",
"      <span class=\"nowrap\">",
"       pounds/week",
"      </span>",
"      after 20 weeks in underweight women and 1.5",
"      <span class=\"nowrap\">",
"       pounds/week",
"      </span>",
"      for women of normal weight. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nutrition'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women who choose to undergo screening for Down syndrome, we suggest the first-trimester combined test rather than either serum testing or nuchal translucency alone (when chorionic villus sampling is available) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This test provides early, fetus-specific risk assessment with a lower false positive rate than second trimester tests. Both fetuses should undergo karyotyping when karyotyping is performed since even monozygotic twins may be discordant. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Prenatal diagnosis of Down syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monozygotic twins are at higher risk of congenital anomalies than dizygotic twins or singletons; the cotwin usually does not also have the anomaly. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Diagnosis and management of congenital anomalies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Twins typically weigh less than singletons of the same gestational age, but their weights usually remain within the range considered to be normal. Abnormal growth is more common than in singleton pregnancy and can be defined in either of two ways: (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Growth restriction and discordance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Estimated fetal weight below the 10th percentile using singleton growth curves, or",
"     </li>",
"     <li>",
"      Presence of &ge;20 percent discordance in estimated fetal weight between the lighter and heavier twin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The monitoring of monochorionic twin pregnancies should include assessment of amniotic fluid volume and fetal bladder in both twins for early detection of twin-twin transfusion syndrome and measurement of MCA-PSV in both fetuses for early detection of twin anemia-polycythemia sequence. There are inadequate data to determine the optimal frequency of monitoring, but ultrasound assessment every two to three weeks after 16 weeks is reasonable.",
"      <br/>",
"      <br/>",
"      In dichorionic twin pregnancies, we perform an ultrasound examination every four to six weeks after 20 weeks of gestation as fetal growth deceleration leading to discordancy is optimally detected between 20 and 28 weeks of gestation. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Evaluation of fetal growth'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H348913278\">",
"       'Frequency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Antepartum fetal testing is indicated in complicated twin pregnancies. There is no proven benefit of routine use of antepartum testing (nonstress tests), biophysical profile, amniotic fluid volume determination, or Doppler velocimetry in uncomplicated twin pregnancies. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Assessment of fetal well-being'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Single fetal death after 20 weeks of gestation occurs in about 5 percent of twin pregnancies. Because of the presence of placental vascular anastomoses between MC twins, the intrauterine death of one twin in an MC pregnancy can cause acute hypotension, anemia, and ischemia in its cotwin, resulting in morbidity or death of the cotwin. For this reason, if fetal assessment after 26 weeks of gestation suggests impending death of one twin, we suggest prompt delivery of MC twins rather than expectant management (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Death of one twin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      No intervention has been proven to decrease the risk of preterm birth. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Preterm birth'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/1\">",
"      Luke B. The changing pattern of multiple births in the United States: maternal and infant characteristics, 1973 and 1990. Obstet Gynecol 1994; 84:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/2\">",
"      Russell RB, Petrini JR, Damus K, et al. The changing epidemiology of multiple births in the United States. Obstet Gynecol 2003; 101:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/3\">",
"      Births: Final data for 2010. Natl Vital Stat Rep 2012; 61:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/4\">",
"      Spellacy WN, Handler A, Ferre CD. A case-control study of 1253 twin pregnancies from a 1982-1987 perinatal data base. Obstet Gynecol 1990; 75:168.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/5\">",
"      Chauhan SP, Scardo JA, Hayes E, et al. Twins: prevalence, problems, and preterm births. Am J Obstet Gynecol 2010; 203:305.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/6\">",
"      Roberts WE, Morrison JC, Hamer C, Wiser WL. The incidence of preterm labor and specific risk factors. Obstet Gynecol 1990; 76:85S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/7\">",
"      Dodd JM, Crowther CA. Specialised antenatal clinics for women with a multiple pregnancy for improving maternal and infant outcomes. Cochrane Database Syst Rev 2012; 8:CD005300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/8\">",
"      Souter VL, Parisi MA, Nyholt DR, et al. A case of true hermaphroditism reveals an unusual mechanism of twinning. Hum Genet 2007; 121:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/9\">",
"      Golubovsky MD. Postzygotic diploidization of triploids as a source of unusual cases of mosaicism, chimerism and twinning. Hum Reprod 2003; 18:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/10\">",
"      Cameron AH, Edwards JH, Derom R, et al. The value of twin surveys in the study of malformations. Eur J Obstet Gynecol Reprod Biol 1983; 14:347.",
"     </a>",
"    </li>",
"    <li>",
"     Martin, JA, Hamilton, BE, Ventura SJ, et al. Births: Final data for 2009. Natl Vital Stat Rep 2009. file://www.cdc.gov/nchs/data/nvsr/nvsr60/nvsr60_01.pdf (Accessed on November 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/12\">",
"      Schieve LA, Devine O, Boyle CA, et al. Estimation of the contribution of non-assisted reproductive technology ovulation stimulation fertility treatments to US singleton and multiple births. Am J Epidemiol 2009; 170:1396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/13\">",
"      Practice Committee of American Society for Reproductive Medicine. Multiple gestation associated with infertility therapy: an American Society for Reproductive Medicine Practice Committee opinion. Fertil Steril 2012; 97:825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/14\">",
"      Nygren KG, Sullivan E, Zegers-Hochschild F, et al. International Committee for Monitoring Assisted Reproductive Technology (ICMART) world report: assisted reproductive technology 2003. Fertil Steril 2011; 95:2209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/15\">",
"      Moayeri SE, Behr B, Lathi RB, et al. Risk of monozygotic twinning with blastocyst transfer decreases over time: an 8-year experience. Fertil Steril 2007; 87:1028.",
"     </a>",
"    </li>",
"    <li>",
"     Bulmer, MG. The Biology of Twinning in Man. Oxford, UK. Clarendon Press, 1970.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/17\">",
"      Hoekstra C, Zhao ZZ, Lambalk CB, et al. Dizygotic twinning. Hum Reprod Update 2008; 14:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/18\">",
"      Moore RK, Erickson GF, Shimasaki S. Are BMP-15 and GDF-9 primary determinants of ovulation quota in mammals? Trends Endocrinol Metab 2004; 15:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/19\">",
"      Nylander PP. The factors that influence twinning rates. Acta Genet Med Gemellol (Roma) 1981; 30:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/20\">",
"      Reddy UM, Branum AM, Klebanoff MA. Relationship of maternal body mass index and height to twinning. Obstet Gynecol 2005; 105:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/21\">",
"      Basso O, Nohr EA, Christensen K, Olsen J. Risk of twinning as a function of maternal height and body mass index. JAMA 2004; 291:1564.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/22\">",
"      Steinman G. Can the chance of having twins be modified by diet? Lancet 2006; 367:1461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/23\">",
"      Khamsi F, Roberge S, Wong J. Novel demonstration of a physiologic/pharmacologic role of insulin-like growth factor-1 in ovulation in rats and action on cumulus oophorus. Endocrine 2001; 14:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/24\">",
"      Muggli EE, Halliday JL. Folic acid and risk of twinning: a systematic review of the recent literature, July 1994 to July 2006. Med J Aust 2007; 186:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/25\">",
"      Vollset SE, Gjessing HK, Tandberg A, et al. Folate supplementation and twin pregnancies. Epidemiology 2005; 16:201.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/26\">",
"      Czeizel AE, M&eacute;tneki J, Dud&aacute;s I. The higher rate of multiple births after periconceptional multivitamin supplementation: an analysis of causes. Acta Genet Med Gemellol (Roma) 1994; 43:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/27\">",
"      Li Z, Gindler J, Wang H, et al. Folic acid supplements during early pregnancy and likelihood of multiple births: a population-based cohort study. Lancet 2003; 361:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/28\">",
"      Ewigman BG, Crane JP, Frigoletto FD, et al. Effect of prenatal ultrasound screening on perinatal outcome. RADIUS Study Group. N Engl J Med 1993; 329:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/29\">",
"      Saari-Kemppainen A, Karjalainen O, Yl&ouml;stalo P, Heinonen OP. Ultrasound screening and perinatal mortality: controlled trial of systematic one-stage screening in pregnancy. The Helsinki Ultrasound Trial. Lancet 1990; 336:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/30\">",
"      Waldenstr&ouml;m U, Axelsson O, Nilsson S, et al. Effects of routine one-stage ultrasound screening in pregnancy: a randomised controlled trial. Lancet 1988; 2:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/31\">",
"      Chasen ST, Chervenak FA. What is the relationship between the universal use of ultrasound, the rate of detection of twins, and outcome differences? Clin Obstet Gynecol 1998; 41:66.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Special problems of multiple gestation. In: ACOG Educational Bulletin 253, American College of Obstetricians and Gynecologists, Washington, DC 1998.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/33\">",
"      Newman RB, Ellings JM. Antepartum management of the multiple gestation: the case for specialized care. Semin Perinatol 1995; 19:387.",
"     </a>",
"    </li>",
"    <li>",
"     Royal College of Obstetricians and Gynaecologists (RCOG). Management of monochorionic twin pregnancy. London (UK): Royal College of Obstetricians and Gynaecologists (RCOG); 2008 Dec. 13 file://www.rcog.org.uk/womens-health/clinical-guidance/management-monochorionic-twin-pregnancy (Accessed on January 27, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/35\">",
"      Dickey RP, Taylor SN, Lu PY, et al. Spontaneous reduction of multiple pregnancy: incidence and effect on outcome. Am J Obstet Gynecol 2002; 186:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/36\">",
"      Spencer K, Staboulidou I, Nicolaides KH. First trimester aneuploidy screening in the presence of a vanishing twin: implications for maternal serum markers. Prenat Diagn 2010; 30:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/37\">",
"      Chasen ST, Perni SC, Predanic M, et al. Does a \"vanishing twin\" affect first-trimester biochemistry in Down syndrome risk assessment? Am J Obstet Gynecol 2006; 195:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/38\">",
"      Misra DP, Ananth CV. Infant mortality among singletons and twins in the United States during 2 decades: effects of maternal age. Pediatrics 2002; 110:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/39\">",
"      Taylor MJ. The management of multiple pregnancy. Early Hum Dev 2006; 82:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/40\">",
"      Matias A, La Sala GB, Blickstein I. Early loss rates of entire pregnancies after assisted reproduction are lower in twin than in singleton pregnancies. Fertil Steril 2007; 88:1452.",
"     </a>",
"    </li>",
"    <li>",
"     www.iom.edu/CMS/3788/48191/68004/68230.aspx. (Accessed May 29, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/42\">",
"      Fox NS, Rebarber A, Roman AS, et al. Weight gain in twin pregnancies and adverse outcomes: examining the 2009 Institute of Medicine guidelines. Obstet Gynecol 2010; 116:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/43\">",
"      Fox NS, Saltzman DH, Kurtz H, Rebarber A. Excessive weight gain in term twin pregnancies: examining the 2009 Institute of Medicine definitions. Obstet Gynecol 2011; 118:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/44\">",
"      Luke B. Nutrition and multiple gestation. Semin Perinatol 2005; 29:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/45\">",
"      Goodnight W, Newman R, Society of Maternal-Fetal Medicine. Optimal nutrition for improved twin pregnancy outcome. Obstet Gynecol 2009; 114:1121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/46\">",
"      Souter VL, Kapur RP, Nyholt DR, et al. A report of dizygous monochorionic twins. N Engl J Med 2003; 349:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/47\">",
"      Yoon G, Beischel LS, Johnson JP, Jones MC. Dizygotic twin pregnancy conceived with assisted reproductive technology associated with chromosomal anomaly, imprinting disorder, and monochorionic placentation. J Pediatr 2005; 146:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/48\">",
"      Miura K, Niikawa N. Do monochorionic dizygotic twins increase after pregnancy by assisted reproductive technology? J Hum Genet 2005; 50:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/49\">",
"      Dub&eacute; J, Dodds L, Armson BA. Does chorionicity or zygosity predict adverse perinatal outcomes in twins? Am J Obstet Gynecol 2002; 186:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/50\">",
"      Sebire NJ, Snijders RJ, Hughes K, et al. The hidden mortality of monochorionic twin pregnancies. Br J Obstet Gynaecol 1997; 104:1203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/51\">",
"      Adegbite AL, Castille S, Ward S, Bajoria R. Neuromorbidity in preterm twins in relation to chorionicity and discordant birth weight. Am J Obstet Gynecol 2004; 190:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/52\">",
"      Leduc L, Takser L, Rinfret D. Persistance of adverse obstetric and neonatal outcomes in monochorionic twins after exclusion of disorders unique to monochorionic placentation. Am J Obstet Gynecol 2005; 193:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/53\">",
"      Hack KE, Derks JB, Elias SG, et al. Increased perinatal mortality and morbidity in monochorionic versus dichorionic twin pregnancies: clinical implications of a large Dutch cohort study. BJOG 2008; 115:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/54\">",
"      Ortibus E, Lopriore E, Deprest J, et al. The pregnancy and long-term neurodevelopmental outcome of monochorionic diamniotic twin gestations: a multicenter prospective cohort study from the first trimester onward. Am J Obstet Gynecol 2009; 200:494.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/55\">",
"      Acosta-Rojas R, Becker J, Munoz-Abellana B, et al. Twin chorionicity and the risk of adverse perinatal outcome. Int J Gynaecol Obstet 2007; 96:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/56\">",
"      Glinianaia SV, Obeysekera MA, Sturgiss S, Bell R. Stillbirth and neonatal mortality in monochorionic and dichorionic twins: a population-based study. Hum Reprod 2011; 26:2549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/57\">",
"      McPherson JA, Odibo AO, Shanks AL, et al. Impact of chorionicity on risk and timing of intrauterine fetal demise in twin pregnancies. Am J Obstet Gynecol 2012; 207:190.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/58\">",
"      Oldenburg A, Rode L, B&oslash;dker B, et al. Influence of chorionicity on perinatal outcome in a large cohort of Danish twin pregnancies. Ultrasound Obstet Gynecol 2012; 39:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/59\">",
"      Southwest Thames Obstetric Research Collaborative (STORK). Prospective risk of late stillbirth in monochorionic twins: a regional cohort study. Ultrasound Obstet Gynecol 2012; 39:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/60\">",
"      Evans MI, Goldberg JD, Horenstein J, et al. Selective termination for structural, chromosomal, and mendelian anomalies: international experience. Am J Obstet Gynecol 1999; 181:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/61\">",
"      Beasley E, Megerian G, Gerson A, Roberts NS. Monoamniotic twins: case series and proposal for antenatal management. Obstet Gynecol 1999; 93:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/62\">",
"      Allen VM, Windrim R, Barrett J, Ohlsson A. Management of monoamniotic twin pregnancies: a case series and systematic review of the literature. BJOG 2001; 108:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/63\">",
"      Shetty A, Smith AP. The sonographic diagnosis of chorionicity. Prenat Diagn 2005; 25:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/64\">",
"      Lee YM, Cleary-Goldman J, Thaker HM, Simpson LL. Antenatal sonographic prediction of twin chorionicity. Am J Obstet Gynecol 2006; 195:863.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/65\">",
"      Wan JJ, Schrimmer D, Tach&eacute; V, et al. Current practices in determining amnionicity and chorionicity in multiple gestations. Prenat Diagn 2011; 31:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/66\">",
"      Lopriore E, Sueters M, Middeldorp JM, et al. Twin pregnancies with two separate placental masses can still be monochorionic and have vascular anastomoses. Am J Obstet Gynecol 2006; 194:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/67\">",
"      Machin GA. Why is it important to diagnose chorionicity and how do we do it? Best Pract Res Clin Obstet Gynaecol 2004; 18:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/68\">",
"      Wood SL, St Onge R, Connors G, Elliot PD. Evaluation of the twin peak or lambda sign in determining chorionicity in multiple pregnancy. Obstet Gynecol 1996; 88:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/69\">",
"      Kurtz AB, Wapner RJ, Mata J, et al. Twin pregnancies: accuracy of first-trimester abdominal US in predicting chorionicity and amnionicity. Radiology 1992; 185:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/70\">",
"      Carroll SG, Soothill PW, Abdel-Fattah SA, et al. Prediction of chorionicity in twin pregnancies at 10-14 weeks of gestation. BJOG 2002; 109:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/71\">",
"      Townsend RR, Simpson GF, Filly RA. Membrane thickness in ultrasound prediction of chorionicity of twin gestations. J Ultrasound Med 1988; 7:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/72\">",
"      D'Alton ME, Dudley DK. The ultrasonographic prediction of chorionicity in twin gestation. Am J Obstet Gynecol 1989; 160:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/73\">",
"      Dias T, Arcangeli T, Bhide A, et al. First-trimester ultrasound determination of chorionicity in twin pregnancy. Ultrasound Obstet Gynecol 2011; 38:530.",
"     </a>",
"    </li>",
"    <li>",
"     American College of Obstetricians and Gynecologists. Prenatal diagnosis of fetal chromosomal abnormalities. ACOG practice bulletin #27. American College of Obstetricians and Gynecologists, Washington, DC 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/75\">",
"      Meyers C, Adam R, Dungan J, Prenger V. Aneuploidy in twin gestations: when is maternal age advanced? Obstet Gynecol 1997; 89:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/76\">",
"      Wald NJ, Rish S. Prenatal screening for Down syndrome and neural tube defects in twin pregnancies. Prenat Diagn 2005; 25:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/77\">",
"      Spencer K, Nicolaides KH. Screening for trisomy 21 in twins using first trimester ultrasound and maternal serum biochemistry in a one-stop clinic: a review of three years experience. BJOG 2003; 110:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/78\">",
"      Chasen ST, Perni SC, Kalish RB, Chervenak FA. First-trimester risk assessment for trisomies 21 and 18 in twin pregnancy. Am J Obstet Gynecol 2007; 197:374.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/79\">",
"      Avgidou K, Papageorghiou A, Bindra R, et al. Prospective first-trimester screening for trisomy 21 in 30,564 pregnancies. Am J Obstet Gynecol 2005; 192:1761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/80\">",
"      Sebire NJ, Souka A, Skentou H, et al. Early prediction of severe twin-to-twin transfusion syndrome. Hum Reprod 2000; 15:2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/81\">",
"      Maymon R, Neeman O, Shulman A, et al. Current concepts of Down syndrome screening tests in assisted reproduction twin pregnancies: another double trouble. Prenat Diagn 2005; 25:746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/82\">",
"      Berm&uacute;dez C, Becerra CH, Bornick PW, et al. Placental types and twin-twin transfusion syndrome. Am J Obstet Gynecol 2002; 187:489.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/83\">",
"      O'Donnell CP, Pertile MD, Sheffield LJ, Sampson A. Monozygotic twins with discordant karyotypes: a case report. J Pediatr 2004; 145:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/84\">",
"      Nieuwint A, Van Zalen-Sprock R, Hummel P, et al. 'Identical' twins with discordant karyotypes. Prenat Diagn 1999; 19:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/85\">",
"      Beattie RB, Manson IW, Whittle MJ. Identical twins with trisomy 21 discordant for exomphalos. Prenat Diagn 1993; 13:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/86\">",
"      Rogers JG, Voullaire L, Gold H. Monozygotic twins discordant for trisomy 21. Am J Med Genet 1982; 11:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/87\">",
"      Edlow AG, Reiss R, Benson CB, et al. Monochorionic diamniotic twin gestations discordant for markedly enlarged nuchal translucency. Prenat Diagn 2011; 31:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/88\">",
"      Campana MA, Roubicek MM. Maternal and neonatal variables in twins: an epidemiological approach. Acta Genet Med Gemellol (Roma) 1996; 45:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/89\">",
"      Chen CJ, Wang CJ, Yu MW, Lee TK. Perinatal mortality and prevalence of major congenital malformations of twins in Taipei city. Acta Genet Med Gemellol (Roma) 1992; 41:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/90\">",
"      Sperling L, Kiil C, Larsen LU, et al. Detection of chromosomal abnormalities, congenital abnormalities and transfusion syndrome in twins. Ultrasound Obstet Gynecol 2007; 29:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/91\">",
"      Bahtiyar MO, Dulay AT, Weeks BP, et al. Prevalence of congenital heart defects in monochorionic/diamniotic twin gestations: a systematic literature review. J Ultrasound Med 2007; 26:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/92\">",
"      Glinianaia SV, Rankin J, Wright C. Congenital anomalies in twins: a register-based study. Hum Reprod 2008; 23:1306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/93\">",
"      Weber MA, Sebire NJ. Genetics and developmental pathology of twinning. Semin Fetal Neonatal Med 2010; 15:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/94\">",
"      Edwards MS, Ellings JM, Newman RB, Menard MK. Predictive value of antepartum ultrasound examination for anomalies in twin gestations. Ultrasound Obstet Gynecol 1995; 6:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/95\">",
"      Winkler N, Kennedy A, Byrne J, Woodward P. The imaging spectrum of conjoined twins. Ultrasound Q 2008; 24:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/96\">",
"      Spitz L. Conjoined twins. Prenat Diagn 2005; 25:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/97\">",
"      Mackenzie TC, Crombleholme TM, Johnson MP, et al. The natural history of prenatally diagnosed conjoined twins. J Pediatr Surg 2002; 37:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/98\">",
"      Brizot ML, Liao AW, Lopes LM, et al. Conjoined twins pregnancies: experience with 36 cases from a single center. Prenat Diagn 2011; 31:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/99\">",
"      Rustico MA, Baietti MG, Coviello D, et al. Managing twins discordant for fetal anomaly. Prenat Diagn 2005; 25:766.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/100\">",
"      Vandecruys H, Avgidou K, Surerus E, et al. Dilemmas in the management of twins discordant for anencephaly diagnosed at 11 + 0 to 13 + 6 weeks of gestation. Ultrasound Obstet Gynecol 2006; 28:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/101\">",
"      Lust A, De Catte L, Lewi L, et al. Monochorionic and dichorionic twin pregnancies discordant for fetal anencephaly: a systematic review of prenatal management options. Prenat Diagn 2008; 28:275.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/102\">",
"      Diehl W, Hecher K. Selective cord coagulation in acardiac twins. Semin Fetal Neonatal Med 2007; 12:458.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/103\">",
"      Dias T, Ladd S, Mahsud-Dornan S, et al. Systematic labeling of twin pregnancies on ultrasound. Ultrasound Obstet Gynecol 2011; 38:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/104\">",
"      Weingertner AS, Kohler A, Kohler M, et al. Clinical and placental characteristics in four new cases of twin anemia-polycythemia sequence. Ultrasound Obstet Gynecol 2010; 35:490.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/105\">",
"      Garite TJ, Clark RH, Elliott JP, Thorp JA. Twins and triplets: the effect of plurality and growth on neonatal outcome compared with singleton infants. Am J Obstet Gynecol 2004; 191:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/106\">",
"      Hamilton EF, Platt RW, Morin L, et al. How small is too small in a twin pregnancy? Am J Obstet Gynecol 1998; 179:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/107\">",
"      Hartley RS, Hitti J, Emanuel I. Size-discordant twin pairs have higher perinatal mortality rates than nondiscordant pairs. Am J Obstet Gynecol 2002; 187:1173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/108\">",
"      Blickstein I, Keith LG. Neonatal mortality rates among growth-discordant twins, classified according to the birth weight of the smaller twin. Am J Obstet Gynecol 2004; 190:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/109\">",
"      Amaru RC, Bush MC, Berkowitz RL, et al. Is discordant growth in twins an independent risk factor for adverse neonatal outcome? Obstet Gynecol 2004; 103:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/110\">",
"      Branum AM, Schoendorf KC. The effect of birth weight discordance on twin neonatal mortality. Obstet Gynecol 2003; 101:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/111\">",
"      Yinon Y, Mazkereth R, Rosentzweig N, et al. Growth restriction as a determinant of outcome in preterm discordant twins. Obstet Gynecol 2005; 105:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/112\">",
"      Demissie K, Ananth CV, Martin J, et al. Fetal and neonatal mortality among twin gestations in the United States: the role of intrapair birth weight discordance. Obstet Gynecol 2002; 100:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/113\">",
"      Kingdom JC, Nevo O, Murphy KE. Discordant growth in twins. Prenat Diagn 2005; 25:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/114\">",
"      Grennert L, Persson PH, Gennser G. Intrauterine growth of twins judged by BPD measurements. Acta Obstet Gynecol Scand Suppl 1978; 78:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/115\">",
"      Grumbach K, Coleman BG, Arger PH, et al. Twin and singleton growth patterns compared using US. Radiology 1986; 158:237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/116\">",
"      Alexander GR, Kogan M, Martin J, Papiernik E. What are the fetal growth patterns of singletons, twins, and triplets in the United States? Clin Obstet Gynecol 1998; 41:114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/117\">",
"      Devoe LD, Ware DJ. Antenatal assessment of twin gestation. Semin Perinatol 1995; 19:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/118\">",
"      Cameron AH. The Birmingham twin survey. Proc R Soc Med 1968; 61:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/119\">",
"      Breathnach FM, McAuliffe FM, Geary M, et al. Definition of intertwin birth weight discordance. Obstet Gynecol 2011; 118:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/120\">",
"      Ananth CV, Demissie K, Hanley ML. Birth weight discordancy and adverse perinatal outcomes among twin gestations in the United States: the effect of placental abruption. Am J Obstet Gynecol 2003; 188:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/121\">",
"      Miller J, Chauhan SP, Abuhamad AZ. Discordant twins: diagnosis, evaluation and management. Am J Obstet Gynecol 2012; 206:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/122\">",
"      Gonz&aacute;lez-Quintero VH, Luke B, O'sullivan MJ, et al. Antenatal factors associated with significant birth weight discordancy in twin gestations. Am J Obstet Gynecol 2003; 189:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/123\">",
"      Fick AL, Feldstein VA, Norton ME, et al. Unequal placental sharing and birth weight discordance in monochorionic diamniotic twins. Am J Obstet Gynecol 2006; 195:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/124\">",
"      Russell Z, Quintero RA, Kontopoulos EV. Intrauterine growth restriction in monochorionic twins. Semin Fetal Neonatal Med 2007; 12:439.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/125\">",
"      Papageorghiou AT, Bakoulas V, Sebire NJ, Nicolaides KH. Intrauterine growth in multiple pregnancies in relation to fetal number, chorionicity and gestational age. Ultrasound Obstet Gynecol 2008; 32:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/126\">",
"      Ananth CV, Vintzileos AM, Shen-Schwarz S, et al. Standards of birth weight in twin gestations stratified by placental chorionicity. Obstet Gynecol 1998; 91:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/127\">",
"      Tai J, Grobman WA. The association of crown-rump length discordance in twin gestations with adverse perinatal outcomes. Am J Obstet Gynecol 2007; 197:369.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/128\">",
"      Bhide A, Sankaran S, Sairam S, et al. Relationship of intertwin crown-rump length discrepancy to chorionicity, fetal demise and birth-weight discordance. Ultrasound Obstet Gynecol 2009; 34:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/129\">",
"      Kalish RB, Chasen ST, Gupta M, et al. First trimester prediction of growth discordance in twin gestations. Am J Obstet Gynecol 2003; 189:706.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/130\">",
"      Memmo A, Dias T, Mahsud-Dornan S, et al. Prediction of selective fetal growth restriction and twin-to-twin transfusion syndrome in monochorionic twins. BJOG 2012; 119:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/131\">",
"      Lynch L, Lapinski R, Alvarez M, Lockwood CJ. Accuracy of ultrasound estimation of fetal weight in multiple pregnancies. Ultrasound Obstet Gynecol 1995; 6:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/132\">",
"      Jensen OH, Jenssen H. Prediction of fetal weights in twins. Acta Obstet Gynecol Scand 1995; 74:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/133\">",
"      Hill LM, Guzick D, Chenevey P, et al. The sonographic assessment of twin growth discordancy. Obstet Gynecol 1994; 84:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/134\">",
"      Caravello JW, Chauhan SP, Morrison JC, et al. Sonographic examination does not predict twin growth discordance accurately. Obstet Gynecol 1997; 89:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/135\">",
"      Chauhan SP, Shields D, Parker D, et al. Detecting fetal growth restriction or discordant growth in twin gestations stratified by placental chorionicity. J Reprod Med 2004; 49:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/136\">",
"      Grobman WA, Parilla BV. Positive predictive value of suspected growth aberration in twin gestations. Am J Obstet Gynecol 1999; 181:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/137\">",
"      Chittacharoen A, Leelapattana P, Rangsiprakarn R. Prediction of discordant twins by real-time ultrasonography combined with umbilical artery velocimetry. Ultrasound Obstet Gynecol 2000; 15:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/138\">",
"      Giles W, Bisits A, O'Callaghan S, et al. The Doppler assessment in multiple pregnancy randomised controlled trial of ultrasound biometry versus umbilical artery Doppler ultrasound and biometry in twin pregnancy. BJOG 2003; 110:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/139\">",
"      Knuppel RA, Rattan PK, Scerbo JC, O'Brien WF. Intrauterine fetal death in twins after 32 weeks of gestation. Obstet Gynecol 1985; 65:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/140\">",
"      Barigye O, Pasquini L, Galea P, et al. High risk of unexpected late fetal death in monochorionic twins despite intensive ultrasound surveillance: a cohort study. PLoS Med 2005; 2:e172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/141\">",
"      Patkos P, Boucher M, Broussard PM, et al. Factors influencing nonstress test results in multiple gestations. Am J Obstet Gynecol 1986; 154:1107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/142\">",
"      Lodeiro JG, Vintzileos AM, Feinstein SJ, et al. Fetal biophysical profile in twin gestations. Obstet Gynecol 1986; 67:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/143\">",
"      Kilby MD, Govind A, O'Brien PM. Outcome of twin pregnancies complicated by a single intrauterine death: a comparison with viable twin pregnancies. Obstet Gynecol 1994; 84:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/144\">",
"      Hillman SC, Morris RK, Kilby MD. Co-twin prognosis after single fetal death: a systematic review and meta-analysis. Obstet Gynecol 2011; 118:928.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/145\">",
"      Pharoah PO. Causal hypothesis for some congenital anomalies. Twin Res Hum Genet 2005; 8:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/146\">",
"      Pharoah PO, Glinianaia SV, Rankin J. Congenital anomalies in multiple births after early loss of a conceptus. Hum Reprod 2009; 24:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/147\">",
"      Benirschke K. Intrauterine death of a twin: mechanisms, implications for surviving twin, and placental pathology. Semin Diagn Pathol 1993; 10:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/148\">",
"      Karageyim Karsidag AY, Kars B, Dansuk R, et al. Brain damage to the survivor within 30 min of co-twin demise in monochorionic twins. Fetal Diagn Ther 2005; 20:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/149\">",
"      Ong SS, Zamora J, Khan KS, Kilby MD. Prognosis for the co-twin following single-twin death: a systematic review. BJOG 2006; 113:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/150\">",
"      Mitra AG, Chescheir NC, Cefalo RC, Tatum BS. Spontaneous resolution of hypofibrinogenemia in a triplet gestation associated with second trimester in utero death of two fetuses. Am J Perinatol 1993; 10:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/151\">",
"      Hasb&uacute;n J, Mu&ntilde;oz H, von M&uuml;hlenbrock R, et al. [The successful prolongation of a twin preterm pregnancy complicated by a dead fetus and disseminated intravascular coagulation]. Rev Chil Obstet Ginecol 1992; 57:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/152\">",
"      Chescheir NC, Seeds JW. Spontaneous resolution of hypofibrinogenemia associated with death of a twin in utero: a case report. Am J Obstet Gynecol 1988; 159:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/153\">",
"      Romero R, Duffy TP, Berkowitz RL, et al. Prolongation of a preterm pregnancy complicated by death of a single twin in utero and disseminated intravascular coagulation. Effects of treatment with heparin. N Engl J Med 1984; 310:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/154\">",
"      Skelly H, Marivate M, Norman R, et al. Consumptive coagulopathy following fetal death in a triplet pregnancy. Am J Obstet Gynecol 1982; 142:595.",
"     </a>",
"    </li>",
"    <li>",
"     Births: Final Data for 2008. file://www.cdc.gov/nchs/data/nvsr/nvsr59/nvsr59_01.pdf (Accessed on January 07, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/156\">",
"      Tan H, Wen SW, Walker M, et al. The association between fetal sex and preterm birth in twin pregnancies. Obstet Gynecol 2004; 103:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/157\">",
"      Dailey TL, Jayakrishnan A, Phipps M, et al. The contribution of maternal race/ethnicity and fetal sex to prematurity in twins. Am J Obstet Gynecol 2009; 201:68.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/158\">",
"      Melamed N, Yogev Y, Glezerman M. Effect of fetal sex on pregnancy outcome in twin pregnancies. Obstet Gynecol 2009; 114:1085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/159\">",
"      Jacquemyn Y, Martens G, Ruyssinck G, et al. A matched cohort comparison of the outcome of twin versus singleton pregnancies in Flanders, Belgium. Twin Res 2003; 6:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/160\">",
"      Ballabh P, Kumari J, AlKouatly HB, et al. Neonatal outcome of triplet versus twin and singleton pregnancies: a matched case control study. Eur J Obstet Gynecol Reprod Biol 2003; 107:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/161\">",
"      Barton SE, Missmer SA, Hornstein MD. Twin pregnancies with a 'vanished' embryo: a higher risk multiple gestation group? Hum Reprod 2011; 26:2750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/162\">",
"      Gibson JL, Macara LM, Owen P, et al. Prediction of preterm delivery in twin pregnancy: a prospective, observational study of cervical length and fetal fibronectin testing. Ultrasound Obstet Gynecol 2004; 23:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/163\">",
"      Wennerholm UB, Holm B, Mattsby-Baltzer I, et al. Fetal fibronectin, endotoxin, bacterial vaginosis and cervical length as predictors of preterm birth and neonatal morbidity in twin pregnancies. Br J Obstet Gynaecol 1997; 104:1398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/164\">",
"      Goldenberg RL, Iams JD, Miodovnik M, et al. The preterm prediction study: risk factors in twin gestations. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1996; 175:1047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/165\">",
"      Singer E, Pilpel S, Bsat F, et al. Accuracy of fetal fibronectin to predict preterm birth in twin gestations with symptoms of labor. Obstet Gynecol 2007; 109:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/166\">",
"      Conde-Agudelo A, Romero R, Hassan SS, Yeo L. Transvaginal sonographic cervical length for the prediction of spontaneous preterm birth in twin pregnancies: a systematic review and metaanalysis. Am J Obstet Gynecol 2010; 203:128.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/167\">",
"      Lim AC, Hegeman MA, Huis In 'T Veld MA, et al. Cervical length measurement for the prediction of preterm birth in multiple pregnancies: a systematic review and bivariate meta-analysis. Ultrasound Obstet Gynecol 2011; 38:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/168\">",
"      Fuchs I, Tsoi E, Henrich W, et al. Sonographic measurement of cervical length in twin pregnancies in threatened preterm labor. Ultrasound Obstet Gynecol 2004; 23:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/169\">",
"      Fox NS, Saltzman DH, Klauser CK, et al. Prediction of spontaneous preterm birth in asymptomatic twin pregnancies with the use of combined fetal fibronectin and cervical length. Am J Obstet Gynecol 2009; 201:313.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/170\">",
"      Urquhart C, Currell R, Harlow F, Callow L. Home uterine monitoring for detecting preterm labour. Cochrane Database Syst Rev 2012; 5:CD006172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/171\">",
"      Crowther CA, Han S. Hospitalisation and bed rest for multiple pregnancy. Cochrane Database Syst Rev 2010; :CD000110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/172\">",
"      Sciscione AC. Maternal activity restriction and the prevention of preterm birth. Am J Obstet Gynecol 2010; 202:232.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/173\">",
"      Juhl M, Andersen PK, Olsen J, et al. Physical exercise during pregnancy and the risk of preterm birth: a study within the Danish National Birth Cohort. Am J Epidemiol 2008; 167:859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/174\">",
"      Dor J, Shalev J, Mashiach S, et al. Elective cervical suture of twin pregnancies diagnosed ultrasonically in the first trimester following induced ovulation. Gynecol Obstet Invest 1982; 13:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/175\">",
"      Newman RB, Krombach RS, Myers MC, McGee DL. Effect of cerclage on obstetrical outcome in twin gestations with a shortened cervical length. Am J Obstet Gynecol 2002; 186:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/176\">",
"      Berghella V, Odibo AO, To MS, et al. Cerclage for short cervix on ultrasonography: meta-analysis of trials using individual patient-level data. Obstet Gynecol 2005; 106:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/177\">",
"      Yamasmit W, Chaithongwongwatthana S, Tolosa JE, et al. Prophylactic oral betamimetics for reducing preterm birth in women with a twin pregnancy. Cochrane Database Syst Rev 2012; 9:CD004733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/178\">",
"      American College of Obstetricians and Gynecologists Committee on Practice Bulletins-Obstetrics, Society for Maternal-Fetal Medicine, ACOG Joint Editorial Committee. ACOG Practice Bulletin #56: Multiple gestation: complicated twin, triplet, and high-order multifetal pregnancy. Obstet Gynecol 2004; 104:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/179\">",
"      Bianco AT, Stone J, Lapinski R, et al. The clinical outcome of preterm premature rupture of membranes in twin versus singleton pregnancies. Am J Perinatol 1996; 13:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/180\">",
"      Mercer BM, Crocker LG, Pierce WF, Sibai BM. Clinical characteristics and outcome of twin gestation complicated by preterm premature rupture of the membranes. Am J Obstet Gynecol 1993; 168:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/181\">",
"      Jacquemyn Y, Noelmans L, Mahieu L, Buytaert P. Twin versus singleton pregnancy and preterm prelabour rupture of the membranes. Clin Exp Obstet Gynecol 2003; 30:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/182\">",
"      Trentacoste SV, Jean-Pierre C, Baergen R, Chasen ST. Outcomes of preterm premature rupture of membranes in twin pregnancies. J Matern Fetal Neonatal Med 2008; 21:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/183\">",
"      Phung DT, Blickstein I, Goldman RD, et al. The Northwestern Twin Chorionicity Study: I. Discordant inflammatory findings that are related to chorionicity in presenting versus nonpresenting twins. Am J Obstet Gynecol 2002; 186:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/184\">",
"      Donovan EF, Ehrenkranz RA, Shankaran S, et al. Outcomes of very low birth weight twins cared for in the National Institute of Child Health and Human Development Neonatal Research Network's intensive care units. Am J Obstet Gynecol 1998; 179:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/185\">",
"      Hashimoto LN, Hornung RW, Lindsell CJ, et al. Effects of antenatal glucocorticoids on outcomes of very low birth weight multifetal gestations. Am J Obstet Gynecol 2002; 187:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/186\">",
"      Blickstein I, Shinwell ES, Lusky A, et al. Plurality-dependent risk of respiratory distress syndrome among very-low-birth-weight infants and antepartum corticosteroid treatment. Am J Obstet Gynecol 2005; 192:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/187\">",
"      Blickstein I, Reichman B, Lusky A, et al. Plurality-dependent risk of severe intraventricular hemorrhage among very low birth weight infants and antepartum corticosteroid treatment. Am J Obstet Gynecol 2006; 194:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/188\">",
"      Murphy DJ, Caukwell S, Joels LA, Wardle P. Cohort study of the neonatal outcome of twin pregnancies that were treated with prophylactic or rescue antenatal corticosteroids. Am J Obstet Gynecol 2002; 187:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/189\">",
"      Kametas NA, McAuliffe F, Krampl E, et al. Maternal cardiac function in twin pregnancy. Obstet Gynecol 2003; 102:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/190\">",
"      Rao A, Sairam S, Shehata H. Obstetric complications of twin pregnancies. Best Pract Res Clin Obstet Gynaecol 2004; 18:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/191\">",
"      Sibai BM, Hauth J, Caritis S, et al. Hypertensive disorders in twin versus singleton gestations. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol 2000; 182:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/192\">",
"      Krotz S, Fajardo J, Ghandi S, et al. Hypertensive disease in twin pregnancies: a review. Twin Res 2002; 5:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/193\">",
"      Fischer RL, Bianculli KW, Hediger ML, Scholl TO. Maternal serum uric acid levels in twin gestations. Obstet Gynecol 1995; 85:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/194\">",
"      Hsu CD, Chung YK, Lee IS, et al. Maternal serum uric acid levels in preeclamptic women with multiple gestations. Am J Perinatol 1997; 14:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/195\">",
"      Fischer RL, Weisberg LS, Hediger ML. Etiology of third-trimester maternal hyperuricemia in nonpreeclamptic twin gestations. Obstet Gynecol 2001; 97:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/196\">",
"      Cohen SB, Kreiser D, Erez I, et al. Effect of fetal number on maternal serum uric acid concentration. Am J Perinatol 2002; 19:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/197\">",
"      Sarhanis P, Pugh DH. Resolution of pre-eclampsia following intrauterine death of one twin. Br J Obstet Gynaecol 1992; 99:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/198\">",
"      Hagay ZJ, Levy R, Zalel Y, Weissman A. Single fetal demise in twin gestation resulting in the resolution of severe pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 1994; 56:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/199\">",
"      Audibert F, Salomon LJ, Castaigne-Meary V, et al. Selective termination of a twin pregnancy as a treatment of severe pre-eclampsia. BJOG 2003; 110:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/200\">",
"      Schwartz DB, Daoud Y, Zazula P, et al. Gestational diabetes mellitus: metabolic and blood glucose parameters in singleton versus twin pregnancies. Am J Obstet Gynecol 1999; 181:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/201\">",
"      Sivan E, Maman E, Homko CJ, et al. Impact of fetal reduction on the incidence of gestational diabetes. Obstet Gynecol 2002; 99:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/202\">",
"      Roach VJ, Lau TK, Wilson D, Rogers MS. The incidence of gestational diabetes in multiple pregnancy. Aust N Z J Obstet Gynaecol 1998; 38:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/203\">",
"      Buhling KJ, Henrich W, Starr E, et al. Risk for gestational diabetes and hypertension for women with twin pregnancy compared to singleton pregnancy. Arch Gynecol Obstet 2003; 269:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/204\">",
"      Henderson CE, Scarpelli S, LaRosa D, Divon MY. Assessing the risk of gestational diabetes in twin gestation. J Natl Med Assoc 1995; 87:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/205\">",
"      Naidoo L, Jailal I, Moodley J, Desai R. Intravenous glucose tolerance tests in women with twin pregnancy. Obstet Gynecol 1985; 66:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/206\">",
"      Gonzalez MC, Reyes H, Arrese M, et al. Intrahepatic cholestasis of pregnancy in twin pregnancies. J Hepatol 1989; 9:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?39/46/40682/abstract/207\">",
"      Hall MH, Campbell DM, Davidson RJ. Anaemia in twin pregnancy. Acta Genet Med Gemellol (Roma) 1979; 28:279.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6821 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.25.216.6-8F673A88A0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_46_40682=[""].join("\n");
var outline_f39_46_40682=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H44\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ZYGOSITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INCIDENCE AND EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      RECOGNITION OF TWIN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EARLY AND LATE LOSS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NUTRITION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H215418\">",
"      Weight gain",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H215425\">",
"      Vitamins and minerals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      AMNIONICITY AND CHORIONICITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Relationship with timing of egg division",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Clinical significance of monochorionicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H348913022\">",
"      Monoamnionicity",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Ultrasonographic assessment of chorionicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - DC twins",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - MC twins",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      PRENATAL DIAGNOSIS OF DOWN SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      DIAGNOSIS AND MANAGEMENT OF CONGENITAL ANOMALIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H180876174\">",
"      Conjoined twins",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Selective fetal termination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H348913135\">",
"      MONITORING DURING THE SECOND TRIMESTER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H276251595\">",
"      Evaluation for TTTS and TAPS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Evaluation of fetal growth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Growth restriction and discordance",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Sonographic assessment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H348913278\">",
"      Frequency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Doppler velocimetry",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Management of growth abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      ASSESSMENT OF FETAL WELL-BEING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      DEATH OF ONE TWIN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      PRETERM BIRTH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Tests for predicting increased risk of preterm birth",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Fetal fibronectin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Measurement of cervical length",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - fFN and cervical length",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Home uterine monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Interventions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Supplemental progesterone",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      - Bedrest",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      - Cerclage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      - Tocolytic drugs",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      PRETERM PREMATURE RUPTURE OF MEMBRANES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      ANTENATAL CORTICOSTEROIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      POTENTIAL MATERNAL COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      Gestational hypertension and preeclampsia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Acute fatty liver",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Gestational diabetes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H115954197\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"OBGYN/6821\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6821|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?35/46/36577\" title=\"diagnostic image 1\">",
"      Twin peak or lambda sign",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?2/38/2657\" title=\"diagnostic image 2\">",
"      Thick intertwin membrane",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?10/29/10706\" title=\"diagnostic image 3\">",
"      Thin intertwin membrane",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6821|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?12/44/12992\" title=\"figure 1\">",
"      Placenta and membranes in twin pregnancies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"OBGYN/6821|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?11/51/12091\" title=\"table 1\">",
"      Outcome of twin pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/53/32603\" title=\"table 2A\">",
"      Mortality per 1000 live births by plurality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/56/23436\" title=\"table 2B\">",
"      GA and BW characteristics of US singleton twin triplet births",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?14/8/14476\" title=\"table 3\">",
"      Cervical length twins and PTB",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/38/24166?source=related_link\">",
"      Acute fatty liver of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/55/31610?source=related_link\">",
"      Antenatal corticosteroid therapy for reduction of neonatal morbidity and mortality from preterm delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/11/2232?source=related_link\">",
"      Antepartum fetal heart rate assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/52/31558?source=related_link\">",
"      Assessment of amniotic fluid volume",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/32/28169?source=related_link\">",
"      Chorionic villus sampling: Risks, complications, and techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/20/25929?source=related_link\">",
"      Clinical features, diagnosis, and treatment of disseminated intravascular coagulation in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/27/39353?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/61/29657?source=related_link\">",
"      Dermatoses of pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/10/165?source=related_link\">",
"      Diagnosis and management of twin reversed arterial perfusion (TRAP) sequence",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/11/16570?source=related_link\">",
"      Diagnostic amniocentesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?14/51/15159?source=related_link\">",
"      Fetal fibronectin for prediction of preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/27/23994?source=related_link\">",
"      Fetal growth restriction: Evaluation and management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/22/7529?source=related_link\">",
"      First trimester combined test and integrated tests for screening for Down syndrome and trisomy 18",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29383?source=related_link\">",
"      Gestational hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/45/1750?source=related_link\">",
"      Induced fetal demise",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/53/35674?source=related_link\">",
"      Inhibition of acute preterm labor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/39/27257?source=related_link\">",
"      Laboratory issues related to maternal serum screening for Down syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/7/13434?source=related_link\">",
"      Management of hypertension in pregnant and postpartum women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/19/4407?source=related_link\">",
"      Management of premature rupture of the fetal membranes at term",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/43/9913?source=related_link\">",
"      Management of twin-twin transfusion syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/62/37866?source=related_link\">",
"      Medical management and follow-up of gestational diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/31/43511?source=related_link\">",
"      Monoamniotic twin pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/9/39065?source=related_link\">",
"      Multifetal pregnancy reduction and selective termination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/60/27594?source=related_link\">",
"      Neonatal outcome, complications, and management of multiple births",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/24/28039?source=related_link\">",
"      Pathogenesis and diagnosis of twin-twin transfusion syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?1/44/1732?source=related_link\">",
"      Patient information: Having twins (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/20/27978?source=related_link\">",
"      Preeclampsia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/23/21882?source=related_link\">",
"      Preeclampsia: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/6/2154?source=related_link\">",
"      Pregnancy outcome after assisted reproductive technology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/31/15866?source=related_link\">",
"      Preterm premature rupture of membranes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/44/40648?source=related_link\">",
"      Prevention of Rh(D) alloimmunization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/33/5657?source=related_link\">",
"      Progesterone supplementation to reduce the risk of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/3/35898?source=related_link\">",
"      Risk factors for preterm labor and delivery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9210?source=related_link\">",
"      Screening and diagnosis of diabetes mellitus during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/41/11928?source=related_link\">",
"      The fetal biophysical profile",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/33/21017?source=related_link\">",
"      Transvaginal ultrasound assessment of the cervix and prediction of spontaneous preterm birth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?5/11/5306?source=related_link\">",
"      Twin pregnancy: Labor and delivery",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f39_46_40683="Screening for type 2 diabetes mellitus in children";
var content_f39_46_40683=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Screening recommendations for type 2 diabetes mellitus in children and adolescents",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Overweight status",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Body mass index &ge;85th percentile for age and gender",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Weight for height &ge;85th percentile",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Weight &ge;120 percent of ideal for height",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Plus any two of the following risk factors:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Family history of type 2 diabetes mellitus in a 1",
"        <sup>",
"         st",
"        </sup>",
"        or 2",
"        <sup>",
"         nd",
"        </sup>",
"        degree relative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        High-risk race/ethnicity (Native American, African-American, Latino, Asian American, Pacific Islander)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Signs of insulin resistance on physical examination or conditions associated with insulin resistance (Acanthosis nigricans, hypertension, dyslipidemia, polycystic ovary syndrome, or small-for-gestational age birthweight)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Maternal history of diabetes or gestational diabetes mellitus during the child's gestation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Screening frequency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Begin screening at age 10 years, or at onset of puberty if this occurs less than 10 years old",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Repeat screening every three years",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     American Diabetes Association. Standards of medical care in diabetes--2013. Diabetes Care 2013; 36 Suppl 1:S11.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_46_40683=[""].join("\n");
var outline_f39_46_40683=null;
var title_f39_46_40684="Echo asymptomatic murmurs";
var content_f39_46_40684=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F50108%7ECARD%2F58419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F50108%7ECARD%2F58419&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Echocardiography in asymptomatic patients with cardiac murmurs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that echocardiography is useful in asymptomatic patients with the following cardiac murmurs:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Diastolic murmurs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Continuous murmurs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Late systolic murmurs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Murmurs associated with ejection clicks",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Murmurs that radiate to the neck or back",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Grade 3 or louder midpeaking systolic murmurs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of usefulness of echocardiography in asymptomatic patients with the following cardiac murmurs:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Murmurs associated with other abnormal physical findings on cardiac examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Murmurs associated with an abnormal electrocardiogram or chest x-ray",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that echocardiography is not useful in asymptomatic patients with the following murmurs:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; Grade 2 or softer midsystolic murmurs considered innocent or functional by an experienced observer",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Echocardiography in symptomatic patients with cardiac murmurs",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class I - There is evidence and/or general agreement that echocardiography is useful in symptomatic patients with heart murmurs who also have one or more of the following",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Symptoms or signs of heart failure",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Myocardial ischemia or infarction",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Syncope",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Thromboembolism",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Infective endocarditis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Other evidence of structural heart disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIa - The weight of evidence or opinion is in favor of the usefulness of echocardiography in the following patients with heart murmurs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       &bull; Symptoms or signs are probably noncardiac in origin but a cardiac cause cannot be excluded by standard evaluation.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Bonow RO, Carabello BA, Chatterjee K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_46_40684=[""].join("\n");
var outline_f39_46_40684=null;
var title_f39_46_40685="BMT in untreated myeloma";
var content_f39_46_40685=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F64033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F64033&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Efficacy of early BMT in multiple myeloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 325px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Survival data from a randomized trial which compared high-dose chemotherapy supported by autologous bone marrow transplantation (BMT) with conventional chemotherapy in 200 previously untreated patients under the age of 65. Five-year survival was significantly increased in the patients receiving BMT (52 versus 12 percent, p = 0.03).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Attal, M, Harousseau, JL, Stoppa, AM, et al, N Engl J Med 1996; 335:91.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_46_40685=[""].join("\n");
var outline_f39_46_40685=null;
var title_f39_46_40686="Homicides in children";
var content_f39_46_40686=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64465&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 604px\">",
"   <div class=\"ttl\">",
"    2007, United States homicide ages 1 to 18, all races, both sexes",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 584px; height: 447px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Total deaths: 2285.",
"    <div class=\"footnotes\">",
"     %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: National Center for Injury Prevention and Control WISQARS&trade; (file://www.cdc.gov/injury/wisqars/fatal.html). Accessed on August 8, 2011.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_46_40686=[""].join("\n");
var outline_f39_46_40686=null;
var title_f39_46_40687="Surgical treatment of hypothenar space abscess";
var content_f39_46_40687=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F66822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F66822&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Surgical treatment of hypothenar space abscess",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 380px; height: 560px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Deep fascial space infections are surgical emergencies and there is no role for nonoperative treatment. The approach to a hypothenar space abscess is depicted here.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f39_46_40687=[""].join("\n");
var outline_f39_46_40687=null;
